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Abstract  
Fibrosis causes muscle dysfunction and contributes to the fatal Duchenne muscular dystrophy (DMD) 
phenotype. By reducing fibrosis and scar formation, antifibrotic therapies aim to improve muscle function 
and enhance muscle regeneration. In addition, antifibrotic therapy may also serve as an adjunct to gene 
and cell therapies for DMD. Periostin(POSTN) is a TGF-β regulated gene and its inhibition has shown to 
reduce fibrosis. Myostatin (MSTN), a member of the Transforming Growth factor β family of signalling 
molecules, is a key regulator of muscle mass and its inhibition has been shown to increase muscle mass 
and strength as well as reduce fibrosis. Periostin and myostatin are now promising therapeutic targets for 
the treatment of Duchenne muscular dystrophy (DMD). The current project is focused on working towards 
a combination therapy for Duchenne muscular dystrophy through development of antisense 
oligonucleotides that target POSTN and MSTN and prevent their successful transcription and translation, 
ultimately leading to a reduction in the amount of functional protein produced by the muscle. 
Theoretically this should lead to a subsequent amelioration of fibrosis and increase muscle mass in the 
dystrophic muscle. More specifically, the project looks at inhibition of MSTN by targeting its poly(A) tail 
and inhibition of POSTN through disruption of the reading frame by exon skipping. These methods were 
examined in vitro in human muscle cell lines as well as mouse muscle and fibroblast cell lines; therapeutic 
potential of the best oligonucleotide was then investigated in vivo using mice. 
First novel contribution in this project is MSTN downregulation through targeting of the poly(A) signal and 
comparison of this method to the previously established exon exclusion method. This investigation 
showed the targeting of poly(A) signal to be successful but not as effective as exon exclusion.  
Another novel contribution by this project was the investigation of POSTN downregulation through exon 
exclusion in the berberine induced damaged TA muscle of the C57 mouse model. This investigation 
showed berberine induced damage in mice to be an ineffective model to assess the effects of POSTN 
downregulation on fibrosis.  
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1. Introduction 
What is Duchenne Muscular Dystrophy  
Duchenne Muscular Dystrophy (DMD) is the most common type of muscular dystrophy 
with a prevalence of 1 in 3,500 live male births (Kharraz, Guerra, Pessina and Serrano, 
2014). DMD is a fatal X-linked and recessive disorder and hence effects mainly boys. The 
disease is characterised by progressive loss of muscle mass and function and is caused 
by mutations in the dystrophin gene that results in an out-of-frame transcript (Kharraz, 
Guerra, Pessina and Serrano, 2014).  
All three muscle types, skeletal, cardiac and smooth, are affected severely in DMD, 
which leads to a shortening of life expectancy. Patients are usually wheelchair-bound by 
the age of 12 and eventually death occurs as a result of cardiac and/or respiratory failure 
(O’Brien and Kunkel, 2001). 
Becker Muscular Dystrophy  
Becker Muscular Dystrophy (BMD) is similar to DMD but less severe with a milder clinical 
course. BMD is caused by the production of a shortened yet partly functional dystrophin 
protein. This is due to the fact that the mutation in BMD leads to an in-frame transcript. 
Muscle wasting and weakness is also central in this type of dystrophy but the weakness 
is mainly proximal with difficulties in walking beginning after the age of 16. Death in 
BMD due to the dystrophy is not common but can occur due to cardiac failure in severely 
affected individuals. BMD clinical signs and severity varies greatly between patients. 
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Severity of disease ranges between losing the ability to walk in late teens to experiencing 
some weakness in proximal muscles or even simply cramping upon exercising (Emery 
and Mutoni, 2003).  
1.1 Skeletal Muscle  
Healthy skeletal muscle has a capacity for regeneration due to the presence of satellite 
cells, a source of muscle progenitor cells which can regulate skeletal muscle growth and 
regeneration (Mauro, 1961; Fukada et al., 2013). In DMD patient however the capacity 
for functional muscle regeneration and growth is absent (McLoon, 2008; Lu et al., 2014). 
Muscle  fibres are composed of single multinucleated cells that provide the basis for the 
locomotion of vertebrates and invertebrates. Muscle fibres can shorten and produce 
force. Myofibrils are the most basic contractile unit of muscle fibres. Myofibrils consist 
of approximately 10,000 sarcomeres attached end to end. These contractile units span 
the length of each muscle fibre and are physically attached to the sarcolemma of the 
muscle fibre (Martini 2011). The tension exerted by myofibrils on the surrounding 
extracellular matrix generates force and allows the contraction of muscle fibres (Small, 
1995). 
1.3.1 Myogenesis  
Myogenesis is the process by which the mesodermal layer of embryonic germ cells gives 
rise to muscle cells (Buckingham, 2006). Myogenesis is a highly conserved process 
among vertebrates. It involves the commitment of stem cells to Myogenic Precursor Cell 
(MPC) pools. These precursor cells then differentiate into myoblasts and migrate and 
fuse to form myofibres (Rochlin et al., 2010). 
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The myogenic process in post-natal muscle and in vitro involves the use of satellite cells 
as precursors. Satellite cells are located between the basal lamina and the sarcolemma 
of the multinucleated fibres. These cells are thought to be the foremost contributors to 
postnatal muscle growth and regeneration (Mauro, 1961; Schultz, 1996). Satellite cells 
are also the major source of primary myoblast (Partridge, 1997). During adult life, the 
absolute number of satellite cells stays relatively constant (Schultz, 1996) though there 
has been evidence of progressive loss of satellite cells more particularly in old age. With 
cycles of degeneration and regeneration in mind, this indicates that self-renewal is at 
work to maintain satellite cell pools (Zammit and Beauchamp, 2001).   
In adults, muscles have reached their adult size, and satellite cells are normally 
quiescent. However, various stimuli, such as exercise, muscle stretch, muscle injury and 
electrical stimulation, induce satellite cells to re-enter the cell cycle and take part in 
myogenesis (Schultz and McCormik, 1994; Appell, Forsberg et al., 1998).  Activation of 
satellite cells induces expression of myogenic genes, myogenic precursor cell, myoblasts, 
then differentiate and fuse with pre-existing myofibres or with each other to form new 
or replacement myofibres (Sabourin and Rudnicki, 2000). Myogenesis is a complex 
process that is tightly controlled throughout the organism lifetime. Many proteins are 
involved in signalling pathways to coordinate muscle degeneration and regeneration; 
one of the essential proteins involved is myostatin.  
1.3.2 Muscle Mass Regulation  
Muscle mass can increase through hypertrophy, an increase in myofibre size, or 
hyperplasia, an increase in the number of myofibres that, as described above, consists 
of the fusion of satellite cells. As mentioned already, the consensus is that an increase 
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in muscle mass in adulthood is mainly due to hypertrophy rather than hyperplasia as the 
general number of fibres is constant during this period. Having said this, small myotubes 
and myofibres expressing myogenic markers are found in adult muscle cells following 
training, indicating the formation of new myofibres (Kadi and Thornell, 1999). 
Change in muscle mass is measured in a change in muscle cross sectional area. It is the 
balance between protein synthesis and protein degradation that determines the muscle 
cross-sectional area (Gibson, Smith and Rennie, 1988). An increase in protein synthesis 
leads to an increase in myofibril content which is contained in larger myofibres (Velloso, 
2008). In myofibres the ratio of DNA/protein is more or less considered to be constant 
(Roy et al., 1999) and therefore, in addition to an increase in protein synthesis, 
hypertrophy requires an increase in myonuclei to maintain a constant myonuclear 
domain (Velloso, 2008). As myofibres are post-mitotic, their nuclei cannot proliferate 
and additional nuclei, when required, are provided by satellite cells (Zammit, Partridge 
and Yablonka-Reuveni, 2006).  
Many signalling pathways are involved in the regulation of muscle mass. One of the most 
important pathways is thought to be the PI3K/AKT pathway. This pathway works to 
activate protein synthesis and inhibit protein degradation. The PI3K/AKT 
(phosphatidylinositol 3-kinase/protein kinase B) pathway is activated by exercise and 
lies downstream of IGF-1 (insulin like growth factor 1) and insulin receptors; both IGF-1 
and insulin stimulate protein synthesis in muscle cells (Bolster, Jefferson and Kimball, 
2004).  
Growth Hormone (GH) is synthesised in the pituitary and leads to the synthesis of IGF-1 
in many tissues but mainly the liver and the muscle although exercise also leads to the 
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synthesis of IGF-1 in muscle. The IGF-1 in circulation is primarily secreted by the liver 
and is referred to as cIGF-1. cIGF-1 is involved in negatively regulating GH synthesis. The 
IGF-1 synthesised in muscle cells is referred to as mIGF-1 and is involved in stimulating 
hypertrophy in an autocrine/paracrine way.  
Upon secretion of mIGF-1 from muscle cells, it binds to its receptors on muscle cell 
surfaces and activates the PI3K/AKT pathway. Among isoforms of AKT it is AKT1 that is 
important in growth regulation. Upon activation, AKT1 protein degradation is 
prevented, through inactivation of FOXO (Forkhead box protein) transcription factors, 
then protein synthesis is increased through activation of mTOR1 (mammalian target of 
rapamycin). mTOR1 is downstream of AKT1 and which activates translation regulators 
leading to both ribosomal biogenesis and translation initiation (Figure 1.1) (Glass, 2005; 
Velloso, 2008). 
Furthermore, AKT is also regulated by myostatin, a negative regulator of muscle mass 
which signals to increase protein degradation. There seems to be cross talk between 
IGF-1 and myostatin activity. In normal circumstances, the IGF-1 signalling pathway is 
dominant and blocks the myostatin pathway. Having said that, it has been shown that 
upon increased expression of Myostatin the IGF-1 pathway is inhibited (Amirouche et 
al., 2009; Trendelenburg et al., 2009; Elkina et al., 2011). It is thought that in muscle 
wasting conditions, where we have a decrease in cross-sectional area of muscle, 
myostatin works to prevent AKT1 from activating mTOR1 and inhibiting FOXO 
transcription factors that lead to a reduction in protein synthesis and an increase in 
protein degradation (Elkina et al., 2011). 
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In DMD the regenerative capacity of skeletal muscle is compromised, as recurrent 
myofibre damage demands a continuous need for repair; ultimately leading to a 
depletion of  the proginator cell pool and loss of succesful muscle regenration (Lu, 
poddar 2014).Despite the presence of the dystrophin mutation at birth, DMD does not 
manifest  itself as muscle wekaness untill 3-5 years of age coinciding with the depletion 
of  proginator cells. Below we will discuss the  clinical and pathological features of DMD. 
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Figure 1.1 IGF-1 regulation of muscle growth through AKT growth axis 
IGF1 binding to receptors on muscle cell surfaces initiates AKT signalling, leading to 
muscle growth. PI3K, activated by IGF1 binding its receptor, phosphorylates AKT. 
Phosphorylated AKT leads to the inhibition of FOXO-induced protein degradation and 
also activates the mTOR complexes which leads to protein synthesis. (Adapted from 
Vellos et al., 2008.) 
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1.2 Clinical and pathological features of Duchenne muscular dystrophy  
Clinically, symptoms in DMD are split into four phases: early phase; late childhood; 
adolescence and adulthood.  
1.2.1 Early Phase  
This phase starts at birth and ends at age eight. Boys will usually start walking late and 
also struggle in performing simple motor tasks and find difficulty in keeping up with 
friends when playing. One clinical feature of DMD at this phase is increased Serum 
creatine kinase (CK), at between 20 and 100 times normal levels, which reflects 
degeneration (Sun, Peng and He, 2008). CK, made in the degenerating muscle, is 
released into the serum as the muscle degenerates; levels peak in 3-5-year-olds. CK 
levels then decrease with age and this may be due to decreased activity of the boys as 
they become less able to move and also due to increased fibrosis as muscle is replaced 
with fibrotic tissue and hence less muscle is available to produce CK. One characteristic 
clinical feature seen in DMD boys is the Gower’s manoeuvre which is where boys in a 
sitting position will use their hands to push down on the floor and then climb up their 
thighs in order to extend their hip and trunk in helping them stand (Figure 1.2). This is 
due to weakness in the knees and hips preventing young boys from being able to stand 
up without help from their hands. Another feature seen in young boys with DMD is 
walking on their toes. This is a reaction to a lack of balance from lumbar lardosis which 
develops as compensation to gluteal maximum weakness (Figure 1.3) (Emery, 1993). 
Lumbar lardosis is in turn exaggerated by the toe walking seen in these children. 
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1.2.2 Late childhood phase  
This stage usually refers to features seen between the age of 6-13. At this phase, an 
increase in contractures is seen in the lower extremities along with decreased muscle 
strength. There is an increase in the frequency of falling over, and it is in this phase that 
the ability to walk is severely affected and even lost. The decrease in muscle strength 
leads to a more exaggerated lumbar lardosis.  
1.2.3 Adolescence phase  
This phase occurs between 8-15 years of age. Patients get fully dependent on 
wheelchairs as there is a significant loss of skeletal muscle strength and a rapid increase 
in joint contractures. Severe kyphoscolisosis, a curvature of the thoraco-lumbar spine, 
can develop in this phase due to a lack of necessary support in the wheelchair (Figure 
1.3). If the kyphoscolisosis progresses beyond 20-30 degrees, it will continue to progress, 
and this progression is associated with a decline in cardiac and pulmonary function.  
Figure 1.2 Gowers Manoeuvre  
Characteristic feature seen in early phase of DMD patients where the child uses his hand to 
press on the floor and then climb up his thigh to stand up (figure from Emery 1993) 
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Figure 1.3 Genetic inheritance of DMD Progression of orthopaedic clinical features in DMD 
boys  
Lumbar lordosis develops in the early phase between the age of 3-8 and gets exaggerated with 
age. When wheelchair bound in adolescence phase extreme kyphoscoliosis commonly occurs 
(Adapted from Greene et al., 2006). 
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1.2.3 Adulthood  
It is in the adulthood phase when symptoms become life-threatening in DMD patients. 
In this phase, deterioration of the myocardium, due to cardiac muscle necrosis and 
fibrosis, becomes a threat to heart failure. Around 90% of patients show cardiac 
manifestations of DMD and only a decade ago many boys would die before the age of 
20 from respiratory failure (McDonald et al., 1995). In the last decade, improved care 
and improved access to appropriate equipment and ventilation have increased this life 
span by up to 10 years (Eagle et al., 2016).  
1.3 Dystrophin  
1.3.1 Dystrophin gene 
Dystrophin has the longest gene in the human genome with a length of 2.4 Mbp 
consisting of 79 exons and 8 tissue-specific promoters (Giacca, 2010). It was first 
discovered in 1987 and localised to band Xp 21 on the human X chromosome (Hoffman, 
Brown and Kunkel, 1987). The gene takes 16 hours to be fully transcribed and once 
spliced makes a 14kb mRNA, 11kb of which codes for the 427 kDa dystrophin protein 
made of 3685 amino acids. The dystrophin gene is mainly expressed in skeletal muscle, 
heart and cortical neurons. 
1.3.2 Dystrophin protein  
The dystrophin protein (427 kDa) is a very long filamentous protein located on the 
cytosolic side of the plasma membrane of striated muscle fibres (Sarcolemma).  The 
protein is in particular concentrated around neuromuscular junctions (Giacca, 2010) and 
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is made of 4 structural domains: the N terminal region (actin binding domain, ABD), a 
central rod domain made of a series of repeats each composed of 3 α-helix bundles, a 
cysteine-rich domain (CR) and the C terminal domain (CT) (Figure 1.4A). The N terminal 
region binds to actin filaments; the CR domain is essential for binding and localises to 
the sarcolemma through the dystrophin-associated glycoprotein complex (DGC) (Figure 
1.4B). The DGC connects the internal cytoskeleton to the extracellular matrix hence 
stabilising the sarcolemma while muscle fibres stretch or shorten (Giacca, 2010). Other 
than a structural role, dystrophin and DGC also contribute to intracellular processes such 
as maintaining the intracellular calcium levels (Niebroj-dobosz et al., 2001). 
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Figure 1.4 Dystrophin and the dystrophin glycoprotein complex  
A) Dystrophin protein is made of 4 structural domains: the N terminal region (actin 
binding domain, ABD), a central rod domain made of a series of repeats each 
composed of 3 α-helix bundles, a cysteine rich domain (CR) and the C terminal 
domain (CT).  
B) The N terminal region binds to actin filaments, the CR domain is essential to bind 
and localises to the sarcolemma through the dystrophin associated glycoprotein 
complex (DGC) 
C) In patients with DMD the dystrophin protein is significantly reduced in quantity or 
the CT domain is missing. In BMD patients the ABD domain and CT domain are intact 
but there are deletions present in the central rod domain. (Figure adapted from 
Giacca, 2010).  
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1.3.3 Dystrophin in DMD 
Dystrophin has been shown to be absent or greatly diminished in the muscle of patients 
with Duchenne muscular dystrophy (McArdle, Edwards and Jackson, 2016). The absence 
of dystrophin leads to the lack of a link between contractile actin and the cell membrane. 
This has been shown to correlate directly with a clear reduction in the DGC proteins. 
This, in turn, disrupts the link between the subsarcolemmal cytoskeleton and the 
extracellular matrix. The lack of membrane integrity leads to a ‘leaky membrane’ and so 
unregulated transit of extracellular calcium into the cytoplasm of muscle cells; this 
considerable rise in calcium levels lead to activation of calcium-dependent proteases 
such as calpains and activation of inflammatory and necrotic signalling pathways 
(Spencer, Croall and Tidball, 1995). Dystrophin-deficient muscle is therefore constantly 
undergoing inflammation, death and fibrosis (Matsumura, Campbell and Nonaka, 1993). 
As mentioned in previous sections the presence of satellite cells means the muscle fibres 
can regenerate, but the new muscle is also dystrophin-deficient and so with every cycle 
of death and regeneration the extent of fibrosis within the muscle increases (Figure 1.5) 
(Wehling, Spencer and Tidball, 2001).  
Several mutations have been identified in the dystrophin gene. Two third of patients 
have deletions in two vital areas of the gene, the first 20 exons and exon 45-53. The 
remaining third of patients have point mutations introducing stop codons, frame shifts, 
modification of splicing signals and some are present in the promoter region of the gene. 
In patients with DMD, the dystrophin protein is significantly reduced in quantity, or the 
CT domain is missing. In BMD patients, the ABD domain and CT domain are intact, but 
15 
 
central rod domain allows the production of a shorter yet functional protein, translated 
from an in-frame transcript as oppose to an out of frame transcript seen in DMD, and 
explains the milder phenotype observed in BMD patients compared to DMD patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5 Cycle of damage in dystrophin deficient muscle  
Lack of dystrophin leads to membrane instability which in turn allows calcium influx and 
activation of calcium dependent proteases and inflammatory and necrotic pathways. Cell 
death is followed by muscle replacement using present satellite cells leading to depletion of 
satellite pools. New muscle fibres are also dystrophin-deficient and so undergo the same cycle 
of calcium influx and cell death. Chronic inflammation and necrosis leads to fibrosis and 
replacement of muscle fibres with fatty fibrous tissue.  
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1.4 Utrophin  
In 1989, utrophin, a 400kDa dystrophin-related protein, was discovered on chromosome 
6 (Love et al., 1989). Utrophin has been found to be expressed in all tissues and is 
expressed in DMD patients at elevated levels (Feener, Koenig and Kunkel, 1989; Koenig 
et al., 1989). Utrophin was found to be enriched at neuromuscular junctions where it 
binds components of the DPAC including dystroglycans and syntrophins allowing the 
connection of the intracellular cytoskeleton to the extracellular matrix. Primary 
sequence and protein structure similarities between utrophin and dystrophin led to an 
interest in up-regulation of utrophin for therapeutic purposes in DMD patients.  
1.5 Animal models for DMD 
Following the identification and characterisation of dystrophin and its mutations in DMD 
patients, animal models were identified to resemble DMD in that they lack dystrophin 
and that skeletal muscle fibres undergo the cycle of damage involving fibrosis, necrosis 
and replacement (Partridge, 1991). The most beneficial models in the field are mouse, 
dog, cat and most recently, rat.  
1.5.1 Golden Retriever (GRMD dog) 
The GRDM golden retriever carries a mutation in the dystrophin gene leading to the 
exclusion of exon 7 of the protein. The GRMD dog shows the most similarity to DMD out 
of all the models. The neonatal dog shows a severe phenotype with muscle weakness 
followed by progressive loss of muscle tissue and the development of fibrosis. 
Investigation of disease pathology in the GRMD dog showed the presence of early fibre 
necrosis and regeneration resulting in severe myopathy (Valentine et al., 1990).  
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1.5.2 Mouse (mdx mouse)  
The mdx mouse is one of the most frequently used animal models in DMD research. This 
is due to similar pathological features between the mdx mouse and DMD patients as 
well as advantages such as short breeding time and low cost.  
The mdx mouse was first reported by Bulfield et al. (1984) as a spontaneous mutation 
in a C57BL10Sc/Sn(C57) colony of mice. This has made C57 a very good control when 
using mdx mice as a model. The genetic defect in these mice is a point mutation in exon 
23 of the dystrophin gene giving rise to a premature stop codon (Sicinski et al., 1989).  
In the mdx mouse the muscle membrane is damaged due to lack of dystrophin. This 
leads to an influx of calcium by the cells and so over-contraction of muscle fibres and 
activation of intracellular proteases (Porte, Morin and Koenig, 1999). Between 3 weeks 
to 18 months, muscle fibres show cycles of degeneration and regeneration as well as 
necrosis (Pastoret and Sebille, 1995). mdx mice also show replacement of muscle with 
connective tissue and fat due to necrosis and the inadequacy to regenerate healthy 
muscle fibres; unlike human patients, these mice show fibrosis at very late stages of the 
disease (Zeman et al., 2000) . The fibrosis evident in the mdx mouse is first present in 
the diaphragm (Stedman et al., 1991) and in the limbs towards the end of the second 
year of the mouse’s life (Pastoret and Sebille, 1995).  
The mdx mouse also shows similar cardiac parameters to that observed in DMD patients 
(Bridges, 1986; Chu et al., 2002). Cardiac muscle in these mice shows myocardial lesions 
accompanied by necrosis, macrophage infiltration and inflammation.  Cardiomyocytes 
in mdx mice of 8-10 weeks have a reduced threshold for development of sarcolemmal 
injury under mechanical stress. At 12-14 weeks the pathophysiology of the mdx 
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myocardium is evident from altered contractile function (Sapp, Bobet and Howlett, 
1996; Danialou et al., 2001). 
1.5.3 Feline (FXMD cat) 
The feline X-linked muscular dystrophy is a dystrophin-deficient model characterised by 
muscular hypertrophy. This model is not often used in DMD research as it never 
exhibited loss of muscle mass and muscle maintains its contractile strength. In addition, 
although there is some fibrosis present in the dystrophic cat, no fatty infiltration is 
observed, unlike the mdx and GRMD models (Porte, Morin and Koenig, 1999). 
1.5.4 Rat (dmdmdx rat) 
In 2014, two lines of Duchenne muscular dystrophy rats were generated using TALENs 
targeting exon 23 of the rat dystrophin gene (Larcher, Lafoux, Tesson, Remy et al., 2014) 
.At 3 months of age, the limb and diaphragm muscles of the dmdmdx rats show 
considerable necrosis and regeneration, and by 7 months of age, severe fibrosis and 
adipose tissue infiltration are displayed. Cardiac parameters in the Duchenne rat is also 
comparable to that of DMD patients with signs of dilated cardiomyopathy accompanied 
by necrotic and fibrotic changes. The rat is, therefore, a relatively new but promising 
small animal model of DMD. 
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1.6 Treatment strategies for Duchenne muscular dystrophy  
There are a variety of treatment options for DMD patients. Most treatments in use are 
directed at controlling symptoms though there are numerous research projects as well 
as clinical trials in the development of genetic drugs that address the cause of Duchenne 
muscular dystrophy.  
1.6.1 Glucocorticoids 
One of the most important medications in use for DMD patients are glucocorticoids such 
as prednisone (Merlini et al., 2003) and its derivative deflazacort (Campbell and Jacob, 
2003). Glucocorticoids have been shown to increase muscle function and strength 
significantly but have some severe side effects associated with them such as weight gain 
and lenticular cataracts (Griggs et al., 1993) as well as psychological side effects such as 
difficulty concentrating, sleeping and controlling emotions.  
There are several modes of action proposed for the mechanism of action of 
glucocorticoids. The first mode of action is thought to be due to glucocorticoid anti-
inflammatory actions; prednisone, for example, has shown to decrease the total T cell 
number as well as cytotoxic cells (Kissel et al., 1991). It is thought that the decrease in 
concentration of inflammatory cells causes an immunosuppressive effect and so slows 
down the rate of muscle degeneration (Wehling-Henricks, Lee and Tidball, 2004). 
Another mode of action could be a decrease in the calcium influx and size of calcium 
pools in the dystrophic muscle fibres which was shown by Matzinger et al. (1995) using 
prednisone. Prednisone has also been shown to enhance the myogenesis of satellite 
cells and increase dystrophin-related protein expression in mdx skeletal muscle cell 
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cultures (Passaquin et al., 1993). mRNA levels of structural, signalling and immune 
response genes are changed after steroid treatment which also helps explain how 
steroid-induced gene expression may improve strength (Mutoni et al., 2002).  
1.6.2 Gene therapy  
Duchenne muscular dystrophy is an attractive candidate for gene therapy since it is 
caused by a single gene mutation. Many advances have been made in developing a 
primary therapy for DMD, but they still remain unsuccessful (Konieczny, Swiderski and 
Chamberlain, 2013) with current trials showing extremely promising results such as that 
reported by Serepta therapeutics on the SRP-4045 resulting in significant dystrophin 
expression in DMD boys. Gene therapy in DMD faces many challenges such as the mode 
of delivery to affected muscles, overcoming immune challenges to technique and 
introduced genetic material, as well as deciding upon what technique is best. It is also 
important to mention that other than the amount of dystrophin delivered the efficiency 
of therapy is also very dependent on the pathological features of the disease and so the 
stage of the disease. In patients were the disease has progressed to the point where 
most muscle fibres are replaced with fatty deposition access to dystrophic muscle 
limited and efficiency of gene or cell therapy to restore dystrophin is compromised 
(Kharraz et al., 2014).  
As mentioned previously, the dystrophin gene is the biggest gene in the human genome 
and so delivering such a big gene is one of the greatest challenges in gene therapy for 
DMD. A lot of effort has gone into developing shorter yet functional dystrophin 
constructs, similar to those seen in BMD patients, which can be used in instead of 
dystrophin in DMD patients (Konieczny, Swiderski and Chamberlain, 2013). Following 
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the generation of transgenic mice that carried dystrophin constructs lacking various 
domains, it was shown that the majority of the rod domain and the C-terminal domain 
are not essential for dystrophin function (Wang, Li and Xiao, 2000; Sakamoto et al., 
2002; Gregorevic et al., 2006). Following this discovery mini-dystrophin and micro-
dystrophin constructs (Figure 1.6) are now being tested using both viral and non-viral 
modes of delivery as potential therapies for DMD.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6 Mini and micro-dystrophin  
This figure shows one mini-dystrophin and 3 micro-dystrophins found to compensate 
for the lack dystrophin in DMD animal models. The spectrin-like repeat of these 
proteins is indicated and compared to wild type protein (Figure taken and modified 
from DMDHelp.org). 
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1.6.2.1 Viral vector-based gene addition therapy   
1.6.2.1.1 Lentivirus  
Murine retroviral vectors were the first vectors to be tested in gene addition therapy for 
DMD (Konieczny, Swiderski and Chamberlain, 2013). These vectors were capable of 
successfully transducing proliferating myoblasts. Mdx mice were injected with this 
vector containing a mini-dystrophin construct, and only a small portion of fibres at the 
injection site expressed the construct (Dunckley et al., 1993). Due to this poor outcome 
with murine retroviral vectors, new retroviral vectors were generated based on human 
or feline lentiviruses (Konieczny, Swiderski and Chamberlain, 2013). The lentivirus has a 
capacity of approximately 8kb and efficiently transduces non-cycling cells including 
muscle fibres (Naldini et al., 1996; Kafri et al., 1997). Lentiviral delivery of a GFP-
dystrophin fusion was shown to be successful in both skeletal muscle and resident 
satellite cells when injected into neonatal mdx mice (Kimura et al., 2009). With all of this 
said, lentiviral vectors have a high chance of inducing an immune response when used 
in high doses, which would be required for transduction in humans. Another problem 
with the use of lentiviral vectors is their ability to integrate into the host genome, and 
this gives rise to the risk of insertional mutagenesis (Konieczny, Swiderski and 
Chamberlain, 2013).  
1.6.2.1.2 Adenovirus 
Adenoviruses are medium-sized, non-enveloped viruses that carry a double-stranded 
DNA genome. The wild type adenovirus has a capacity of approximately 35kb 
(Konieczny, Swiderski and Chamberlain, 2013). Adenoviruses can successfully transduce 
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both dividing and non-dividing cells, and this makes them attractive for the treatment 
of muscle fibres (Dai et al., 1995). Furthermore, adenoviral infection with the most 
common serotype has shown minimum pathogenicity in human populations and is 
therefore considered safer than lentiviral vectors.  
First- and second-generation adenoviral vectors were constructed and modified to have 
a capacity of 8kb. A first-generation adenoviral vector was the first vector to successfully 
deliver a miniaturised human dystrophin cDNA into mdx mice (Ragot et al., 1993). 
Following this, first- and second-generation adenoviral vectors showed leaky expression 
of remaining viral proteins in vivo, leading to a host immune response (Konieczny, 
Swiderski and Chamberlain, 2013).  
To improve the adenoviral vector delivery technique viruses were ‘gutted’, where the 
vector backbone was eliminated of all viral coding sequences, allowing the vector to 
carry the whole dystrophin gene (Haecker et al., 1996). These vectors have reduced the 
immune response, improved transgene expression and a larger transgene carrying 
capacity (Schiedner et al., 1998). Despite the improvements in these vectors, 
neutralising antibodies were found to be produced against them straight after first 
administration, preventing repetitive administration, which makes them of no use in the 
case of humans where repetitive administration is required for persistence and long-
term transduction (Morral et al., 1999). Therefore, improvements are required to make 
the use of adenoviral vectors safe in gene therapy.  
1.6.2.1.3 Adeno-associated virus (AAV) 
Another common vector used in gene therapy are the adeno-associated vectors. Many 
AAV vectors efficiently transduce skeletal muscle fibres, and the resulting gene 
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expression can be persistent for years in healthy muscle (Gilbert et al., 2003). Several 
serotypes of AAV even have a natural tropism for skeletal muscle (Schultz and 
Chamberlain, 2008). Recombinant AAV (rAAV) vectors have all their viral genes deleted. 
rAAV vectors are good candidates for gene therapy in DMD, but their limited capacity is 
the limitation. This limitation has led to them being used to deliver micro or mini 
dystrophin genes shown to be successful in neonatal and adult mdx mice(Gregorevic et 
al., 2004). Other approaches such as trans-splicing also make use of the rAAV. Here the 
gene is split into two one with a splice donor and one with splice acceptor site. They are 
delivered using different vectors co-transfected in cells (Lai et al., 2005; Liu et al., 2005). 
This method potentially enables rAAV-mediated delivery of full-length dystrophin, 
though this would require three vectors. 
Several clinical studies have been initiated to test the safety and tolerability of AAV 
micro-dystrophin which have shown very promising results in preclinical data 
(Chamberlain, 2017) 
1.7.2.2 Non-viral gene therapies  
1.7.2.2.1 Unencapsulated plasmids  
In the early nineties, it was reported that gene expression could be achieved by injection 
of naked plasmid DNA (Wolff et al., 1990). The simplicity, low cost and safety of this 
method outweighed the low initial efficacy of gene transfer it showed, and so it became 
very attractive for further investigations and optimisations. Mdx mice were injected with 
plasmids (both locally and systemically) and have shown expression of dystrophin 
persisting 6 months as well as an increase in peripheral nuclei indicating increased 
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muscle regeneration (Liang et al., 2004). A clinical trial was carried out with a group of 9 
Duchenne and Becker patients ({Romero, Norma B and Braun et al., 2004). Plasmids of 
full-length dystrophin were injected into the radial muscle of patients. Using low dose 
injections 6 patients showed moderate dystrophin expression. Further to this, no 
adverse effects were observed from the treatment.  
Although it was shown that dystrophin positive fibres were stable in mdx mice following 
intra-arterial delivery the number of plasmid DNA molecules decreases over 
time(Molnar et al., 2004; Sandri et al., 2004). In order to prevent this limitation of 
plasmid DNA decreasing over time it was suggested that co-administration of the 
plasmid with phage integrase could mediate the integration of plasmids into the 
mammalian genome(Bertoni et al., 2006). The study carried out by Hence, Bertoni et al. 
showed sustained higher levels of dystrophin expression. However the risk of insertional 
mutagenesis limits the application of this approach (Maherali, 2007).  
1.7.2.2.2 Antisense oligonucleotide-induced modulation of splicing  
Pre-mRNA Splicing  
The main focus of this thesis will be using small antisense oligonucleotide (AON) 
reagents to modulate gene expression either through masking of key regulatory 
elements such as the polyA signal or through modulating splicing of pre-mRNA to disrupt 
the translational reading frame. The mechanisms of pre-mRNA splicing will initially be 
discussed  
The mammalian genome is made up of short exons (50-300 nucleotides) with longer 
intronic sequences in between (Black, 2003). Exons are defined by 5’ splice sites, which 
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act as splice donor sites, the branchpoint followed by a pyrimidine-rich region and the 
3’ splice site, which acts as a splice acceptor site  
 In a mature mRNA, introns are spliced out, and exons are joined together. This process 
occurs in pre-mRNA and is catalysed by the spliceosome complex made up of small 
nuclear RNAs (snRNA) and 50-100 non snRNP (small nuclear ribonucleoproteins) factors. 
The snRNAs work by binding to the pre-mRNA sequence and identify the 5’ splice site, 
branch point and 3’ splice site. There are no strong splice consensus sequences 
identified (Cartegni et al., 2002).  
Initially, an early complex is formed on the pre-mRNA; it is made up of the U1 snRNP 
binding to the s5’ splice site, the U2 snRNP auxiliary factor (U2AF65) binding to the 
pyrimidine-rich region, and U2AF35 to the 3’ splice site (Mollet et al., 2006). U2AF65 then 
recruits U2 snRNP to the branch point, leading to U1 being displaced by a U4-U5-U6 
snRNP complex forming the B complex. U4 is then displaced forming the catalytically 
active spliceosome C complex with U6 snRNP interacting with U2 snRNP. This is followed 
by two transesterification reactions which join the two exons together and release the 
intervening intron in a branched lariat structure (Black, 2003). The intron is very shortly 
after splicing dissociated from the snRNPs and degraded; snRNPs, on the other hand, 
are recycled and used in a new round of splicing. The spliced pre-mRNA then undergoes 
3’ end processing where a polyA tail is added to the 3’end (for more detail see section 
1.3). The mature mRNA is then exported out of the nucleus into the cytoplasm to 
undergo translation (Proudfoot, et al, 2002).  
As mentioned, splice donor and acceptor sites are very weakly defined (Zhang, 1998). 
Additional sequences in the exons are used in order to distinguish correct splice sites 
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from pseudo splice sites, which are very similar to splice sites but are never used, 
(Faustino and Cooper, 2003). These additional sequences are termed exonic splicing 
enhancers (ESE) and exonic splicing silencers (ESS).  
ESEs are located 80-120 bases away from exon splice acceptor sites. ESEs bind SR 
(serine/arginine-rich) proteins to enable exon recognition (Wu et al., 2005). At weakly 
defined exons, SR proteins bind to ESE sequences and recruit snRNPs, aiding the 
initiation of splicing but not directly participating in the splicing mechanism (Wong et 
al., 2005; Cortegni et al., 2002). 
ESS sequences interact with negative regulatory proteins such as heterogeneous nuclear 
ribonucleoprotein (hnRNP) (Cartegni et al., 2002).  
Pre-mRNA can also be alternatively splices leading to several different isoforms of the 
gene. In these cases, the pre-mRNA contains certain exons that are always required to 
be included in the transcript to maintain the reading frame, as well as alternatively 
spliced exons which can be spliced and not disrupt the reading frame (Black, 2003). 
15% of point mutations that lead to human disease cause splicing defects, and though 
the mutations can be some distance away from the splice site they often alter ESE 
sequences, disrupting splicing (Krawczak et al., 1992).  
Antisense oligonucleotide reagents 
Antisense oligonucleotides (AON) are synthetic, short nucleic acids that are made 
complementary to target sequences and hence bind RNA or DNA through Watson Crick 
base pairing. (Danckwardt, Hentze and Kulozik, 2008; van Roon-Mom and Aartsma-Rus, 
2012). The use of AONs to target the pre-mRNA is one of the most widely studied gene 
therapy approaches used, particularly in the correction of aberrant splicing or the 
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restoration of the functional reading frame (Figure 1.8). In addition to this AONs can also 
be used to knockdown or reduce the expression of a gene by skipping an out of frame 
exon (Veltrop and Aartsma-Rus, 2014) or skipping a fundamental regulatory sequence.  
Regular RNA and DNA oligonucleotides are rarely used as alternative AON chemistries. 
Alternative chemistries (Figure 1.7) have been designed to improve affinity, increase 
stability in circulation and target cells and augment cell penetration and nuclear 
accumulation (Siva, Covello and Denti, 2014).  
Phosphorothioate (PS) AONs have a sulphate atom in place of the non-bridging oxygen 
in the phosphate backbone. PS AONs have increased cellular uptake and resistance to 
nucleases but have decreased the affinity of AON to its target (Siva, Covello and Denti, 
2014). 
2’OMe and 2’OME have been synthesised by the addition of a methyl or methocyethyl 
group respectively. This modification renders the RNA-AON hybrid RNase H-resistant 
and also increases the affinity of the AON to its target (Sproat et al., 1989). Most AON in 
this study has both the PS and the 2’O modification giving rise to both 2’OMe-PS and 
2’O-MOE-PS. These AONs have a good safety profile and are relatively cheap to 
synthesise. 2’OMe-PS were the first AONs to be used for dystrophin exon-skipping in 
cultured primary muscle cells from mdx dystrophic mice (Dunckley et al., 1998). 
Another type of AON is the locked nucleic acid or LNA. The AON is made by the addition 
of a methylene bridge that connects the 2’O and the 4’Cof the ribose, clamping the 
nucleotide in the ‘endo’ formation. These LNAs have a high affinity for target nucleic 
acid but a low specificity. To increase specificity, a mixture of LNA and DNA backbone 
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sequence or LNA and 2’OMe backbone are used (Fabani and Gait, 2008; Siva, Covello 
and Denti, 2014).   
Not all antisense oligonucleotide chemistries are negatively charged like the ones 
already discussed. Peptide nucleic acids (PNAs) and phosphorodiamidate morpholino 
oligomers (PMOs) are charge neutral AON.  Both these AONs are resistant to exo- and 
endonucleases as well as RNase H-cleavage (Siva, Covello and Denti, 2014). PNAs have 
a high affinity to RNA and DNA targets and increase sequence specificity (Egholm et al., 
1993).  
PMOs contain morpholine rings that are connected through phosphorodiamidate 
groups. PMOs are usually longer that 2’OMe-PS AONs due to their marginally lower 
affinity (Siva, Covello and Denti, 2014). A study by Schmajuk and colleagues 
demonstrated that an 18-mer PMO was more effective than a corresponding 18-mer 
2’OMe-PS (Schmajuk, Sierakowska and Kole, 1999). Gebski and colleagues 
demonstrated that a 25-mer PMO targeting the dystrophin gene in the mdx mouse 
achieved higher exon skipping and dystrophin expression compared to the identical 
2’OMe-PS version of the AON (Gebski et al., 2003). A 30-mer PMO targeting exon 51 has 
proven to be successful in intramuscular clinical trials (Kinali et al., 2009a) (Figure 1.8). 
IV administration of PMO chemistries are currently in clinical trials and showing 
promising results. Another clinical trial was also conducted using 2’OMePS targeting 
exon 51 of the dystrophin gene ( van Deutekom et al., 2007). This trial was successful 
with patient biopsies after 4 weeks showing restoration of dystrophin in 64-97% of 
myofibres. The trial was discontinued due to limited efficacy after 5 weeks of treatment. 
Eteplirsen, a PMO targeting dystrophin exon 51, has received FDA approval (Rus and 
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Krieg 2016) . There are currently other PMOs targeting exon 52 and 45 in clinical trials 
(Motohashi et al 2019) 
 
Due to their neutral charge, PMOs are difficult to transfect. Various cell-penetrating 
peptides have been designed to be conjugated to PMOs, generating pPMOs, and 
facilitate the delivery into cells ex vivo and in vivo (Siva, Covello and Denti, 2014).
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Figure 1.7 Antisense oligonucleotide chemistries  
The figure shows the backbone of two adjacent nucleotides in natural DNA and in 
various types of modified oligonucleotides. For phosphorothioate (in yellow 
background) and second and third generation chemistries (in purple background) 
relevant modifications over natural DNA are shown in red (Figure from Li, Tan, Kooger, 
Zhang et al.,  2014). 
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Figure 1.8 Exon 51 skipping therapy in DMD patients  
An example of exon skipping to restore the reading frame of dystrophin in 
patients with a deletion of exon 50. A is a normal dystrophin transcript and 
mRNA. B shows deletion of exon 50 which disrupts the reading frame, 
leading to a premature stop codon, unstable mRNA and a truncated 
unstable protein. C portrays targeted skipping of exon 51 using antisense 
oligonucleotides (blue line), restoring the reading frame and producing a 
truncated but functional dystrophin that lacks exon 50 and 51 (Image from 
Sugita and Takeda, 2010). 
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1.7 Fibrosis and DMD 
Most emphasis in therapeutic research of muscular dystrophy has been placed on 
correcting the genetic fault causing the disease in the case of DMD the correction of 
dystrophin expression. Little attention has been given to understanding and modifying 
the pathological background of the disease. Recently, therapeutic research has shown 
that the pathogenesis of the well-developed fibrosis and fat replacement affecting the 
muscle has a big impact on the outcome of treatment for restoring dystrophin 
expression. It is now well established that many of the pathological features of DMD are 
not only caused by the lack of dystrophin and/or the failure of satellite cells but are also 
due to the complex interactions of these cells with the surrounding environment 
(Kharraz et al., 2014). 
It is commonly assumed that the proliferation of connective tissue is a secondary 
phenomenon and even a compensatory mechanism in DMD patients for the lack of 
muscle regeneration. In contradiction, many researchers have reported an increase in 
endomysial tissue volume before any apparent muscle degeneration. It has been 
suggested that the increase in collagenous connective tissue could be a significant co-
determining factor in DMD pathology including an adverse effect on the nutrition of the 
enclosed muscle cells (Bell and Conen, 1968; Duance et al., 1980). A study was carried 
out over 10 years on 25 DMD patients examining the correlation of the severity of the 
pathology and the different pathological features including myofibre atrophy, necrosis 
and fatty degeneration. The study showed that endomysial fibrosis was the only 
myopathologic parameter that significantly correlated with poor motor outcome 
(Desguerre et al., 2009). In DMD, membrane instability of muscles leads to constant 
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myofibre breakdown which is not compensated for by satellite cell proliferation. 
Inflammation following muscular necrosis leads to fibrotic remodelling of tissue and 
fatty cell replacement (Klingler et al., 2012). These changes in the environment can delay 
existing muscle repair and regeneration and further enhance inflammation leading to 
disease exacerbation and further fibrosis development.  
Fibrosis refers to the unregulated and excessive deposition of extracellular matrix (ECM) 
components. During normal repair and growth, there is a regulated and controlled 
deposition of ECM components, but excessive and uncontrolled deposition can lead to 
the replacement of tissue with fatty cells and loss of tissue function. In the case of DMD, 
there is an additional problem to loss of muscle function because of fibrosis, which is 
the loss of muscle fibres which can be targets for therapy and repair. It is therefore now 
clear that in order to treat DMD we also need to understand, address and treat fibrosis 
in this disease.  
1.7.1 Molecular mechanism of fibrosis in DMD 
1.7.1.1 Cation influx  
Due to the lack of dystrophin and membrane instability in muscle fibres of DMD patients 
the cells have decreased resistance to mechanical shear and are prone to the excess 
influx of electrolytes such as calcium and sodium. The increase of intracellular sodium 
levels leads to ATP depletion as the Na+/K+ pumps must work to their full capacity in an 
attempt to restore homeostasis. Water molecules follow sodium into cells, and this 
leads to cellular oedema (Klingler et al., 2012). At rest, the extracellular calcium 
concentration exceeds the cytoplasmic calcium concentration by a factor of 10,000. This 
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Figure 1.9 From dystrophin deficiency to fibrosis 
Muscle fibre membranes lacking dystrophin are more vulnerable to mechanical and 
oxidative stress. Overuse and overstrain leads to activation of stretched activated cation 
channels. The high influx of sodium and calcium is not compensated for by pumps and 
so leads to oedema. The Oedema and calcium overload lead to energy depletion. 
Calcium a cascade of inflammatory processes. Further stress on the muscle membrane 
and activation of cation channels occurs. This leads to unsustainable cellular integrity. 
Myofibre necrosis and inflammation finally lead to tissue remodelling and fibrosis.  
leads to calcium overload which causes mitochondrial uncoupling and reactive oxygen 
species (ROS) production (Klingler et al., 2012). All these changes lead to downstream 
effects such as necrosis, accumulation of acidic metabolites and amplification of 
inflammatory substances such as cytokines (Klingler et al., 2012)  (Figure 1.9).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
oedema 
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1.7.1.2 Acidosis induced tissue damage 
Lactic acid produced by the dystrophic muscle breaks down into lactate (La-) and H+ at 
physiological pH. La- in return increases collagen (a key component of the ECM) 
promoter activity leading to an increase in procollagen messenger RNA production and 
collagen synthesis (Trabold et al., 2003). La+ also causes an increase in vascular growth 
factor (VEGF) production in macrophages (Trabold et al., 2003; Klingler et al., 2012).  
1.7.1.3 Fibrous tissue production  
Fibrous tissue consists of extracellular fluid containing fibronectin, glycosaminoglycans 
and proteoglycans, in addition collagen fibres and elastin is also present in the ECM. 
Mechanical stimuli as well as chemotaxis is known to initiate the production of fibrous 
tissue (Klingler et al., 2012). The main cells present in fibrous tissue are fibrocytes and 
myofibroblasts. Precursor cells differentiate into these cells with different stimuli (Figure 
1.10). Fibrocytes and myofibroblasts are present for the short term during tissue repair 
such as that in wound healing. In DMD, myofibroblasts are persistently activated due to 
the continuous presence of stimuli as myofibres continue to break down. This results in 
an altered ECM. The composition of the ECM produced in fibrosis is different from that 
seen in healthy tissue, and the components mainly originate from myofibroblasts. In the 
early stages of fibrosis, the ECM has a high content of fibronectin and hyaluronan. This 
creates a much-hydrated matrix which aids cell migration to the area. This provisional 
matrix is then replaced with a denser ultrastructure (Kjær et al., 2009; Klingler et al., 
2012). There are various growth factors and cytokines involved in the process of fibrosis; 
some key players are discussed here. 
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1.7.1.3.1 Transforming growth factor β (TGF-β) 
Transforming growth factor β (TGF-β1) is one of the most important profibrogenic 
factors that not only stimulates ECM component transcription but also leads to fibrocyte 
and myofibroblast differentiation (Bowen, Jenkins and Fraser, 2013). Latent TGF-β1 is 
stored in the ECM where it is activated upon tissue damage or by other growth factors 
(Horiguchi, Ota and Rifkin, 2012). TGF-β1 is expressed in regenerating muscle after injury 
and in dystrophic muscle of DMD patients and mdx mice (Zhou et al., 2006; Ardite et al., 
2012; Kharraz et al., 2014). Here TGF-β1 stimulates fibroblasts to produce ECM proteins 
like collagen and fibronectin as well as proteins required for ECM deposition such as 
periostin (POSTN). TGF-β1 and other profibrogenic polypeptides can also be produced 
by infiltrating immune, inflammatory, mesenchymal and tissue-specific cells (Wynn, 
2008; Kharraz et al., 2014).  
TGF-β1 is known to signal through the canonical TGF-β1 signalling pathway or other 
alternative pathways (Figure 1.10). It has been shown that the extent of signalling 
through these different pathways modulates fibrotic effect. In fibroblasts, the canonical 
signalling pathway works through phosphorylation of Smad2 and 3 which then bind to 
Smad4 to form a complex targeting the nucleus and activating transcription of 
profibrotic genes (Wynn, 2007; Samarakoon et al., 2013; Kharraz et al., 2014). TGF-β can 
also signal through Ras/MEK/ERK, P38 MAPK, c-abl, and NJK pathways (Shi and 
Massague, 2003). Signalling through these pathways changes gene expression in a 
promoter selective fashion. For example, signalling through ERK is required for collagen 
I expression whereas FAK, NJK and TAKI are required for ECM contraction and 
myofibroblast differentiation (Shi-Wen et al., 2009; Kharraz et al., 2014). 
38 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.10 TGF-β Signalling  
TGF-β is known to signal through the canonical TGF-β signalling pathway or other alternative 
pathways. The canonical signalling pathway works through phosphorylation of Smad2 and 3 
which then bind to Smad4 to form a complex targeting the nucleus and activating 
transcription of profibrotic genes. TGF-β1 also signals through Ras/MEK/ERK, P38 MAPK, c-
abl, and NJK pathways leading to promoter selective gene expression. AngII also signals 
through AT1 and AT2 leading to Smad activation and increased expression of profibrotic 
genes. (Image taken and modified from Kharraz et all 2014) 
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1.7.1.3.2 Connective tissue growth factor (CTGF) 
In addition to TGF-β signalling through smad in the fibrotic pathway, the renin-
angiotensin pathway also signals through smad as well as P38 to increase TGF- β and 
connective tissue growth factor (CTGF) which has also been found to have an important 
role in fibrosis (Figure 1.10).  
CTGF is a non-structural regulatory protein present in the ECM. Dystrophic muscle from 
DMD patients as well as the dystrophic dog and the mdx mouse all show elevated levels 
of CTGF (Sun et al., 2008). CTGF has also been shown to reproduce effects of TGF- β, a 
good example being its ability to increase collagen type 1, α5 integrin and fibronectin 
expression in fibroblasts (Morales et al., 2013; Kharraz et al., 2014). It is therefore 
established that the renin-angiotensin system along with the TGF- β system are key 
signalling pathways in the process of fibrosis.  
1.7.1.3.3 Inflammatory cells and cytokines 
One of the first events following damage to tissue is the infiltration of inflammatory cells 
in the site of injury. In response to muscle injury, the first cells that infiltrate the muscle 
are principally neutrophils and macrophages (Arnold et al., 2007). Disruption in the 
organised and coordinated initiation, progression and resolution of inflammation can 
cause persistent muscle damage, impairment of regeneration and so the development 
of fibrosis (Kharraz et al., 2014). 
1.7.1.3.3.1 Macrophages  
Studies carried out on the diaphragm of the mdx mouse have shown that macrophages 
are an important source of TGF- β suggesting they have a role in the development of 
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fibrotic tissue (Zhou et al., 2006). Further investigation into the role of macrophages in 
fibrosis revealed that not all macrophages have a profibrotic role. More and more 
studies show evidence of M2, or alternatively activated, macrophages being profibrotic 
as appose to the M1, or classically activated, macrophages which have more of a 
proinflammatory role (Gordon, 2003). 
M2 macrophages are activated by Th2 derived cytokines such as IL-13. Further to this IL-
13 in conjugation to TGF- β amplify the expression of arginase I, a key enzyme in the 
initiation of collagen synthesis in fibroblasts, in M2 macrophages (Wynn, 2004). In 
support of this, it has been demonstrated that M2 macrophages are expressing TGF- β 
and arginase I are present in the mdx diaphragm; and this expression increases with age 
correlating with an increase in IL-13 (Kharraz et al., 2014, Vidal et al 2008). 
Having discussed the important role of M2 macrophages in fibrosis development, it is 
important to mention that though M1 macrophages are proinflammatory, they could 
have a role in sustaining chronic inflammation which is an important cause of fibrosis. 
This has been indicated by looking at fibrinogen and its signalling through Mac-1 which 
is expressed on M1 macrophages. Fibrinogen stimulates expression of proinflammatory 
cytokines and chemokines, thereby potentially promoting muscle degeneration (RYU, 
DAVALOS and AKASSOGLOU, 2009; Kharraz et al., 2014).  
1.7.1.3.3.2 Lymphocytes  
Lymphocytes, in particular, T helper (Th) and cytotoxic cells (CTL), have also been 
suggested to have a role in the development of fibrosis in muscular dystrophies. Studies 
done in the scid/mdx mouse, which lack T and B lymphocytes, showed a decrease in 
fibrosis in the diaphragm which correlates with a decrease in TGF- β protein in the 
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dystrophic muscle (Farini et al., 2007). To identify which lymphocyte is responsible for 
the decrease in fibrosis in the scid/mdx mice further studies were carried out in the 
mouse mode of immunodeficiency, the nu/nu/mdx mice, which lacks functional T cells 
but not B cells (Morrison, Lu, Pastoret, Partridge, & Bou-Gharios, 2000). Studies using 
antibodies against Th and CTL cells showed that both T cells contribute to the 
development of fibrosis in the mdx mice (Wehling, Spencer and Tidball, 2001). 
1.7.2 Treatment of fibrosis  
While it is generally perceived that gene therapy is used to address the core cause of the 
disease, ie the missing gene, treatment in order to prevent fibrosis or its progression 
should be seen as adjunct therapy for muscular dystrophy. There are three main reasons 
that targeting fibrosis is very important in the future of gene therapy for DMD (Kharraz 
et al., 2014). The most obvious reason is that the presence of fibrotic tissue and 
replacement of muscle with fibrous tissue interferes in gene and cell therapies as it 
reduces the amount of available tissue for therapy. Secondly preventing fibrosis on its 
own can significantly improve quality of life and lifespan of dystrophic patients (Kharraz 
et al., 2014). Thirdly Pharmacological treatments targeting fibrosis are being tested, and 
some show very good results in human and animal models(Abdel-Hamid and Clemens, 
2012).  
1.7.2.1 Targeting the RAS  
Losartan targets the angiotensin 2 type 1 receptor involved in the RAS (Figure 1.11) 
(discussed above). Losartan is commonly used to lower blood pressure but 
administration in dy(2J) /dy(2J) mice, with laminin 2α deficient congenital muscular 
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dystrophy,  has been shown  to increase muscle strength and ameliorate fibrosis(Elbaz 
et al., 2012) . Another study on mdx mice has also shown decrease cardiac fibrosis upon 
losartan administration (Bish et al., 2011).  
Another drug targeting the RAS is Lisinopril. Lisinopril is an ACE-inhibitor (Figure 1.11) 
and has been shown to preserve cardiac and skeletal muscle integrity in mdx mice 
(Rafael Fortney 2011). A clinical trial has been started comparing Lisinopril and Losartan 
in a double-blind randomised trial on human DMD patients (Allen et al., 2013; Kharraz 
et al., 2014). So far both drugs have shown to be effective in tackling dilated 
cardiomyopathy. Interestingly administration of angiotensin1-7n contrast to 
angiotensin 2, inhibited TGF-β smad signalling and decreased a number of fibroblasts 
leading to lower fibrosis (Acuña et al., 2014).  
1.7.2.2 Targeting the growth factor and cytokines  
Antibodies against profibrotic growth factors have been shown to decrease fibrosis. FG-
3019 antibody which neutralises CTGF as well as antibodies against TGF-β have been 
shown to slow down fibrosis and improve phenotype of mdx mice (Andreetta et al., 
2006).Having said this, these growth factors are pleiotropic and targeting them has 
many undesired side effects such as increased amount of CD4+T cells infiltrating muscle 
(Andreetta et al., 2006). Severe immune dysregulation has been shown in TGF-β1 
knockout mice, where approximately 2 weeks after birth mice showed severe wasting 
syndromes and death (Christ et al., 1994). 
Imantinib, a tyrosine kinase inhibitor and a cancer drug, has been shown to be beneficial 
for muscular dystrophy when tested in mdx mice (da Silva Bizario et al., 2009). Imantinib 
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has been shown to target mesenchymal proginators specifically by inhibiting their 
proliferation and expression of fibrosis markers in vitro (Ito et al., 2013). Halofuginone, 
a synthetic halogenated derivative of febrifugine, is an anti-inflammatory molecule and 
has been shown to significantly improve muscle histopathology and fibrosis in the 
dysferlin-deficient mouse (Sundrud et al., 2009). A clinical trial was carried out to assess 
the safety of halofuginone in DMD patients, but results are not yet available.  
Although anti-inflammatory molecules, as well as drugs targeting the fibrotic signalling 
pathways, have shown encouraging results in animal models very few, have currently 
progressed into clinical trials in DMD patients. 
1.8 Periostin  
Periostin (POSTN), originally known as osteoblast-factor 2, was first identified in mouse 
osteoblastic cell line (Takeshita 1993, thesis). It was later named periostin due to its 
expression in the periodontal ligament and the periosteum in the adult mice.  The 
human homologue was found using murine cDNA as probes (Takeshita 1993, Hoersch 
2010). 
1.8.1 Periostin gene and protein  
In the human genome, POSTN is 36 kilobases, found on chromosome 13 and contains 
23 protein-coding exons (Figure 1.11) (Hoersch and Andrade-Navarro, 2010). The POSTN 
protein is made of an N-terminal region, a cysteine-rich Emilin-Like (EMI) domain, four 
repeats of FAS1 domain and a C terminal domain (Takeshita et al., 1993; Hoersch and 
Andrade-Navarro, 2010). Exon 1 codes for 23 amino acids that make up the N terminal 
signal sequence. This signal sequence lacks a transmembrane domain indicating 
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POSTNis a secreted protein. Exons two and three code for the EMI domain which is 
involved in protein-protein interactions (Callebaut et al., 2003). The FAS1 repeats, which 
are homologous to the insect axon guidance protein fascilin 1, are coded for by exon 3-
14.  The FAS1 domains are thought to be involved in cell adhesion and protein-protein 
interactions. Proteins such as bone morphogenic protein-1(BMP1), tenascin C, and 
integrins are reported to bind to POSTN at the FAS1 domain (Kim, Kim and Lee, 2000; Kii 
et al., 2010; Maruhashi et al., 2010). Exon 16-23 encode for the C terminal domain which 
doesn’t contain many known motifs. Exon 17-21 are subjected to alternative splicing, 
and therefore there are various POSTN isoforms ranging in size from 83-93 kDa (Morra 
and Moch, 2011). A nuclear localisation signal present in the C terminal domain is 
encoded by exon 22-23 and indicates an intracellular role of POSTN (Litvin, Selim and 
Montgomery, 2004; Hoersch and Andrade-Navarro, 2010). In addition to this, there is a 
hairpin binding site in exon 23 which provides a potential site for glycoproteins and 
proteoglycans.  
Secondary structure studies have shown consecutive beta strands present in the C 
terminal domain of POSTN. These beta strands are thought to play an important part in 
facilitating the binding of POSTN to collagen and fibronectin (Hoersch and Andrade-
Navarro, 2010). The interaction of POSTN with the ECM is therefore affected by the 
number of beta strands present in the C terminus of the mature protein, and that’s 
dictated by alternative splicing (Hoersch and Andrade-Navarro, 2010).  
Nine POSTN splice variants have been reported on ENSEMBEL with six splice variants 
being protein coding. POSTN splicing is regulated in multiple tissues, and additional 
POSTN splice variants are expressed in lung and kidney during foetal development 
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(Morra et al., 2012). POSTN alternative splicing and the specific function of each isoform 
is not very well understood, having said that tissue-specific expression of certain 
isoforms have been reported with isoform 6 detected in renal tissue but not in lung and 
isoform 1 expressed in breast, ovary and heart tissue while isoform 3 is expressed in 
adipose, colon, kidney, lymph and prostate (Viloria and Hill, 2016)(ENSEMBEL accessed 
March 2016).  
Research in bladder cancer has revealed that the bladder cancer tissue had lost the full-
length mRNA, isoform 1, but commonly expressed isoform 4. This variant showed to be 
unable to inhibit cell invasion and metastasis that were observed in isoform 1, and 3 
suggesting that switching from isoform 1 to alternative splicing is involved in bladder 
cancer metastasis (Bai et al., 2010). Bai et al identified  eight coexisting isoforms of 
POSTN in the thyroid, this is the first time eight isoforms have been reported in the same 
issue (Bai et al., 2010). 
Of the nine reported splice variants only four have been fully sequenced, and many 
further studies are needed to characterise these splice variants and assess their function 
and differences In interacting with various ECM components.  
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Figure 1.11 POSTN gene and periostin protein  
A) Showing 23 exons of the POSTN gene and portraying which domain of the protein each exon codes for. 
B) Showing the function of different domains in POSTN. The FAS1 repeats are involved in tenascinC 
binding as well as interaction with integrins. The EMI domain is responsible for binding of collagen-I and 
fibronectin. (Figure A modified from www. Shino-test.co and Hoerch and Navarro 2010). 
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1.8.2 Role of Periostin  
POSTN is classified as an extracellular protein. This means that POSTN does not directly 
serve a structural role in the ECM but is a link between the ECM and cells and helps 
modify cellular response to external stimuli (Bornstein et al., 1995). 
POSTN has been shown to interact with a several structural ECM proteins such as 
collagen I and V, fibronectin and tenascin-C (Takayama, Arima and Kanaji, 2006; Norris, 
Damon and Mironov, 2007; Kii et al., 2010) as well as interacting with bone morphogenic 
protein 1 (BMP-1) which promotes proteolytic activation of lysyl oxidase required for 
collagen cross-linking (Kii et al., 2010). POSTN has also been shown to serve as a ligand 
for of integrins such as avb3 and avb5 and promote cell motility and has been shown 
to promote tumour cell survival through PI3K/Akt in human colon cancer cells and 
pancreatic ductal adenocarcinoma cells cultured in vitro  (Bao, Ouyang and Bai, 2004; 
Baril, Gangeswaran and Mahon, 2007).  
As with other matricellular proteins, POSTN is expressed at low levels in most normal 
adult tissue but is up-regulated during embryonic development and in response to 
injury. POSTN is expressed at very low levels in the adult heart but is up-regulated in 
severe heart disease such as dilated cardiomyopathy, myocardial hypertrophy or 
myocardial infarction (Zhao et al., 2014). Up-regulation of POSTN in myocardium 
infarction plays an important role in early scar formation and collagen deposition 
preventing cardiac rupture (Oka, Xu and Kaiser, 2007; Shimazaki, Nakamura and Kii, 
2008). POSTN has also been shown to be highly expressed locally during renal disease 
contributing to fibrotic tissue replacement and loss of healthy tissue architecture in the 
kidneys (Mael-ainin et al., 2014). Mael Ainin et al. demonstrated that renal inflammation 
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and fibrosis could be reduced with the inhibition of POSTN using antisense 
oligonucleotides.  A recent proteomic study has also shown that in Duchenne muscular 
dystrophy POSTN expression is up-regulated more than any other protein (Ozdemir et 
al 2014). A study by Lorts et al. demonstrates genetic knockdown of POSTN in the Sgcd-
/- model of muscular dystrophy leads to reduced muscular dystrophy and fibrosis by 
modulating the TGF-b pathway (Lorts et al., 2012). 
POSTN null mice have been generated and as expected with matricellular proteins lack 
of POSTN results in subtle abnormalities in the mouse which look normal at birth, and 
there is no embryonic lethality (Rios, Koushik and Wang, 2005; Oka, Xu and Kaiser, 
2007). Serious abnormalities become apparent as the mouse gets older and is exposed 
to injury. Approximately 15% of POSTN-null mice die in the first three weeks due to 
cardiac defects (Rios, Koushik and Wang, 2005; Snider, Hinton and Moreno-Rodriguez, 
2008). POSTN null mice show delayed wound healing due to defective re-
epithelialization and decreased myofibroblast population (Nishiyama et al., 2011; 
Ontsuka et al., 2012). These mice also have increased the rate of cardiac rupture 
following myocardium infarction, and this is due to impaired collagen fibrillogenesis and 
myofibroblast differentiation (Oka, Xu and Kaiser, 2007; Shimazaki et al., 2008).  
Decreased bone formation and mass are also evident in these mice due to defects in 
collagen fibrillogenesis and osteoclast inactivation in the periosteum (Bonnet et al., 
2009; Merle and Garnero, 2012).  
Based on the above observations POSTN has a role in the repair process across the body 
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matricellular nature of POSTN and its role in repair and specifically in fibrosis has made 
it an attractive candidate for tackling fibrosis.  
1.8.3 Mechanistic view of periostin function  
A shown in the diagram below (Figure 1.12) following injury macrophages and 
neutrophils (in the case of inflammation) and other types of cells such as muscle cells (in 
the case of mechanical stress induced injury) begin expressing TGF-b and/or IL-4 and IL-
13 (Takayama, Arima and Kanaji, 2006; Kudo, 2011). The expressed cytokines induce the 
expression of POSTN, fibronectin and tenascin-C in fibroblasts. Some POSTN is secreted 
and placed in the ECM where it interacts with integrins such as avb3 on myofibroblasts 
and induces their cell migration. The myofibroblasts then, in turn, express type I collagen 
to repair the tissue. Inside the cell, POSTN comes together with tenascin C to form a 
meshwork with fibronectin to produce a scaffold for the cross-linking of type I collagen. 
POSTN is also involved in the cross-linking in that it associated with BMP-1 activating 
lysyl oxidase to enhance cross-linking inside the cells.  
Consistent damage or stress on a tissue leads to an over-protective reaction by POSTN 
leading to pathological fibrillogenesis which gives rise to fibrosis. In the studies 
mentioned above in the roles of POSTN, it was discussed that many studies have looked 
at deletion or inhibition of POSTN in disease and seen a considerable reduction in 
fibrosis and maintenance of normal tissue architecture. This portrays POSTN’s role in 
tight collagen fibre formation.  
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Figure 1.12 Mechanistic view of POSTN function  
Mechanical stress and inflammation lead to the expression of chemokines and TGF-b 
from inflammatory cells or muscle cells under mechanical stress. These chemokines and 
growth factor induce expression of POSTN and other ECM proteins such as fibronectin 
and tenascin C. In the event of repair or fibrosis the POSTN forms a meshwork with 
tenascin C and fibronectin for collagen I to be incorporated and cross-linked (Figure 
taken and modified from Kudo 2011). 
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1.9 Myostatin  
Myostatin or growth and differentiation factor 8 (GDF-8) was discovered in 1997 in a 
screen for novel mammalian members of the transforming growth factor(TGF-β) 
(McPherron, Lawler and Lee, 1997).  The expression pattern of myostatin suggested that 
it could be involved in the regulation of muscle function and development. The 
involvement of myostatin was confirmed when myostatin-deficient mice were 
generated and were shown to have a significant increase in muscle mass (McPherron, 
Lawler and Lee, 1997).  It is now clear that myostatin acts as a negative regulator of 
muscle mass and it acts in part by inhibition and activation of satellite cells in skeletal 
muscle.  Over the last few years, myostatin has emerged as a novel therapeutic target 
for the treatment of a range of disease that involves muscle degeneration including 
muscle dystrophies, cachexia, sarcopenia and a variety of chronic disease.  
1.9.1 Conservation of myostatin  
The myostatin gene is conserved across a broad range of species ranging from zebrafish 
to humans. The conservation of the myostatin sequence suggests conservation of 
function. One of the best-known phenotypes associated with Myostatin in nature is seen 
in the double muscle muscling phenotype in cattle; where mutations in the Myostatin 
gene have been shown to be responsible (McPherron, Lawler and Lee, 1997). 
Interestingly the zebrafish has shown to express myostatin in some non-muscle tissue 
such as the eyes, gill filament, gut, brain, ovaries and testes, as well as muscle tissue. 
(Rodgers and Garikipati, 2008). 
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1.9.2 Validation of myostatin as a therapeutic target  
Myostatin-deficient mice were generated to investigate the role of myostatin. These 
mice showed a considerable increase in muscle mass. These models confirmed the 
hypothesis that myostatin is involved in the regulation of muscle function and 
development (McPherron, Lawler and Lee, 1997; Tobin and Celeste, 2005). The increase 
in muscle mass was shown to be due to both hypertrophy and hyperplasia. These 
heterozygote animals also showed partial muscle phenotype indicating that complete 
inhibition of Myostatin is not necessary to achieve an increase in muscle mass (Tobin 
and Celeste, 2005). There is contradicting evidence as to whether myostatin regulates 
muscles mass through hyperplasia or hypertrophy. It seems like both pathways are used 
at different points depending on the stage of the development and the method used to 
antagonise myostatin (Tobin and Celeste, 2005).  
Several studies have shown that myostatin action regulates adult muscle mass as well 
as embryonic development. Use of neutralising antibodies in adult mice, and the 
generation of myostatin-deficient mice, where the myostatin genes have been deleted 
postnatally, are examples where adult animals showed an increase in muscle mass 
(Bogdanovich et al., 2002; Grobet et al., 2003).   
There are several examples of naturally occurring myostatin phenotypes. The first are 
the well-known double muscle phenotype cattle, the Belgian blues and the Piedmontese 
(Ménissier, 1982; Tobin and Celeste, 2005). The double muscle phenotype segregates 
with a region of the bovine chromosome 2 that is comparable to the human myostatin 
gene on chromosome 2 (McPherron and Lee, 1997; Tobin and Celeste, 2005). The first 
case of myostatin mutation in a human child was reported in 2004 (Hübner et al., 2004). 
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The child showed extraordinary muscle mass at birth. It was shown that a point mutation 
caused a mis-spliced myostatin mRNA in this child and this lead to undetectable levels 
of myostatin protein. At four years of age, this child was reported to be healthy, and 
exceptionally strong with increased muscle mass.  
It is, therefore, evident that myostatin can regulate muscle mass during development 
and in adult life when muscle size has reached its adult size. This regulation occurs 
through both hyperplasia and hypertrophy of muscle fibres. 
1.9.3 Molecular organisation of the MSTN1 gene 
The human MSTN1 gene maps to chromosome 2q:32:2 (McPherron and Lee, 1997) and 
in the mouse to chromosome 1 27.8cM (Szabo et al., 1998). The myostatin gene is 7.8kb 
with a simple molecular arrangement. It contains three exons with 2 intervening introns 
along with a 5’ untranslated region and a 3’ untranslated region which contains the core 
elements required for 3’ end processing following transcription. The myostatin gene 
gives rise to a 3.1kb mRNA. Exon 1-3 in humans are approximate of equal size and give 
rise to a protein containing 375aa (Gonzalez-Cadavid et al., 1998).  It is the third exon 
that codes for the mature myostatin protein. Comparison of the myostatin protein 
between human and mouse has revealed 90% identity and this identity increases to a 
100% when only the mature proteins are aligned. (McPherron and Lee, 1997). Myostatin 
is found to be predominantly expressed in skeletal muscle and to a lesser extent in fat 
tissue (McPherron, Lawler and Lee, 1997). 
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1.9.4 Processing and signalling of myostatin  
Myostatin belongs to the subgroup of Growth and Differentiation Factors and is 
therefore also called GDF-8. The myostatin gene encodes for a small N-terminus signal 
sequence followed by a large propeptide and an 18kDa mature region at the C-terminus 
(McPherron, Lawler and Lee, 1997). The signal sequence is responsible for the 
processing and secretion of the protein. The propeptide is involved in the biological 
regulation of myostatin and renders the mature protein inactive.  When active the 
mature myostatin then binds to one of the two activin type II (ActRII) receptors and 
initiates a signalling cascade (Lee, 2004).  
Myostatin can exist in an active or inactive state depending on the post-transcriptional 
modification (McPherron, Lawler and Lee, 1997; Hill et al., 2002). Following the 
transcription of myostatin, the propeptide and the mature region form a homodimeric 
protein as disulphide bonds form in both portions. Peptide bonds are then broken, and 
the propeptide remains in contact with the mature region via non-covalent forces and 
renders myostatin inactive. When secreted from muscle cells proteases on muscle cells 
free the mature protein from the propeptide, and the Myostatin is then activated and 
free to bind to its Activin type II receptors(Zimmers et al., 2001; Patel and Amthor, 2005) 
(Figure 1.13).   
This binding of myostatin leads to the phosphorylation and activation of Activin type I 
receptor, which then goes on to phosphorylate the receptor-regulated proteins Smad2 
and Smad3 and initiates an intracellular signalling cascade. When activated these Smads 
form heterodimers with Smad4 and Smad complexes then translocate from the 
cytoplasm to the nucleus and activate target genes (Shi and Massague, 2003) (Figure 
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1.13). The systematic effects of myostatin have been documented, and latent myostatin 
is detected in serum (Zimmers et al., 2001), but there is contradicting evidence on the 
distribution of active myostatin. One study has shown that active myostatin is 
detectable in human serum (Gonzalez-Cadavid et al., 1998) whereas another study by, 
Zimmers and colleagues (Zimmers et al., 2001), was unable to detect it. In both studies, 
antibodies were used to detect myostatin, and, therefore, one reason for the 
inconsistencies may be related to the different antibodies used to detect the active 
myostatin.  
The signalling process described above is referred to as the canonical signalling pathway 
of myostatin. Myostatin also signals via two other pathways: MAPK activation and 
inhibition of Akt signalling. MAPK activation is mediated via myostatin through two 
pathways: TAK1/MAPKK or Ras/Raf/MEK1.MAPK activation leads to the inhibition of 
genes responsible for myogenesis. Myostatin signalling through inhibition of Akt 
signalling is outlined in the above section called muscle mass regulation but is briefly 
described here. Myostatin inhibits Akt1 from phosphorylating FOXO and inhibiting 
protein degradation. Hence FOXO is dephosphorylated and accumulates in the nucleus 
leading to transcription of E3 ubiquitin ligase responsible for protein degradation (Figure 
1.14) (Sandri et al., 2004; Yang et al., 2007; Elkina et al., 2011) 
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Figure 1.13 Processing of myostatin and myostatin canonical signalling  
Myostatin processing and signalling via the activin receptor. Dimerised myostatin and 
propeptide are cleaved, and the propeptide stays attached to the mature portion with non-
covalent links rendering it inactive. Inactive myostatin is secreted by muscle cells. Proteases 
on muscle cells cleave the propeptide from the mature myostatin. Mature myostatin binds 
type II activin receptor. Transphosphorylation leads to activation of type I receptor. Type I 
receptor phosphorylates Smad3 and Smad2, which recruit Smad4 into a Smad complex. The 
Smad complex is translocated into the nucleus to elicit transcriptional changes of 
downstream genes that result in muscle wasting. 
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Figure 1.14 Myostatin signalling  
Myostatin signals through three known pathways. The canonical pathway labelled 1 
is described in figure 1.13. Myostatin also signals through its interplay with the 
IP3K/AKT signalling pathway. When bound to the activin type II receptor myostatin 
inhibits AKT phosphorylation and so inhibits muscle growth by decreasing mTOR 
regulated protein synthesis and increasing FOXO regulated protein degradation. 
Furthermore, myostatin leads to MAPK (p38 and ERK1/2) activation which lead to the 
inhibition of myogenesis responsible genes (Figure taken and modified from Yulia, 
2011) 
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1.9.5 Myostatin splice variants  
The conservation of the myostatin gene in a broad range of species ranging from sea 
urchins to humans indicates a common ancestral gene about 900 million years ago 
(McPherron, Lawler and Lee, 1997).  Gene duplication events have given rise to multiple 
Myostatin genes in bony fish, but only one Myostatin gene was reported in mammals 
(McPherron and Lee, 1997; Maccatrozzo et al., 2001). The presence of only one 
myostatin gene does not exclude the possibility of the presence of splice variants of 
myostatin.  The presence of multiple poly(A) signal and alternative splicing of pre-mRNA 
allows the generation of multiple mRNA transcripts and so the translation of distinct 
proteins from one gene (Jeanplong et al., 2013).  Alternative splicing contributes to the 
wide variety of proteins present in mammals. Splice variants of myostatin have been 
identified in crabs, fish, chickens, and ducks (Castelhano-Barbosa et al., 2005; Covi, Kim 
and Mykles, 2008; Huang et al., 2011). Among mammals, Myostatin splice variants have 
not been as easy to identify, and only recently two reports have been made of a splice 
variant, one in the sheep skeletal muscle and the other in mice (Jeanplong et al., 2013). 
Interestingly Jeanplong and colleagues showed that the alternative splice variant in 
sheep had a role in negatively regulating myostatin, so this way stimulated myogenesis.  
Due to the high conservation of the myostatin gene and its function among species, it 
seems likely that myostatin splice variants are present in other mammals including 
humans.  It could be that these alternative splice variants are present in specific muscles 
at particular stages of development, and this could contribute to the challenge of 
identifying them.  
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1.9.6 Roles of myostatin  
The role of myostatin as a negative regulator of muscle mass was established very early 
on with the discovery of the molecule and generation of myostatin-deficient mice which 
showed abnormally high muscle mass (McPherron, Lawler and Lee, 1997). Further 
confirmation was made with the association of the double-muscled phenotype in cattle 
with mutations in the myostatin gene and recently, the report of a human child born 
with gross muscle hypertrophy due to a point mutation in his myostatin gene 
(McPherron and Lee, 1997; Hübner et al., 2004) .  
A year after that, in a study by Gonzalez and colleagues, it was shown that myostatin 
expression levels correlate inversely with fat-free mass in humans. It was also shown 
that there seems to be a correlation between the increase in the expression of myostatin 
and weight loss in men with AIDS wasting syndrome (Gonzalez-Cadavid et al., 1998).  In 
another study by McPherron and colleagues, it was revealed that myostatin null mice 
showed reduced fat accumulation with increased age, compared to wild-type mice; they 
concluded that the loss of myostatin improves upon the obese and diabetic phenotype 
of mouse models (McPherron and Lee, 2002).  
1.9.7 Myostatin binding proteins  
There is great interest in discovering the identity of myostatin-binding proteins due to 
their potential in antagonizing myostatin’s downregulation of muscle mass. The 
identified binding proteins consist of Myostatin Propeptide, Follistatin, Follistatin 
related proteins FLGR (Follistatin Related Gene) , GASP-1 (Growth and Differentiation 
Factor-Associated Serum Protein-1) and Activin Receptor (Patel and Amthor, 2005). In 
addition to this, antibodies have been developed based on the findings on the structure 
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of myostatin. These antibodies bind and inactivate myostatin or bind and inhibit the 
dissociation of the propeptide from myostatin.  
1.9.8 Myostatin inhibition and its clinical application  
Muscle wasting is not only the hallmark of muscle disorders such as muscular 
dystrophies but it's also a hallmark of immobility and chronic disease such as kidney 
failure, tumour cachexia moreover, it also accompanies patients with AIDS wasting 
syndrome (Gonzalez-Cadavid et al., 1998; Patel and Amthor, 2005). In addition to this 
sarcopenia, the decrease in muscle mass with age causes various health problems in 
addition to immobility. Therefore, being able to increase muscle mass would greatly 
benefit a large proportion of the world’s population.  
A wide range of approaches to inhibit myostatin have been evaluated clinically and 
preclinically. Most of these approaches target myostatin extracellularly, by binding 
myostatin itself or targeting components of the receptor complex. Some of these 
approaches consist of antibody administration of myostatin propeptide, Follistatin or 
soluble ActRIIB receptors. The targeting of the myostatin ActRIIB receptor has been 
found to be quite non-specific as the receptor has other ligands such as Activin and 
BMP9 (Smith and Lin, 2013a). Therefore targeting the ActRIIB receptor or use of an 
ActRIIB as a soluble decoy may not inhibit myostatin action only. Other than extracellular 
targeting of myostatin there has recently been promising advances in the use of 
antisense oligonucleotides to disrupt the myostatin reading frame by exon skipping (Han 
and Mitch, 2011; Kang et al., 2011a; Malerba et al., 2012; Veltrop and Aartsma-Rus, 
2014).  
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1.9.8.1 Preclinical application of myostatin inhibition  
Cachexia is a muscle wasting condition associated with a disease such as cancer. 
Approximately 80% of patients with cancer develop cachexia, and cachexia causes 25% 
of deaths associated with cancer. Mice with Colon-26 and Lewis Lung carcinoma treated 
with ActRIIB-Fc antibody, a soluble myostatin receptor, showed an increase in body and 
muscle weight, grip strength and a decrease in resting time (Zhou et al., 2010; Busquets 
et al., 2012). In another study, the same animal model was used to look at an antibody 
to myostatin which was able to revoke completely the reduction in total muscle force 
induced by tumours (Murphy et al., 2011). These results show that inhibiting myostatin 
can significant benefits to patients with decreased mobility due to decreased muscle 
function.  
Muscular dystrophies are inherited myogenic disorders that are characterised by 
progressive muscle degeneration and weakness (Emery, 2002). Myostatin inhibition in 
animal models of dystrophy has shown a positive effect on muscle mass but inconsistent 
results on muscle function and histopathology(Amthor and Hoogaars, 2012). Having said 
that, there have been promising improvements, and research is moving at a fast pace. 
Methods looked at so far in dystrophic models consist of the use of ActRIIB-Fc soluble 
receptor and ActRIIB shRNA to target the receptor. Both these approaches show an 
increase in muscle mass and total force but no change in the specific force (George 
Carlson et al., 2011; Pistilli et al., 2011). In contrast to these results, in another study, 
there was an increase in the specific force of the soleus muscle in dystrophic models 
exposed to a myostatin propeptide over an extended period (Morine et al., 2010). The 
use of antisense oligonucleotides for exon skipping of myostatin is also under 
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investigation. It has been shown in a study that the administration of PMOs targeting 
exon two in dystrophic mice leads to a considerable increase in the soleus muscle of the 
mice (Kang et al., 2011a).  It is thought that skipping of myostatin alongside dystrophin 
in Duchenne Muscular Dystrophy, could attenuate the severity of the disease as shown 
in mdx mice models (Wagner, 2002). In a recent study, it was shown that combining two 
antisense oligonucleotides to inhibit myostatin and restore the dystrophin reading led 
to significant muscle mass growth and dystrophin expression(Malerba et al., 2012). It is 
also hoped that by inhibiting myostatin, it would be possible to attenuate muscle fibrosis 
in dystrophic muscle due to the role myostatin plays in inducing dystrophic muscle 
fibroblast proliferation (Bo, Zhang and Wagner, 2012).  
There has also been evidence that is inhibiting myostatin effects metabolism. Models 
show a decrease in fat mass and an increase in insulin sensitivity. There is a promise that 
myostatin inhibition could also be used to target obesity and obesity-related insulin 
resistance (Argilés et al., 2012). 
1.9.8.2 Clinical application of myostatin inhibition  
There are currently clinical trials studying the effect of myostatin inhibition in patients 
with severe cachexia using antibodies. One of the antibodies being used is LY2495655.  
In healthy volunteers, this antibody was well tolerated and lead to an increase in thigh 
muscle volume (Smith and Lin, 2013a). In the Phase 1 study in advanced cancer patients 
without chemotherapy, there was an increase in muscle volume and an increase in 
handgrip strength. Phase 2 trials involving locally advanced or metastatic pancreatic 
cancer patients receiving chemotherapy treatment is ongoing, with overall survival as 
an endpoint (Smith and Lin, 2013a).  Another antibody also in phase 2 trials is an ActRIIB 
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antibody BYM-338. This antibody is being used in patients with stage IV non-small cell 
lung cancer and stage III/IV adenocarcinoma of the pancreas. The endpoint in this study 
is the thigh muscle volume at eight weeks assessed by MRI. In healthy volunteers, this 
antibody has been well tolerated and leads to an increase in thigh muscle volume (Smith 
and Lin, 2013b). 
 
There have been recent developments in the clinical investigations of myostatin 
inhibition for the treatment of muscular dystrophies. A phase I/II trial using an anti-
myostatin antibody, Myo-029, failed to show effects on muscle strength or function in 
patients with Becker muscular dystrophy, limb girdle and facioscapulohumeral muscular 
dystrophy, at a clinically relevant dose and was therefore discontinued (Wagner et al., 
2008). ACE-031, an anti-ActRIIB antibody, was shown to be very effective in healthy 
volunteers, leading to an increase in lean body mass and thigh muscle volume. In phase 
2 trials involving DMD boys, it was also very efficient and slowed down the decline in 
thigh muscle mass and a six-minute walk and increased lean body mass. However, due 
to the onset of side effects such as nose bleeds and skin telangiectasia in healthy 
volunteers as well as in the phase 2 study, the trials were discontinued (Attie et al., 
2013).  PF-06252616 is an anti-myostatin antibody currently in Phase I healthy volunteer 
trial and has been given an orphan drug designation for the treatment of Duchenne 
muscular dystrophy (Smith and Lin, 2013a).  
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1.10 Polyadenylation  
All eukaryotic mRNA, except some histone mRNAs, contain poly (A) tails at their 3’ end. 
The pre-mRNA undergoes a two-step reaction to obtain a poly (A) tail:  1) 
endonucleolytic cleavage and 2) poly (A) tail addition. The presence of specific elements 
at the 3’ end of the pre-mRNA is required for the recruitment of multiprotein complexes 
which then allows the pre-mRNA to undergo 3’end processing. Most cellular mRNAs 
contain two core elements: the polyadenylation (poly(A)) signal (canonical signal AUAAA 
or the less frequent AUUAAA) and the downstream sequence element (DSE) 
characterised by a high-density G/U or U residues. The polyadenylation signal is located 
upstream of the cleavage site and is recognized by the multimeric cleavage and 
polyadenylation specificity factor (CPSE). The binding of this factor to the poly(A) signal 
determined the cleavage site (10-30nt downstream). The DSE is recognised and bound 
by a subunit of the cleavage stimulating factor (CstF) which promoted the efficacy of the 
3’ end processing (Danckwardt, Hentze and Kulozik, 2008). The length of the poly(A) tail 
(which is similar in different mRNAs) is thought to be determined by the interaction of 
the nuclear poly(A) binding protein (PABPN1 and PABPN2), CPSF and PAP) (Kuhn and 
Wahle, 2004; Danckwardt, Hentze and Kulozik, 2008). It is worth mentioning that 
approximately half of human mRNAs contain more than one poly(A) site (Tian et al., 
2005a). Alternative poly(A) site choice is influenced by the intrinsic strength of the 
sequence elements, the concentration and activity of polyadenylation factors and  by 
tissue or stage-specific regulatory factors (Barabino and Keller, 1999).  
Following the assembly of the basal 3’ end processing machinery, the endonucleolytic 
cleavage is catalysed by CPSF 73 (Ryan, Calvo and Manley, 2004). A nuclear poly(A) 
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polymerase (PAP) then adds approximately 250 adenine nucleotides to the 3’ end in a 
template-independent manner (Danckwardt, Hentze and Kulozik, 2008).  
1.10.1 Role of the poly(A) tail 
Correct 3’ end processing is functionally interconnected with transcription termination, 
mRNA capping and correct splicing of the pre-mRNA (Colot, Stutz and Rosbash, 1996; 
Danckwardt, Hentze and Kulozik, 2008). The poly(A) tail is also required for the release 
and export of the mRNA from the nucleus as well as mRNA abundance and correct  
translation of the mRNA (Proudfoot, Furger and Dye, 2002a; Danckwardt, Hentze and 
Kulozik, 2008). Loss or gain of function of the poly(A) tail therefore severely interferes 
with other gene expression steps.  
Mutations of sequence elements in the 3’ end of pre-mRNAs are known to be associated 
with a variety of disease. A good example is Alpha thalassemia and beta thalassemia 
where mutation of the poly(A) signal is a well-known cause of illness (Maniatis et al., 
1976; Danckwardt, Hentze and Kulozik, 2008).  It is, however, important to note that 
mutation in the poly(A) signal does not always cause disease. Sometimes mutations 
reduce but do not completely inactivate mRNA translation and protein expression. An 
example of this is seen in individuals who carry an AAUAAC TO AGUAAC mutation of the 
arylsulfatase a gene poly(A) signal. This mutation reduces but does not halt mRNA and 
enzyme expression (Barth, Fensom and Harris, 1993).
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1.11 Aims, objectives and methods  
A diverse range of methods are being investigated for the treatment of Duchenne 
muscular dystrophy, and there are some promising results. Having said this none of the 
methods address the fibrotic replacement of muscle tissue simultaneously or prior to 
dystrophin restoration. The scope of this project is to block myostatin production using 
alternative methods such as the use of antisense oligonucleotides to interfere with the 
polyadenylation (poly(A)) of the myostatin mRNA and compare to previously developed 
exon skipping method, block POSTN production using antisense oligonucleotides to 
induce exon skipping, go in-vivo, treating C57 mice with antisense targeting POSTN and 
testing the effect of the designed antisense oligonucleotides on POSTN expression and 
muscle regeneration. This method, in theory, would lead to a multicombinatorial 
treatment for DMD, reducing fibrotic tissue allowing better restoration of dystrophin in 
muscle fibres as there would be more of them and increasing muscle mass, overall 
improving muscle function and pathology in DMD patients.  
The short-term goal of this project was to see a decrease in MSTN RNA produced by 
muscle cells following treatment with antisense oligonucleotides targeting the poly(A) 
signal and induce exon skipping of POSTN in muscle cells and fibroblasts following 
treatment with antisense oligonucleotides inducing disruption in open reading frame . 
Given the in vitro nature of the short-term goal of this study, the use of appropriate 
culture models is an important consideration. Firstly, many studies have used 
rhabdomyosarcoma, RD muscle cells as a model of healthy human muscle, then DMD 
patient cells as a disease model of human muscle. These two cell lines are ideal for the 
in vitro experiments in this study as they produce myostatin as well as POSTN, can be 
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maintained in proliferation for multiple passages and do not differentiate. C2C12 
(healthy myoblasts) mouse cells are also an ideal model for in vitro muscle studies as 
they produce abundant myostatin and perisotin, and they provide an additional model 
to investigate the antagonistic activities of myostatin and perisotin. Mouse 
myofibroblasts were also used as they are a main source of POSTN expression in fibrotic 
tissue. The use of mouse cells will allow further validation of the results obtained from 
the human muscle cells. In vitro investigations will be carried out to test two hypotheses: 
1. Blocking the polyadenylation (PolyA) of myostatin pre-mRNA will lead to 
decreased RNA abundance in the cytoplasm and, therefore, decrease the 
production of myostatin by muscle cells. 
2. Blocking out-of-frame exons of perisotin will lead to the production of out-of-
frame transcripts which will not give rise to mature POSTN protein and 
therefore will reduce production of functional POSTN by cells. 
The long-term goal was to take the study in vivo and look at the effect of antisense 
mediated POSTN knockdown in C57 mice injected with BaCl2.  
Specific objectives of this project and planned methods: 
Objective 1: Identify polyadenylation (ATTAAA) signal in human and mice and 
investigate the homology of this region between various species. 
Methods:  
• Perform a pairwise sequence alignment of mouse and human at the third exon 
and analyse for homologous runs containing polyadenylation signals.  
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• Should a region of homology exist, analyse sequence and design of PMO capable 
of targeting both species. 
Objective 2: Design PMOs targeting the polyA signal  
Methods:  
• Identify the poly(A) used in the human and mouse Myostatin transcript. 
•  Following identification look at all possible 30-mer sequences of PMOs, 
targeting the signals, varying by one base.  
• Determine the overall strength of all antisense oligonucleotide sequences to 
target sequence and their % GC. 
• Look at where the PMO would bind on the folded pre-mRNA structure 
Objective 3: Determine whether the use of the designed PMOs to polyA signal 
causes a decrease in the Myostatin mRNA  
Methods: 
• Set up RD (rhabdomyosarcoma muscle cells) cell lines 
• Harvest of mRNA using Qiagen RNAeasy kit. 
• Running a 1 step RT-PCR, with primers in exon 1 and exon 3 of Myostatin 
(table 5), to look for a change in band intensity between treated and non-
treated cells. This represents the amount of RNA exported from the nucleus. 
Use of a house-keeping gene such as 18s to compare expression rate. 
• Use of gene tool to semi-quantify the gels from the RT-PCR by densitometry 
• Run a q-PCR for accurate quantitative results. 
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Objective 4: Identify out of frame exons in POSTN in human and mice and assess 
homology  
Methods: 
• Look at POSTN1 exons and identify those not divisible by 3 
• Upload POSTN sequence of human and mouse onto SnapGene and align 
sequences, assessing homology of identified exons. 
• Identify Exons with highest percentage homology which would be ideal to design 
PMOs to. 
Objective 5: Design PMOs to induce exon exclusion and disruption of the open 
reading frame 
Methods: 
• Identify exonic splice enhancers in the selected exons 
• Design PMOs targeting strong ESE sites and avoiding ESS sites. 
• Determine the overall strength of all antisense oligonucleotide sequences to 
the target sequence and their % GC. 
• Assess the position of binding of PMO to pre-mRNA secondary structure  
Objective 6: Determine whether the designed PMOs induce exon skipping in patient 
muscle cells, murine C2C12 muscle cells and murine muscle fibroblasts 
     Methods: 
• Design primers to all selected exons and optimize PCR 
• Transfect human patient cells with 10uM PMOs, 20ng TGF-b and Endo-Porter  
• Harvest RNA 24 hours after transfection 
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• Run PCR and look at product on 3% agarose gel 
• Semi-quantitatively calculate percentage skipping using gene tools 
• Select most successful PMOs and test them in C2C12 cell line 
• Assess PMO bioactivity in C2C12 cells using RT-PCR as well as quantitatively using 
RT-qPCR.  
• Assess Fibronectin mRNA expression 
• Carry out western blots to assess POSTN and Fibronectin protein expression 
• Identify successful PMOs and repeat in murine myofibroblast cell line 
Objective 7: Antisense modulation of POSTN per-mRNA splicing in the C57 mouse 
model.  
Methods: 
• Injection of mouse TA with BaCl2 and harvesting of TA at various time points 
• Injection of mouse TA with BaCl2 followed by PMO and harvest at various time 
points 
• Investigate POSTN and fibronectin expression through RT-qPCR  
• Investigate POSTN and fibronectin protein expression via Western blots 
• Assess muscle regeneration and expression of POSTN, fibronectin, collagen VI 
and α-SMA via immunohistochemistry.  
• Assess fibrosis using Sirius red staining.  
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2. Material and Methods  
2.1 General laboratory reagents  
All general chemical reagents were purchased from Sigma, Invitrogen, BDH or VWR 
(unless stated otherwise) with chemical purity grade AnalaR (Analytical Reagents for 
analysis applications). More commonly used chemicals are listed below, whereas the 
reagents required for only more specialised assays are described in the relevant 
materials section.  All the reagents were dissolved in double distilled H 2O (ddH2O) unless 
stated otherwise. The majority of solutions required as sterile for tissue culture were 
autoclaved at 1210°C for 15 min, except for solutions containing protein, detergents or 
glucose which were sterilized by passing through a brand new 0.22 µm filter (Falcon) 
under sterile conditions. All solutions were stored at room temperature unless indicated 
otherwise. 
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 Reagent : Manufacturer: 
Acetic acid (CH3COOH) VWR 
Agarose Invitrogen 
Ammonium acetate AcO(NH4)2 BDH 
Bovine Serum Albumin Sigma 
Boric acid Sigma 
CaCl2 Sigma 
Citric acid Sigma 
Dimethyl sulphoxide (DMSO) Sigma 
EDTA Sigma 
Ethanol (EtOH) VWR 
Glucose Sigma 
Hydrochloric acid (HCl)  BDH 
Liquid broth (LB) Sigma 
Methanol VWR 
Magnesium chloride (MgCl2) Sigma 
Magnesium sulphate (MgSO4) BDH 
NaOH Sigma 
Na2HPO4 Sigma 
NP-40 Fluka Biochemica 
Paraformaldehyde (PFA) Sigma 
Potassium chloride (KCl) Sigma 
Phosphate buffered saline (PBS) pH 7.3  Oxoid Ltd 
Sodium chloride (NaCl) Sigma 
Sodium dodecylsulphate (SDS)  Sigma 
Sodium bicarbonate (NaHC03) Sigma 
Sucrose Sigma 
Tri-sodium citrate Sigma 
Trizma Base Sigma 
Trizma hydrochloride (HCl) Sigma 
  Table 2.1 General reagents 
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2.2 Tissue culture techniques  
2.2.1 Materials 
• Dulbecco’s Modified Eagle’s Medium (DMEM): High glucose (4.5 g/l), 
GlutMAXTM-I (862 mg/l), Pyruvate (110 mg/l) and phenol red (15 mg/l) 
(ThermoFisher). Stored at 4°C. 
• Skeletal Muscle Cell Growth Medium (SMGM) (PromoCell) 
• Foetal bovine serum (FBS), certified heat inactivated (Invitrogen). Stored at -20°C 
in 50 ml aliquots.  
• L-glutamine (Sigma) 
• L-methionine (Sigma) 
• L-proline (Sigma) 
• Penicillin-streptomycin 100 Units/ml (Sigma) 
• Trypan blue (Gibco) 
• Trypsin-EDTA (10x)- 0.5% trypsin, 0.2% EDTA in PBS (Sigma) 
2.2.2 Cell lines  
Rhabdomyosarcoma (RD) cells (ATCC CCL-136TM): stored in vapour phase of liquid 
nitrogen at 1,000,000 cells/vial in growth media plus 10% DMSO. 
DMD Patient immortalised myoblast cells (D52 Vincent Mouly Institute of Myology) 
stored in the vapour phase of liquid nitrogen at 1,000,000 cells/vial in growth media plus 
10% DMSO. They grown in muscle SMGM media with 20% FCS, 1%P/S, 25ml Gentamycin 
and 5ml Glutamine. 
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Mouse Muscle Fibroblast Cells (Mocha MH cell line, ATCC) were purchased from ATCC, 
stored in the vapour phase of liquid nitrogen at 1,000,000 cells/vial in growth media plus 
10% DMSO.  They were grown in DMEM with FCS. 
2.2.3 Culture of cells  
All work for this project was performed under sterile conditions, using new, sterile 
plastic inside a grade 2 laminar flow hood. Cells were incubated at 37°C with 5% CO2.  
1 x 106 cells were seeded in T175 flask using 25 ml of the corresponding growth media. 
When 80% confluency was observed, the media was aspirated, and cells were washed 
with 5 ml of sterile 1X PBS. PBS was replaced with 5 ml of 1X Trypsin/EDTA solution and 
incubated at 37°C for 2-3 minutes to encourage cells to detach from the surface of the 
flask. 10ml of growth media was then used to neutralise the trypsin, and the cell 
suspension transferred to a 50ml falcon tube (Corning) and spun at 200 rpm for 5 
minutes to RT pellet the cells. The supernatant was aspirated and the pellet of cells 
resuspended in their growth media to achieve a concentration of 1x106 cells/ml. 1 ml of 
the resuspended cells were then placed in a T175 flask containing 25ml of their 
corresponding growth media and incubated for 3-4 days until 80% confluency was 
reached again.  
2.2.4 Cell viability and quantifying assessment  
Trypan blue stain was used to assess the viability of cells. This staining method is based 
on the assumption that dead cells have a damaged cell membrane and will take up the 
dye. Viable cells maintain a clear cytoplasm in the presence of Trypan blue, while dead 
or damaged cells stain blue. Typically, 10 µl of cell suspension was mixed with 10 µl of 
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Trypan blue (0.4%) and left for 1 minute before assessing and counting the cells using a 
haemocytometer under a light microscope. The ratio of live to dead cells was assessed.  
2.2.5 TGF-β treatment of cells  
TGF-β was dissolved in filtered citric acid pH 3 to produce a stock solution of 1µg/20µl. 
The stock was diluted to 5 ng/µl using pH 3 citric acid.  
Cells were seeded in 6-well plates using their corresponding media as described in 
section 2.2.3. Each well contained 8.3 x 104 cells in 2ml of corresponding media. When 
80% confluent, around 48 hours after seeding, the media was aspirated off and replaced 
with 2 ml of corresponding media. 4µl of TGF- β was pipetted into each well and the 
plates gently swirled to mix. RNA was harvested and analysed 24 hours after exposure 
to TGF-β. 
2.2.6 PMO transfection of cells  
PMOs, supplied by GeneTools, LLC, were dissolved in ddH2O to produce a stock solution 
of 1mM and transfections were carried out in a final volume of 1 ml.  
Cells were seeded at 8.3 x 104 in 6-well plates using 2ml of corresponding media per 
well. When 80% confluent the media was aspirated off and replaced with the 
appropriate volume of corresponding media with 10% FCS instead of the usual 20%. For 
Perisotin investigations, 20ng of TGF-β was added to each well and plates were 
incubated at 37°C for 1 hour before transfection with PMO. For myostatin investigations, 
PMO transfection was carried out with no prior treatment.  
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Each well was then transfected using 3µl of aqueous Endo-Porter and the PMO 
concentration range used between 0-10µM. PMO was added to each well followed by 3 
µl Endo-Porter. The final volume of each well was made up to 1 ml using appropriate 
media with 10% FCS.  
Plates were incubated for 24 hours at 37 °C with 5% CO2 and then RNA harvested; 
alternatively, the plates were incubated for 48 hours and protein harvested.  
2.3 RNA extraction from cells and muscle tissue  
2.3.1 Materials  
• QIAshredder kit (Qiagen Ltd.): Stored at room temperature.  
• RNeasy Mini Kit (Qiagen Ltd.): Stored at room temperature.  
• RNeasy Fibrous Tissue Mini Kit (Qiagen Ltd): stored at room temperature 
• RNase-free DNase-I (Qiagen Ltd.): Stored at 4°C. Once reconstituted, stored in 50 
µl aliquots at -20°C.  
• Absolute ethanol (100%) 
• ND-1000 NanoDrop spectrophotometer (Thermo Fisher). 
• TissueLysser (Qiagen) 
• Stainless steel 5mm beads (Qiagen) 
2.3.2 RNA extraction from cells  
RNeasy mini kits and QiaShredder columns were used to extract RNA from cells seeded 
in 6-well plates. 350 µl of RLT lysis buffer was added to each well. The buffer was 
pipetted over the well surface 3-4 times to ensure complete lysis of cells. The cell lysate 
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was transferred into Qiashredder column and placed into the 2 ml collection vessel 
provided. The column in the collection tube was then centrifuged for 2 minutes at full 
speed. The flow-through could then be stored at -80°C at this point and defrosted at 
37°C for 10 minutes before further processing. To process it, 350 µl of 70% ethanol was 
added to the flow-through and pipetted up and down several times to ensure mixing. 
700 µl of the mixture was transferred to an RNeasy mini column placed in a 2ml 
collection tube. The column inside the tube was then centrifuged for 30 seconds at 
≥8,000xg. The flow-through was discarded for this and all of the following steps. 350 µl 
of buffer RW1 was added to the RNeasy column. The column was then centrifuged for 
30 seconds at ≥8,000xg. 10 µl of reconstituted RNase-free DNase and 70 µl of RPE buffer 
were mixed together and carefully pipetted on to the column. The column was then 
incubated at room temperature for 15 minutes. After incubation 350 µl of RW1 buffer 
was pipetted to the column and centrifuged for 30 seconds at ≥8,000xg. 500 µl of RLP 
buffer (with ethanol added prior to this as indicated on the label of the bottle) was 
pipetted onto the column. The column was centrifuged for 30 seconds at ≥8,000xg. 
Another 500 µl of RLP buffer was added to the column and centrifuged for 2 minutes at 
≥8,000xg. The column was then transferred into an RNase-free; DNase-free 1.5 ml 
Eppendorf tube and 30 µl of RNase-free, DNase-free water was added onto the 
membrane directly, and this time the flow-through was kept. The column was then 
centrifuged for 1 minute at ≥8,000xg to elute the RNA. The quality and concentration of 
the harvested RNA were then assessed using an ND-1000 NanoDrop spectrometer. RNA 
was stored in a -80°C freezer.  
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2.3.3 RNA extraction protocol from sectioned TA muscle  
Eppendorf tubes containing tibialis anterior sections were placed on ice and very quickly 
1x5mm steel bead was added to each tube along with 300µl of Buffer RLT. Tubes were 
placed in the TissueLyser, and the Tissuelyser was operated for 2 minutes at 20Hz 
allowing even homogenization. The lysate was then pipetted into a new microcentrifuge 
tube. 590 µl of RNase free water was added to the lysate followed by 10µl of proteinase 
K solution and mixed by pipetting. The tubes were then incubated at 55°C for 10 
minutes. The tubes were then centrifuged for 3 minutes at 10,000 x g. The supernatant 
was pipetted into a new 1.5ml microcentrifuge tube. A 0.5 volume (usually 450µl) of 
ethanol was added to the lysate and mixed by pipetting. 700µl of the sample was 
transferred to an RNeasy Mini spin column placed in a 2ml collection tube, and the 
columns were then centrifuged for 30 seconds at 8000 x g. The flow-through was 
discarded. This was repeated for any sample remaining in the 1.5ml microcentrifuge 
tube. 350µl of buffer RW1 was added to the RNeasy Mini column and centrifuged for 30 
seconds at 8000 x g. In order to eliminate DNA, the RNase-free DNase-I kit was used at 
this point. 10 µl DNase I solution was added to 70µl of Buffer RDD for each sample. The 
DNase I mix (80 µl) was then directly added onto the RNeasy spin column membrane 
and left on the benchtop for 15 minutes at room temperature. 350µl of RW1 buffer was 
then added to each RNeasy Mini column and the columns centrifuged for 30 seconds at 
8000 x g. The flow-through was discarded after this and after every centrifuge step after 
this. 500µl of buffer RPE was added to the columns and centrifuged for 30 seconds at 
8000 x g. Another 500µl of buffer RPE was added to the columns and centrifuged for 2 
minutes at 8000 x g. The RNeasy Mini spin columns were then placed in new 1.5ml 
collection tubes. 30µl RNase free water was directly pipetted onto the columns and the 
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flow-through kept by centrifuging the tubes for 1 minute at 8000 x g. The columns were 
discarded, and the flow-through containing the RNA was stored at -80°C. The quality and 
concentration of harvested RNA were assessed using an ND-1000 NanoDrop 
spectrometer. 
2.4 Polymerase chain reaction-based methods  
2.4.1 Reverse transcriptase polymerase chain reaction (RT-PCR) 
2.4.1.1 Materials for PCR  
• cDNA generated using Methods 2.4.2 
• GoTaq DNA polymerase kit (Promega). Stored at -20°C. 
• Gene specific primers and housekeeping primers designed using PrimerQuest 
tool at https://eu.idtdna.com/PrimerQuest/Home/Index (IDT).  
• Peltier Thermal cycler PCT-200 (MJ Research) 
2.4.1.2 PCR standard conditions  
In this section, only general procedures for PCR will be outlined. The more detailed 
details of the primer sequences and PCR program will be outlined in the appropriate 
section.  
Typically, cDNA was previously prepared by RT-PCR. Primers were diluted to 1 µM. All 
components of the GoTaq kit were thawed on ice except the polymerase which was kept 
at -20°C until needed. Master stock solution for each reaction was prepared in the order 
shown in the table below:  
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RT-PCR reaction set up  
Component  Volume  
GoTaq polymerase 5u/µl   0.25μl  
Forward primers (10 μM each)  0.5 μl  
Reverse primers (10 μM each)  0.5 μl  
MgCl22 (25mM) 1.5 µl  
GoTaq Buffer (5x)  5 µl 
dNTP (5nM) 1 μl  
Nuclease-Free water   12.25 μl  
Final volume  21 μl  
 
21µl of the master mix reaction was added to each PCR tube containing 4µl of cDNA 
template. At least one negative control was set up that lacked cDNA, which was replaced 
with nuclease-free water. The PCR tubes were placed in the PCR machine, and the 
appropriate programmes were run. In the standard PCR protocol, the template was 
initially denatured at 94°C for 2 minutes followed by 30 to 45 cycles of 1-minute 
denaturation, 1-minute annealing and 30 seconds extension (or 1 minute per 1000bp) 
at 92°C, 45-68°C and 72°C respectively. The final extension was carried out at 72°C for 5 
min. The final product was stored at 4°C or -20°C. The annealing temperature was 
predicted separately for each primer pair.  
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2.4.1.3 Mstn PCR  
The expected amplicon size of the mstn gene was 938bp. Sequence of the primers used 
were: forward primer, 5'-CCTCAGTAAACTTCGTCTGGA-3'; reverse primer, 5'-
CACAGCGGTCTACTACCATC-3'. The reaction was set up as described in 2.4.1.1 with 
annealing temperature of 56.4°C and a total of 30 cycles. 
This protocol was also used for multiplex PCR where 18S was amplified alongside Mstn 
as a housekeeping gene to assess expression. In this case, 0.38µl of 10µM 18S sense and 
antisense primers were added, and the volume of water decreased to 7.89µl to 
accommodate the addition of primers in the same total volume.  
2.4.1.4 Periostin PCR  
2.4.1.4.1 Human: 
Nested PCR was optimised for exons 3, 7, 10 and 16. In the first round of PCR, 4µl of 
cDNA product was used and the reaction set up as described in 2.4.1.1 with annealing 
temperatures of 53°C, 55°C, 54°C and 51°C respectively for each exon, with a total of 20 
cycles. In the second round, 0.25-1µl of the first round PCR product was used, and the 
reaction was set up as described in 2.4.1.1 with the annealing temperatures 50°C, 52°C, 
60°C and 53°C respectively for each exon and a total of 30 cycles.  
Primers specific to each exon of human Periostin are listed in the tables below:  
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Primers used to amplify the human Periostin exon 3 in RT-PCR  
 Primer  Sequence  (5’-3’)  Location  
Product 
size  
Exon 3 
1st 
round 
PCR 
Forward:  TTGGGCACCAAAAAGAAATACT Exon2  
264bp  
   
 Reverse  CGGTGCAAAGTAAGTGAAGGAT Exon4   
Exon 3 
2nd 
round 
PCR  
Forward:  TTGGGCACCAAAAAGAAATACT Exon2  
159bp  
Reverse  ATAAACATGGTCAATGGGCAA Exon4  
 
 
Primers used to amplify the human Periostin exon 7 in RT-PCR  
 Primer  Sequence  (5’-3’)  Location  
Product 
size  
Exon 7 
1st 
round 
PCR 
Forward:  TATCCGTAGAGGTTTGGAGAGC Exon6  
643bp  
   
 Reverse  ATCAATCAAATGGATCACACCA Exon8   
Exon 7 
2nd 
round 
PCR  
Forward:  
TGGCATGATTATTCCTTCAATG 
 
Exon6  
544bp  
Reverse  ATCAATCAAATGGATCACACCA Exon8  
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Primers used to amplify the human Periostin exon 7 in RT-PCR  
 Primer  Sequence  (5’-3’)  Location  
Product 
size  
Exon 
10 1st 
round 
PCR 
Forward:  TGGAATCAAAATGGTGAACAAA Exon9  
608bp  
   
 Reverse  TTCCCTTAAAAGCATCATTGGT Exon11   
Exon 
10 2nd 
round 
PCR  
Forward:  
ATGGTGTGATCCATTTGATTGA 
 
Exon9  
521bp  
Reverse  
AGGTTGTGTCAGGAGCTCTTTC 
 
Exon11  
 
 
Primers used to amplify the human Periostin exon 16 in RT-PCR  
 Primer  Sequence  (5’-3’)  Location  
Product 
size  
Exon 
16 1st 
round 
PCR 
Forward:  TGACATCATGACAACAAATGGT Exon15  
263bp  
   
 Reverse  GTGTGGGTCCTTCAGTTTTGAT Exon17   
Exon 
16 2nd 
round 
PCR  
Forward:  
CTGTTGGAAATGATCAACTGCT 
 
Exon15  
168bp  
Reverse  
GAAGACTGCCTTCAATCACTTT 
 
Exon17  
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2.4.1.4.2 Mouse  
Nested PCR was optimised for exons 3 and 16. In the first round of PCR, 4 µl of cDNA 
product was used and the reaction set up as described in 2.4.1.1 with annealing 
temperatures of 60°C and 69°C respectively for each exon with a total of 20 cycles. In 
the second round, 0.5-1µl of the first round PCR product was used, and the reaction was 
set up as described in 2.4.1.1 with the annealing temperatures 65° and 64°C respectively 
for each exon and a total of 30 cycles.  
Primers specific to each exon of human Periostin are listed in the tables below:  
Primers used to amplify the mouse Periostin exon 3 in RT-PCR  
 Primer  Sequence  (5’-3’)  Location  
Product 
size  
Exon 3 
1st 
round 
PCR 
Forward:  CTGGGCACCAAAAAGAAATACT Exon2  
260bp  
   
 Reverse  GCGAAGTACGTCTATGACCCTT Exon4   
Exon 3 
2nd 
round 
PCR  
Forward:  GTATCAAGGTGCTATCTGCGG Exon2  
169bp  
Reverse  GACATCGGAGTAGTGCTGAGTG Exon4  
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Primers used to amplify the mouse Periostin exon 3 in RT-PCR  
 Primer  Sequence  (5’-3’)  Location  
Product 
size  
Exon 
16 1st 
round 
PCR 
Forward:  CGTCGTGGACAAACTCCTCTAT Exon15  
229bp  
   
 Reverse  GTGGATCACTTCTGTCACCGT Exon17   
Exon 
16 2nd 
round 
PCR  
Forward:  GGAAATGATCAGCTCTTGGAAT Exon15  
131bp  
Reverse   TCAATTTGGATCTTCGTCATTG Exon17 
 
2.4.2 cDNA synthesis  
2.4.2.1 Materials  
• GoScript reverse transcription system kit (Promega): Stored at -20°C.  
• Random primers (Invitrogen)  
• Oligo(dT) primers (Promega)  
• Thermal cycler (VWR) 
2.4.2.2.Protocol  
The GoScript Kit (Promega) was used for cDNA synthesis. All components of the kit were 
thawed on ice except for the reverse transcriptase, which was kept at temperatures 
close to -20°C until needed.  
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600ng of RNA and 500ng of random primers and oligo(dT) were pipetted into an RNase-
free PCR tube. RNase-free water was then used to adjust the total volume of RNA/primer 
mixture to 10 µl. The PCR tube was then placed in a PCR machine, and a single cycle was 
run for 5 minutes at 70°C followed by at least 5 minutes at 4°C. The resulting samples 
were stored on ice until the reverse transcription master mix was ready.  
The reverse transcription reaction master mix was prepared on ice in the order listed in 
the table below. 
Composition of the reverse transcription reaction master mix:  
Components Volume 
GoScript 5x Reaction Buffer   4 μl  
 MgCl2 (25 mM)  2 μl  
dNTP (5 mM)  2 μl  
GoScript Reverse Transcriptase  1 μl  
Nuclease-free water  6 μl  
Final volume  15 μl  
 
15 µl of the reverse transcription master mix was then added to the 10µl RNA/primer 
mix and placed in the PCR heat block. The PCR programme run consisted of: annealing 
for 5 minutes at 25°C, extension for 1 hour at 42°C and heat denaturation for 15 minutes 
at 70°C. cDNA samples were then stored at -20°C for long term storage.  
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2.4.3 Quantitative real-time PCR 
2.4.3.1 Materials  
• 3LightCycler 488 SYBR Green I Master (Roche). Stored at -20°C.  
• cDNA generated in Methods 2.4.2 
• LightCycler 480 (Roche) for quantitative PCR  
• Housekeeping realtime primers and gene-specific primers (Primetime 
qPCR primers from IDT) 
• DEPC-treated water (Ambion) 
2.4.3.2 Standard Protocol  
The described protocol has been optimised for use with ROCHE SyBr Green master mix 
and the Roche LightCycler 480 machine using 380-well plates. All procedures described 
were carried out in a UV-treated, nucleic acid-free safety cabinet. Sequences of human 
and mouse primers used for qPCR are detailed in the table below. 
 
Target 
gene  Accession No  Primer  Sequence (5’-3’)  Location  
Species  
 Posnt  Hs.PT.58.4452022 
Forward 
Reverse  
GTTGCTCTCCAAACCTCTACG  
CGCTATTCTGACGCCTCAA 
Exon4  
Exon5  Human  
Posnt Mm.PT.58.9884244  
Forward 
Reverse  
CCTTTCATCCCTTCCAATTCTCA 
CCTGTAAGAACTGGTATCAAGGT  
Exon2  
Exon3  Mouse  
GAPDH  Hs.PT.58.40035104 
Forward 
Reverse  
GCGCCCAATACGACCAA 
CTCTCTGCTCCTCCTGTTC  
Exon1  
Exon4  Human  
GAPDH  Mm.PT.39a.1 Forward Reverse  
GTGGAGTCATACTGGAACATGTAG 
AATGGTGAAGGTCGGTGTG  
Exon2  
Exon3  Mouse  
Fbn1 Mm.PT.58.8135568 
Forward 
Reverse 
TTGTTCGTAGACACTGGAGAC 
GAGCTATCCATTTCACCTTCAGA 
Exon26 
Exon27 Mouse 
Mstn Hs.PT.58.40523213 
Forward 
Reverse 
TCGTGATTCTGTTGAGTGCT 
TGTAACCTTCCCAGGACCA 
Exon2  
Exon3  Human 
List of primers  
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The cDNA generated (section 2.4.2) was diluted in nuclease-free water. Control sample 
cDNA was used to set up standard dilutions (i.e., 1:50, 1:500, 1:5,000 and 1:50,000) for 
calculation of primer binding efficiency. The final volume of each dilution was made up 
to at least 50µl. A 380-well plate was set up by including the four serial dilution standards 
and one negative control that included nuclease-free water instead of cDNA. Each plate 
included at least three biological replicates of treated and untreated samples. Each of 
the biological replicates had 3 technical replicates to control for machine and pipetting 
errors.  
The master mix for each reaction, gene-specific and the housekeeping gene, was set up 
as outlined in the table below: 6µl of master mix was pipetted into each well followed 
by 4µl of diluted cDNA making a total volume of 10 µl.  
Composition of RT-qPCR reaction  
Components  Initial concentration  Volume  Final concentration  
SYBR Green  2x  5 μl  1x  
Primer concentration  10 μM  0.5 μl  0.5 μM/primer  
cDNA  n.a.  4 μl  n.a.  
Nuclease-free water  n.a.  0.5 μl  n.a.  
Final volume/well  n.a.  10 μl  n.a.  
  
The plate was sealed using the provided covers and spun at high speed briefly to ensure 
all components are mixed and at the bottom of the wells. The plate was then placed 
inside the machine, and the programme shown in the table below was initiated: 
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RT-qPCR cycling parameters  
PCR 
programme  No. of cycles  Temp. (°C)  Time  
Preincubation  1  95  10 minutes  
Amplification  40  
95  
60  
10 seconds  
5 seconds  
  72  10 seconds  
  
 A melting curve programme was added at the end of the programme to assess any off 
target amplification (Figure 2.1). Each primer set is expected to have a single distinct 
peak if there are no off-target primer binding or contamination present.  
 
Figure 2.1 Example of a melting curve acquired at the end of a reaction from the Roche 
LightCyclers480 
Two distinct peaks specific for Postn (green) and GAPDH (red) housekeeping gene indicate 
that the primers are amplifying a single product and no off-target amplification or sample 
contamination is present.  
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2.5 Semi-quantitative densiometric analysis of gene expression  
2.5.1 Materials  
• Agarose. Stored at room temperature.  
• 10x TAE buffer: diluted to a 1X solution. containing 40mM Tris, 40mM acetate, 
and 1mM EDTA, pH 8.3. Stored at room temperature.  
• 5x TBE buffer: diluted to a 1X solution. containing 45mM Tris-borate and 1mM 
EDTA, pH 8.0. Stored at room temperature  
(http://cshprotocols.cshlp.org/content/2006/1/pdb.rec8458.full).  
• SYBR Safe (x10,000) DNA gel stain (Invitrogen). Stored at room temperature.  
• DNA Hyperladder IV and V (Bioline UK Ltd.). Stored at 4°C.  
• Horizontal electrophoresis system (Bio-Rad).  
• E-BOX VX2 gel documentation system (PeqLab).  
• Access to GeneTools software (Syngene) for densitometric analysis.  
• Polyacrylamide 10% precast TBE gels (Invitrogen). Stored at 4°C.  
2.5.2 Protocol  
To examine the expression of a skipped target gene relative to the full-length target gene 
or the expression of the target gene relative to a housekeeping gene, the specific PCR 
products were separated by agarose gel electrophoresis. For separation of products 
amplified using periostin specific primers, products were run on a horizontal 3% (w/v) 
agarose gel, prepared by dissolving 3g of agarose in 100ml of 1x TAE buffer and heated 
in a microwave to aid dissolving. The mixture was heated until a transparent solution 
was formed; 10µl of 10,000xSYBR safe was added to the solution and mixed thoroughly 
by swirling. After allowing to cool to 65°C. The gel was then poured into a casting tray 
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with the appropriate comb inserted and allowed to solidify at room temperature. The 
gel was submerged in 1X TAE running buffer. Each sample, containing loading dye, is 
loaded directly into the well at consistent volumes. 7 µl of the appropriate molecular 
weight markers were used to measure PCR product sizes and loaded at each side of the 
gel. The gel was then run at 100 volts for 45 minutes and visualised under UV light using 
an Ebox VX2 imaging system. The semiquantitative analysis of skipped Postn mRNA 
expression was done by normalising its expression to the total level of expression 
(skipped plus full-length). In cases where the skipped transcript was not being 
quantified, the expression level of Postn and Mstn were analysed by normalising to the 
level of the housekeeping gene (i.e. 18S). The analysis was performed using GeneTools 
software. The two formulae below were used to calculate expression levels (pixel count 
was used). 
 
Skipped Postn   (Skipped POSTN−background) 
expression =       
 ((Full length POSTN−background) + (Skipped POSTN-background)) 
 
(POSTN−background) 
Postn expression =   
   (18S−background) 
 
(MSTN−background) 
Mstn expression =   
   (18S−background) 
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2.6 Protein extraction from cells and tissue  
2.6.1 Materials  
• RIPA Buffer (TBS PH7.5(25nM Tris/HCl, 140nM NaCl), 1%Triton (v/v) x100, 
0.5% (w/v) SDS, 1mM EDTA, 1mM PMSF, 1mM Na3V04, 1mM NaF, 1 tablet of 
Protease inhibitor cocktail (Roche)). 
• 5mm steel bead (Qiagen Ltd)  
• TissueLyser (Qiagen Ltd) 
2.6.2 Protocol  
2.6.2.1 Protein extraction from sectioned TA muscle  
Frozen Eppendorf tubes containing sections of TA muscle were placed on ice and very 
quickly one bead, and 100 µl of RIPA buffer was added to each tube. Tubes were then 
placed in the TissueLyser which was then operated for 2 minutes at 20Hz. The 
homogenised TA was then centrifuged at 4°C for 10 minutes at 13,000 rpm, and the 
supernatant containing total protein was transferred to a new tube and stored at -80°C. 
2.6.2.2 Protein extraction from cells  
All procedures were carried out on ice to avoid protein degradation.  
Media was aspirated from each well. Wells were rinsed with PBS. 50µl of RIPA buffer 
was pipetted onto the surface of each well. The surface of each well was scraped to 
ensure lysis of all cells, then the buffer pipetted into Eppendorf tubes and vortexed. The 
lysate was then kept on ice for 2 minutes. The tubes were then centrifuged at 4°C with 
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at 13,000 rpm for 10 minutes. The supernatant containing the protein was then pipetted 
into fresh Eppendorf tubes and the pellet discarded. Protein was stored at -80°C. 
2.7 Protein quantification using DC assay  
2.7.1 Materials  
• DC protein assay kit (BIO-RAD) 
• BioTek spectrophotometer  
• 96 well microtiter plate  
2.7.2 Protocol  
All steps in this protocol were carried out on ice.  
10 dilutions of BSA protein standard containing 0.2mg/ml to 2mg/ml in RIPA buffer was 
made. 5µl of each standard and 0.5 µl of each protein sample was pipetted into a dry 
96-well plate. Each well was replicated three times in order to have three technical 
replicates. 25µl of reagent A’ (made up of 20 µl of reagent S in 1 ml of reagent A) was 
then pipetted into each well followed by 200µl of reagent B. The plate was then gently 
rocked to mix the reagents. The plate was left on ice for 15 minutes before being placed 
in the spectrophotometer and read at 750 nm; the concentration of protein in each well 
was calculated based on the standard curve produced using the BSA standard curve.  
2.8 Western Blotting  
2.8.1 Materials  
• NuPAGE Novex Gels: 4-12% Bis-Tris gel and 3-8% Tris-Acetate gel (stored 
at 4°C) 
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• NuPAGE MOPS Running Buffer (20x) (stored at room temperature) 
• NuPAGE T/A Running Buffer (20x) (Stored at room temperature) 
• NuPAGE Transfer buffer (20x) (Stored at room temperature) 
• NuPAGE LDS sample buffer (Invitrogen) (Stored at 4°C) 
• NuPAGE sample reducing agent (Invitrogen)(Stored at 4°C) 
• NuPAGE antioxidant (Invitrogen) (Stored at 4°C)  
• Novex Sharp Pre-stained protein standard (Invitrogen) (Stored at -20°C) 
• HiMark pre-stained protein standard (Stored at -20°C) 
• Chameleon protein standard (LI-COR Bioscience) (Stored at -20°C) 
• nitrocellulose membrane 
• Phosphate Buffered Saline (PBS) 
• Dried skimmed milk (Marvel) 
• Odyssey Blocking Buffer (PBS) (LI-COR) (Stored at 4°C) 
• Rabbit anti-Periostin (Abcam. ab14041),Stored at -20°C. 
• Rabbit anti-Fibronectin (Abcam, ab2413): Stored at -20°C. 
• Rabbit α-tubulin antibody  
• Mouse Vinculin antibody  
• IRDye 800CW Goat anti-rabbit antibody (LI-COR) (Stored at 4°C) 
• IRDye 680RD Goat anti-rabbit antibody (LI-COR) (Stored at 4°C) 
• IRDye 680RD Goat anti-mouse antibody (LI-COR) (Stored at 4°C) 
• High salt buffer: (0.5g SDS, 10.2g NaCl in 500ml of PBST) 
• Odyssey CLx Imager (LI-COR Bioscience)  
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2.8.2 Protocol  
Protein samples were diluted to 4µg/µl with 4µl of reducing agent, 10µl of LDS sample 
buffer and water to make up a final volume of 40µl. The samples were then heated at 
70°C for 10 minutes. Appropriate gels were set up using their corresponding running 
buffers (4-12% Bis-Tris gel with 1xMOPS running buffer for periostin and 3-8% TA gel 
with 1xTA running buffer). 10µl of each sample was loaded into the premade gels. 7 µl 
of a protein standard was loaded on either side of the gel. The middle chamber of the 
tank was filled with running buffer and 500µl of antioxidant. The gel was run for 1 hour 
at 200V for the Bis-Tris and 1 hour 20 minutes at 200V for the TA gel.  
Transfer buffer was prepared by adding 100ml of methanol and 1ml of NuPage 
antioxidant to 50ml of 20xNuPage transfer buffer and made up to 1 litre using water. 2x 
filter paper, 4x blotting sponge and nitrocellulose membrane were cut to the same size 
as the gel and soaked in the transfer buffer prepared. The gel cassette was opened and 
the gel placed in a Novex blot module in a sandwich in the following order: 2x blotting 
sponge, filter paper, gel, transfer membrane, filter paper, 2x blotting sponge. The 
module was placed in the electrophoresis running tank and secured. The module was 
filled with running buffer leaving 1cm at the top of the module empty. The outside of 
the module was filled with leftover transfer buffer or water. The lid was placed on the 
gel tank, and it was run for 2 hours at 30V.  
Appropriate blocking buffer was used to block the membranes. For periostin Western 
blots, Odyssey Blocking Buffer (Li-Cor) was used. For fibronectin, 5% milk in PBS was 
used. Membranes were placed in appropriate blocking buffers and placed on a shaker 
for 1 hour.  
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Primary antibody was prepared in the appropriate blocking buffer with 0.1% (v/v) Tween 
20 added. For periostin Western blots primary antibody was prepared with a dilution of 
1:4000 of rabbit anti-periostin antibody and 1:2000 dilution of rabbit α-tubulin antibody 
(independently, as host species are the same). For fibronectin Western blots, primary 
antibody was prepared with a 1:1000 dilution of rabbit anti-Fibronectin antibody and a 
1:10,000 dilution of mouse Vinculin antibody (in the same solution, as host species are 
different).  
Blocked membranes were placed in boxes and covered with their appropriate primary 
antibody solutions. Boxes were placed on shakers at 4°C overnight.  
The membranes were then washed with PBST (0.1% Tween 20 in PBS) 3 times for 3 
minutes on a shaker at RT. The periostin blots were also washed with a high salt buffer 
for 10 seconds prior to PBST wash.  
Secondary antibody solutions were made with the appropriate blocking buffers with an 
additional 0.1% Tween 20 at a dilution of 1:10,000. Membranes were placed in black 
boxes with lids and covered in secondary antibody solution. The boxes were placed on 
shakers at room temperature for 1 hour. The membranes were then washed with PBST 
3 times for 3 minutes on the shaker. This was followed by 2 washes with PBS for 3 
minutes each, on the shaker.  
The developed membranes were then imaged using the Odyssey CLx and analysed using 
the Image Studio software configured to use with Odyssey CLx images. Alternatively, or 
NIR fluorescence imaging using Odyssey was used to visualise the blot and the Odyssey 
software, Image Studio, was used to quantify the obtained image. All analysis was 
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performed blind (without prior knowledge of which sample was being measured) and 
normalised to tubulin or vinculin expression. 
2.9 In-vivo study  
2.9.1 Materials  
• Sterile 0.9% injectable sodium chloride solution (Sigma) 
• Isoflurane (Sigma) 
• Pain relief cream  
• Isopropanol (Sigma) 
• Liquid nitrogen  
• OCT (Thermo scientific) 
• Mice used were: C57BL/10 
Animals for all in vivo experiments were purchased from Harlan (UK) and maintained 
in-house. All experiments were carried out under statutory Home Office 
recommendations, regulatory, ethical and licensing procedures under the Animals 
(Scientific Procedures) Act 1986. Licence Holder Name: Golnoush Golshirazi  
2.9.2 Protocol  
The desired antisense oligonucleotide dilution was prepared in sterile injectable saline 
as was the desired BaCl2. Mice were anesthetised using Isoflurane and injection of 25µl 
of sterile saline solution, AO in sterile saline or BaCl2 carried out into the tibialis anterior 
(TA). Pain relief cream was applied to the TA of animals injected with BaCl2. Animals were 
placed into an isolated chamber until fully conscious and then returned to their normal 
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cage where they were monitored daily. TAs from mice was excised post mortem and 
weights were recorded. The muscles were embedded in OCT embedding medium and 
frozen in iso-propanol cooled with liquid nitrogen. Cryosectioning was performed with 
OTF 5000 cryostat, and 10µm transverse sections of each TA were sectioned up to 10 
levels through the muscle length. The tissue cut in the intervening sections between the 
levels of a block was collected at 10µm in 1.5ml Eppendorf tubes for protein and RNA 
extraction and stored at -80°C.  
2.10 Picro-red Sirius red staining  
2.10.1 Materials  
• Slides with 10µm thick sections cut as outlined in section 2.9 
• Sirius Red  
• Saturated aqueous solution of picric acid  
• 4% (v/v) formaldehyde solution in PBS 
• 100% Absolute Ethanol  
• 0.5% (v/v) Acetic acid  
• Xylene (BDH) 
• DPX mountant (BDH) 
• Nikon NiE upright microscope  
2.10.2 Protocol  
0.3g of Sirius red was dissolved in 100ml of saturated aqueous solution of picric acid to 
make a 0.3% picro-sirius red solution. This solution was filtered before use.  
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Slides were air dried and fixed in 4% formaldehyde for 10 minutes. They were then 
washed twice in tap water for 5 minutes and once in distilled water for 5 minutes. The 
slides were then placed in 100% ethanol for 5 minutes and air dried for 20 minutes at 
least, to allow slides to be completely dry. The dry slides were then submerged in 0.3% 
Sirius red solution for one hour. The slides were then washed quickly in distilled water 
and fixed in two washes of 0.5% acetic acid, 5 minutes each wash. After fixing, the slides 
were dehydrated in three washes of 100% ethanol, 5 minutes each wash. The slides 
were then placed in xylene for 10 minutes and mounted using DPX. The slides were then 
visualised and photographed using the Nikon NiE upright microscope where Collagen I 
and III were stained in red and cytoplasm in yellow. Random regions of a section were 
captured at 10X making sure no overlaps took place. Three images were taken per 
section. The images were recorded and processed using identical parameters of 
exposure and saturation between differentially treated and control samples. Analysis 
was performed using ImageJ. All analysis was performed blind. 
2.11 Immunofluorescence staining  
2.11.1 Materials  
• 4% Formaldehyde solution in PBS  
• Phosphate Buffered Saline (PBS) 
• Goat Serum 
• Triton X-100 
• Tween 20  
• Rabbit anti-Periostin (Abcam. ab14041): 1/400 dilution. Stored at -20°C. 
• Rabbit anti-Fibronectin (Abcam, ab2413): 1/400 dilution. Stored at -20°C. 
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• Rabbit alpha-SMA (abcam, ab5694): 1/200 dilution. Stored at -20°C. 
• Rabbit anti-Collagen VI: 1/400 dilution. Stored at -20°C 
• Rat anti-Laminin (Sigma, L9393): 1/800 dilution. Stored at -20°C. 
• Goat anti rabbit-Alexa Fluor 488 (ab150077): 1:200 dilution. Stored at 4°C 
• Goat anti Rat Alexa Fluor 568 (ab175476): 1:200 dilution. Stored at 4°C 
• Dapi (Sigma)(1µg/ml):1/1000 dilution Stored at -20°C. 
• Mounting medium (Vector Labs) 
• Nikon NiE upright microscope  
2.11.2 Protocol  
Blocking buffers were made individually for different staining: 
• Periostin staining blocking buffer: 1xPBS, 20% Goat Serum, 0.1% Triton X-100 
• Alpha-SMA staining blocking buffer: 1xPBS, 5% Goat Serum, 0.1% Triton X-100 
• Collagen VI and Fibronectin staining blocking buffer: PBST(0.05% Tween 20), 5% 
milk 
Slides were air dried at room temperature for 15 minutes. The slides were then fixed in 
4% PFA for 10 minutes. Slides were washed quickly with PBS then blocked in appropriate 
blocking buffer for either 1 hour for Alpha-SMA, Collagen and Fibronectin staining or 1 
hour 30 minutes for Periostin staining, all at room temperature. Slides were then quickly 
dipped into a jar filled with 1XPBST (0.05% Tween 20). Antibody dilutions containing the 
appropriate antibody as well as laminin antibody were made in the specific blocking 
buffer and added directly onto the slides; slides were incubated either overnight at 4°C 
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in the case of Periostin and Alpha-SMA staining or 1 hour at room temperature in the 
case of Collagen VI and Fibronectin.  
Slides were washed three times in 1XPBST (0.05% Tween 20) for 5 minutes. Secondary 
antibody dilutions were made in 1XPBST (0.05% Tween 20) and 1% goat serum, added 
directly onto the slides and incubated for 1 hour at room temperature in the dark. The 
slides were then washed 5 times in 1XPBST (0.05% Tween 20) for 5 minutes, protected 
from the light. DAPI was diluted in 1XPBST (0.05% Tween 20) and 1% goat serum and 
added directly onto slides and incubated for 10 minutes protected from the light. Slides 
were washed 3 times in PBST (0.05% Tween 20) for 3 minutes, protected from the light.  
 The slides were then mounted using mounting medium and left to air dry overnight at 
4°C protected from light. The slides were stored at 4°C. Slides were then visualised and 
photographed using the Nikon NiE upright microscope. Random regions of a section 
were captured at 20X making sure no overlaps took place. The images were recorded 
and processed using identical parameters of exposure and saturation between 
differentially treated and control samples. Analysis was performed using ImageJ. 
Analysis was performed blind. 
2.12 Bioinformatics Tools 
The following bioinformatics are available on-line and free for academic use: 
• Gene sequences, with protein translations, gene structures and transcription 
products (intron-exon structures) are available with many graphic displays from 
NCBI and Ensembl: https://www.ncbi.nlm.nih.gov;  www.ensembl.org 
• Transcript sequences for mstn and postn were obtained from Ensembl (above) 
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• Homology between orthologue sequences was using SnapGene and EMBOSS 
Matcher. from the European Bioinformatics Institute:  
https://www.snapgene.com/academics/for-academics/ 
https://www.ebi.ac.uk/Tools/psa/emboss_matcher/nucleotide.html) 
• For AON short sequence, off-target binding site searches, BLAST was performed 
over the nucleotide collection nr/nt database run under search parameters 
adjusted for ‘short input sequences':  
https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE_TYPE=BlastSearch 
• Free energies of PMO binding to target and target free energy were calculated 
using RNAup server: http://rna.tbi.univie.ac.at/cgi-bin/RNAxs 
• Secondary structures for portions of mstn mRNA were predicted with Mfold 
software: http://mfold.rna.albany.edu/?q=mfold 
• Splice motifs were predicted using Human Splicing Finder and ESEfinder: 
http://www.umd.be/HSF3/HSF.shtml; http://krainer01.cshl.edu/cgi-
bin/tools/ESE3/esefinder.cgi?process=home  
• For a second method of predicting ESE sites RESCUE-ESE was used: 
http://genes.mit.edu/burgelab/rescue-ese/ 
• Oligonucleotide Tms and %GC were calculated for PMOs using the IDT 
OligoAnalyzer tool: www.idtdna.com/tools/oligoanalyzer. 
 
2.13 Statistics  
All statistics for this project was carried out using Prism software. Where comparison of 
two groups was concerned a student t-test was performed between the groups. In the 
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case where multiple groups were compared One Way ANOVA was performed. T-test 
was used to compare groups after one-way ANOVA. 
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3. Design and In-vitro testing of antisense oligonucleotides 
targeting MSTN expression  
3.1 Introduction  
Myostatin downregulation has been suggested as an effective approach to decrease 
fibrosis and increase muscle mass, especially in dystrophic disease models (discussed in 
section 1.9). We have previously demonstrated that an AON-based exon-skipping 
strategy is particularly effective in decreasing myostatin expression by creating an out-
of-frame transcript of the gene (Kang et al., 2011b; Lu-Nguyen et al., 2015). Here, we 
have speculated whether targeting other transcriptional signals regulating processing 
and maturation of mRNA (e.g. polyA signal) could also serve as an efficient method to 
downregulate myostatin expression. Therefore, PMOs against the myostatin polyA 
signal were designed and compared to the previously tested PMO (i.e., D30-PMO) that 
induces frameshift of the myostatin transcript.  
3.1.1 Objectives 
In this Chapter we designed new PMOs predicted to bind the polyA binding region of 
the MSTN gene, using bioinformatics tools. Three were selected based on various 
bioinformatic predictions: they were tested by transfecting cells, and measuring MSTN 
mRNA levels.  Downregulation of myostatin mediated by three novel PMOs targeting 
the polyA signal was compared with downregulation achieved by the previously 
designed PMO which targeted exon 2 to cause a frame-shift of myostatin. It was 
anticipated that targeting the polyA control region of the gene might abrogate gene 
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transcription more severely than the previously designed oligonucleotide, and that this 
might be reflected in the mRNA levels as measured by RT-PCR and qPCR. 
PMO chemistry was used in this in vitro study. PMOs are third generation antisense 
oligonucleotides with the main modification being on the furanose ring of the nucleotide 
(Chan, Lim and Wong, 2006). They have better target affinity, nuclease resistance, 
biostability and pharmacokinetics. PMOs are non-charged antisense oligonucleotides 
and are resistant to nucleases and proteases in biological systems making them very 
stable (Amantana and Iversen, 2005). The lack of charge on PMOs means they cannot 
be delivered efficiently across cells using cationic liposomes and therefore need to be 
used at high concentrations (Sazani et al., 2001). Many different methods for the 
delivery of PMOs to cells have been studies such as conjugation of peptides to PMOs (P-
PMOs or ARP-PMOs) (Nelson et al., 2005), annealing of an anionic single-stranded 
nucleic acid molecule a ‘leash’(Marsollier et al., 2016) or the use of a transfection 
reagent called an Endo-Porter. Endo-Porter delivers substances into the cytosol by an 
endocytosis-mediated process and has been previously used and proved to be efficient. 
A previous study in the lab as well as a published study has shown that using the Endo-
Porter reagent at 6µM is successful at delivering PMOs into cells (Summerton, 2005). 
Based on the mentioned, we used 6µM of the Endo-Porter in this study. 
3.1.2 Choosing a target sequence common to mouse and human 
In order to identify optimal target sequences for AON design, the homology between 
the human and mouse exon 3 sequences (where the polyA signal resides) were aligned 
using pairwise alignment, with EMBOSS Matcher. To predict off-target binding of the 
PMOs designed to target the 3’UTR of the MSTN transcript, a BLAST search of each of 
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the PMO sequences was run through the nucleotide collection nr/nt database run under 
search parameters adjusted for ‘short input sequences’ (NCBI Resource Coordinators, 
2014). For BLAST, a very strong match for short sequences has an E-value (Expect value, 
where a score of 10 means that 10 hits will be found by chance, 
https://blast.ncbi.nlm.nih.gov/Blast.cgi?CMD=Web&PAGE_TYPE=BlastDocs&DOC_TYP
E=BlastHelp#expect) of 1e-04 or smaller, whereas a poor match indicating that the PMO 
is less likely to bind to its target, is considered to be greater than the threshold of 1e-03. 
3.1.3 Bioinformatic prediction of mRNA secondary structure as a design principle 
for antisense oligonucleotides  
To design an antisense oligonucleotide that successfully hybridises with its target, 
several factors must be considered. The most likely structure of the folded, 3-
dimensional target RNA molecule in the cell appears to affect binding; it is discovered 
by predictive software. Base pair interactions, as well as interactions with the 
environment, make the pre-mRNA polymers prone to formation of secondary and 
tertiary structures; these become one or more thermodynamically stable conformations 
(Mathews and Turner, 2006). During translation, this secondary structure is unwound 
by ribosomes (Qu et al., 2011). Antisense oligonucleotides do not have an intrinsic ability 
to unwind mRNA, and therefore antisense-based downregulation is believed to be 
limited by the secondary structure of mRNA and the position of the target sequence 
within that structure (Popplewell et al., 2009). Pre-mRNA secondary structures can be 
divided into several types of structural motifs, such as stems (i.e. double helices), 
internal loops, hairpin loops, bulge loops and pseudoknots (Qu et al., 2011). Three-
dimensional tertiary structures can also be produced as a result of the interaction 
between multiple secondary structural motifs (e.g. tRNA or G-quadruplexes).  
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Higher structural ordering inflicts changes in the free energy (kcal/mol) of the structure 
(Eddy, 2004). The measurement of free energy is indicated by the proportion of enthalpy 
(energy) and entropy (disorder) of the system. Chemical systems including nucleic acids 
show a tendency to minimise their free energy in order to maximise structural stability. 
The lower the free energy, the more stable is the predicted structure so, for an RNA 
molecule, the structure with the lowest free energy is determined. Mfold is the most 
widely utilised software for predicting secondary structure for an RNA molecule by 
finding energy minima and analyses sequences input in FASTA format (Zuker, 2003).  
Knowing the most likely secondary structure of the pre-mRNA allows antisense 
oligonucleotides to be designed which target more accessible sequences. Previous 
research has shown that antisense oligonucleotides targeting sequences with little or no 
local structure are more effective (Vickers, Wyatt and Freier, 2000). In addition, a more 
recent study looking at PMO chemistry of AONs has shown that candidates designed to 
target sequences with less structure had better bioactivity (Popplewell et al., 2009). 
Therefore, antisense oligonucleotides were designed so that both ends or at least one 
end of the antisense sequence is targeting an open conformation of the transcript to 
increase the efficacy of the AON.   
3.1.4 Antisense oligonucleotide thermodynamics and its effects on bioactivity 
Guanine-cytosine (GC) content, melting temperature (Tm) and energies of AON-target 
complexes have a profound effect on AON bioactivity. Generally, a GC content of around 
30-40% and Tm around 50°C yield the most effective 2’OMe AON chemistry (Aartsma-
Rus et al., 2009). A higher theoretical total binding energy (∆"#) of the AON to target 
sequence also results in a more effective drug in a biological system (Aartsma-Rus et al., 
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2009; Popplewell et al., 2009). The information needed to work out the theoretical total 
binding energy is: (1) opening energy of target sequence; (2) opening energy of the AON 
and (3) energy from duplex formation between target and AON. The theoretical binding 
energy of AON to tathe rget can be calculated following the formula below.  
∆"# = ('()*+,	.*/0	1234)5	./*067#/() − (/3)(#(+	)()*+,	/.	9:)− (:3)(#(+	)()*+,	/.	76*+)7	;)<2)(=)) 
It has also been suggested that longer PMOs have better binding energies and are more 
likely to bind to target its sequence (Pramono et al., 2012). S-fold 
(http://sfold.wadsworth.org/cgi-bin/index.pl) is a software that has been used over the 
past two decades for bioinformatic prediction of antisense and siRNA given target 
sequences. S-oligo, a module of S-fold, produces a series of potential antisense 
sequences, each varying by one base pair, for an input sequence (Ding, Chan and 
Lawrence, 2004). S-oligo was therefore used to design a series of potential antisense 
oligonucleotides with a specified length (maximum 30nt), each varying by one base pair.  
RNAup server is software that calculates the factors above to obtain the total theoretical 
binding energy and produce an optimal secondary structure predicted to occur upon 
hybridisation of AON to its target (Golshirazi et al., 2018). RNAup server was therefore 
used to calculate the theoretical binding energies of the series of designed antisense 
oligonucleotides.  
3.1.5 PMO bioactivity and transfection in an In-vitro model  
PMO chemistry of antisense oligonucleotides has previously been tested for the 
restoration of dystrophin expression through exon skipping in the context of the DMD 
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disease model (details in section 1.6). In addition, PMOs were used to knock down 
myostatin through skipping of exon 2, producing an out of frame protein artefact (Kang 
et al., 2011b; Lu-Nguyen et al., 2015). Interestingly, PMO chemistries were also 
successfully used to downregulate the expression of a toxic gene, DUX4, by targeting its 
polyA signal in the 3’UTR of its pre-mRNA (Marsollier et al., 2016).  
The main chemical properties of PMO include high nucleic acid binding affinity, 
nuclease-resistance and high solubility in aqueous solutions (Alter et al., 2006; 
Summerton and Weller, 1997). Compared to other AO chemistries, PMO shows 
particularly high bioactivity in restoring dystrophin expression in mdx mice and 
dystrophic dogs across various skeletal muscles (Yokota et al., 2009). However, due to 
the lack of charge of the PMO molecules, their diffusion across cell membranes is limited 
and considerably high amounts of PMO have to be administered into cell cultures in 
order to achieve a biologically significant effect (Suwanmanee et al., 2002; Sazani et al., 
2002).  
Endo-Porter reagent provides an alternative way of effective PMO delivery into cultured 
cells (Summerton, 2005). Endo-Porter is a peptide-based reagent that mediates 
endocytosis, functions in the presence of serum and has the capacity to deliver a number 
of PMOs at various concentrations (Gene Tools, Manufacturer's manual, 
https://www.gene-tools.com/endo_porter). The process of PMO delivery by Endo-
Porter requires both the AON and Endo-Porter to be taken up simultaneously from the 
media into the cell via endocytosis. The ionic properties of the Endo-Porter rupture the 
endosomal membrane inside the cell and release its contents into the cytoplasm. Endo-
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Porter-mediated PMO delivery into various skeletal muscle cell line types, derived from 
both mouse and humans, have been effectively tested in numerous studies. 
Changes in MSTN mRNA expression were assessed by transfection with the three PMOs 
targeting the polyA signal as well as the previously designed PMO targeting MSTN exon 
2, MSTN-D30 PMO (Lu-Nguyen et al., 2015). As a control PMO (presumed to bind at 
random) a Gene Tools scrambled PMO sequence was synthesised. PMO transfection 
was of rhabdomyosarcoma (RD) human immortalised myoblast cells from a line that 
expressed MSTN. Cells were transfected with 2 µM PMO and 6 µM of Endo-Porter in 2% 
(v/v) serum media. MSTN mRNA levels were assessed semi-quantitatively using 
multiplex RT-PCR and quantitatively using RT-qPCR. 18s and GAPDH were used as 
housekeeping genes for the multiplex RT-PCR and RT-qPCR, respectively. For semi-
quantitative analysis products from the multiplex RT-PCR were ran on a 1.5 % (w/v) 
agarose gel and bands were quantified using the Gene Tool software.  
3.1.6 Quantitative polymerase chain reaction  
Quantitative polymerase chain reaction (qPCR) or real-time polymerase chain reaction 
(Real-Time PCR) quantify relative gene expression by detecting and quantifying the 
amplification products in real time (Gibson, Heid and Williams, 1996; Nolan, Hands and 
Bustin, 2006). Fluorescent reporter dyes are used to label PCR DNA products and aid 
their quantification (Tania et al., 2006). The point where the fluorescence levels exceed 
a defined background threshold is recorded and given as a value called the Ct (threshold 
cycle) or Cp (crossing point) (Tania et al., 2006). Therefore, the more abundant the 
target, the lower the Ct value. The Ct values obtained from a target gene is then 
normalised to Ct values of a housekeeping gene. The high sensitivity and quantitative 
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nature of qPCR have been found particularly useful in detecting small changes in gene 
expression levels that are not attainable by other conventional methods for gene 
expression detection (e.g. reverse transcription PCR products visualised on gels or in-
situ hybridisation, Smith and Osborne, 2008).  
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3.2 Results  
3.2.1 Comparison of human and mouse polyA signal and the surrounding sequence  
PolyA signals were identified in both the human and mouse myostatin transcripts and 
using the NCBI nucleotide database (Figure 3.1). EMBOSS Matcher revealed sequences 
conserved between human and mouse in exon 3, which, combined with the polyA signal 
sequence could potentially indicate functional importance and serve as a candidate 
target for AON-based strategy to downregulate myostatin expression. The alignment 
analysis showed a high degree of homology between the mouse and human exon 3 
(Figure 3.2). EMBOSS Matcher calculated a percentage similarity of 76.4% between the 
human and mouse exon 3. The 22 base pairs surrounding the polyA signal is completely 
homologous (highlighted in grey) showing conservation between species and suggesting 
that this region may be important in regulating myostatin expression if the two species 
regulate this gene in the same manner (Figure 3.2).
Figure 3.1 NCBI Nucleotide database output for human and mouse 3’ MSTN transcript  
The polyA signal (red writing on white) identified in the NCBI gene database which precede 
gene sequences (green for human and black in mouse).  
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Figure 3.2 Alignment of Mstn 3’ UTR in the human and mouse. 
Alignment was carried out using EMBOSS Matcher with sequences obtained from 
Ensembl (http://www.ensembl.org). The polyA signal is indicated by a red font; a 22bp 
region with 100% homology between human and mouse (and including the polyA signal) 
is highlighted in grey.  
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3.2.2 Prediction of the secondary structure surrounding the human Mstn polyA 
signal and PMO design  
Mfold was used to assess putative secondary structure of the transcript region 
surrounding the polyA signal. Mfold was given an input of 230 nucleotide sequence 
comprising exon 3 (and including the polyA signal previously identified). RNA secondary 
structure prediction indicated that 3 nucleotides of the polyA signal has an open 
configuration (Figure 3.3), consistent with it being a binding site for further processing.  
S-fold was used to derive all potential PMO sequences targeting this polyA signal and 
the surrounding regions (Table 3.1). Due to the low GC content of the region containing 
the polyA signal, a series of longer PMO 30mers was designed. These include PMOs 
which were chosen and used for experiments: HpA1 and HpA2. The HpA1 PMO was 
predicted to bind the open conformation of the mRNA secondary structure, whereas the 
HpA2 targeted the closed conformation of the transcript but had a more optimal %GC 
and Tm values (Figures 3.4 & 3.5). Choosing PMOs with complementary binding targets 
allows investigation of the importance of binding to predicted secondary structures 
albeit complicated by the different thermodynamic properties of the PMO. In addition 
to the two 30mer PMOs, a 22-mer PMO, HMpA, was designed to target the polyA signal 
and the 22mer found to be conserved between mouse and human (Figure 3.2 & 3.4). 
The 3’ end of HMpA spanned 7 nucleotides of the open conformation of the transcript, 
whereas its 5’ end bound the part of the target that had a closed configuration (Figure 
3.4). 
The overall binding energy of the designed PMOs to their target sequence was assessed 
using RNAup server. The 3’UTR of human myostatin was submitted as the target 
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sequence and the PMO sequences as binding candidates. PMOs HpA1, HpA2 and HMpA 
all showed relatively low overall free-binding energies of -34.21kcal/mol, -34.01kcal/mol 
and -25.12kcal/mol, respectively, that is, exhibiting strong binding (Figure 3.5). As 
predicted, the longer PMOs (i.e. HpA1 and HpA2) have considerably lower binding free-
energy compared with the shorter HMpA sequence so are predicted to bind better to 
the target (Figure 3.5). 
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Figure 3.3 Secondary structure of the human MSTN polyA signal and its surrounding region predicted by Mfold. 
The figure shows four predicted structures of the MSTN exon 3 sequence, along with their respective free-binding energies. The structures are 
shown in order of increasing  free energy as indicated below each structure. 
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Table 3.1 Prediction of 30-mer PMOs spanning though the polyA signal region of the MSTN. 
The list was generated by S-fold includes the GC content and Tm values for each PMO.  
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Figure 3.4 Positioning of designed PMOs on the human MSTN transcript  
A) Placement of PMOs along exon 3 of the MSTN transcript. The polyA signal is shown with 
a red font and marked with a white box. The alignment of human and mouse sequence is 
shown with mismatches highlighted in red.  
B) Position of designed PMOs on the human MSTN secondary structure targeting the polyA 
signal (circled in red). HpA1, HpA2 and HMpA PMOs are shown in green, orange and purple, 
respectively. 
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Figure 3.5 PMO overall free energy of binding was calculated using RNAup server. A) The RNAup 
derived plot shows the interaction free energy of the PMO along the target sequence (RED) deltaGi and 
the energy needed to open the structure in the longer sequence (BLACK). The Y axis indicates 
nucleotide position of the sequence. B) Three designed PMOs, their target sequence along with their 
thermodynamic properties are shown.   
Figure 3.5 Thermodynamic properties of PMO calculated by RNAup server 
A) The RNAup derived plot shows the overall free-binding energy between PMO and the target 
sequence along the transcript. In red, the free-binding energy of t PMO to th  target sequence 
is indicated. The energy required to resolve the secondary structure of the target sequence is 
indicated in black. The y-axis shows the free energy in kcal/mol, while the x-axis indicates the 
nucleotide position in the sequence.  
B) Summary of the thermodynamic properties of the PMO sequences designed to target the MSTN 
exon 3 polyA region (from RNAup). 
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3.2.3 Off target prediction of designed PMOs  
The nr/nt BLAST search for off-target binding of the PMO sequences (Table 3.2) 
throughout the human genome For each of the PMO sequence analysed, two distinct 
gene target sequences were selected by the highest alignment scores as represented by 
smallest E-values (Table 3.2).  For all the BLAST-analysed PMO sequences the predicted 
target sequences with the highest alignment score (i.e. lowest E-value) was the MSTN 
transcript (Table 3.2). Therefore, all designed PMOs were predicted to have a very strong 
binding to the MSTN transcript (E-value ≤ 7e-08), whereas the off-target gene 
candidates show markedly higher values, greater than 1e-03 (Table 3.2). 
 
Table 3.2 PMO of off-target prediction 
Each of the predicted series of PMOs was run through Ensembl BLASTN, under conditions 
for short input sequences and limited to human and nr/nt databases. E-values were 
generated which revealed these three PMOs have the highest probability of binding the 
MSTN transcript and a very low likelihood of binding any other gene.  
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3.2.4 In-vitro testing of PMOs targeting MSTn 3’UTR in RD cells 
Having designed three specific PMOs based on the bioinformatic analysis, it was then 
important to test their effect on myostatin expression in vitro. RD cells are a human 
myoblast cell line that was previously used to study MSTN exon 2 skipping with one of 
the test (control) PMOs, MSTN-D30 (Nguyen et al., 2015). MSTN message levels were 
assessed by PCR. Firstly, multiplex RT-PCR showed downregulation of MSTN by all PMOs 
tested, compared to the control PMO, a scrambled sequence (Figure 3.6). However, the 
reduction of MSTN by the HpA1 PMO was not statistically significant (Figure 3.6). Out of 
the three PMOs designed to target the polyA site, HMpA treatment resulted in the 
highest downregulation of the MSTN expression (p<0.01). Overall, the highest 
downregulation of MSTN mRNA, as measured by PCR, was that induced by MSTN-D30 
targeting the MSTN exon 2 to induce exon skipping (p<0.001) (Figure 3.6). Multiplex 
PCRs are always complex because of interference between PCR products, so results are 
rarely quantitative and should be treated with caution. 
To quantitatively assess the expression of the MSTN levels in the PMO treated cells, RT-
qPCR was carried out. With this method, MSTN mRNA levels showed statistically 
significant downregulation with HpA1 treatment compared to the control (p<0.01), so 
that the relative sensitivity of the mono-PCR resulted in a greater sensitivity of RT-qPCR 
to changes in regulation, compared to the multiplex RT-PCR assay (Figure 3.7). The 
remaining PMO chemistries, showed a similar pattern of MSTN downregulation as 
measured by the RT-PCR. (Figures 3.6 & 3.7). However, the magnitude of statistical 
significance in RT-qPCR compared to the RT-PCR was increased by 10- fold for 
HpA2(p<0.001) and MSTN-D30(p<0.0001), and 100-fold for HMpA(p<0.0001).  
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Figure 3.6 Myostatin expression following PMO transfection  
RD cells were transfected with PMO: either HpA1, HpA2, HMpA or MSTN-D30-PMO; Mstn and 18S RNA primers were used together for PCR.  
A) Multiplex PCR was run using MSTN and 18S primers. The RT-PCR products were separated on a 2% agarose gel along with molecular weight 
markers. The strongest bands in the ladders are 1013 (marked Mstn) and 300bp (Hyperladder IV, Ecogen). 
 B) Intensities of the bands were quantified using GeneTools software. Expression is inhibited by all PMOs compared to the control, in order 
HpA1 < HpA2 < HMpA (polyA targetting) < MSTN-D30 (truncated product). Statistical comparison was using a one-way Anova test , N=3. 
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Figure 3.7qPCR assay of MSTN expression normalised to GAPDH.  
RD cells were transfected with HpA1, HpA1, HMpA or MSTM-D30 PMOs. RT-qPCR of the cells was with primers to MSTN and GAPDH housekeeping 
gene. Replicate standard deviations are much smaller with this method. The same pattern of suppression of mRNA levels is seen as in Figure 3.6. 
A) MSTN expression relative to GAPDH was quantified and compared to levels in control PMO samples using a one-way ANOVA statistical test, N=3. 
B) Melting curves of MSTN and GAPDH showed two and only two distinct peaks (MSTN in blue and GAPDH in green) indicating primer specificity 
and absence of contamination arising from alternative PCR primer binding sites: only MSTN and GAPDH were amplified. 
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3.3 Discussion  
Antisense oligonucleotides targeting the MSTN’s polyA signal within the 3’UTR were 
designed, with a view to downregulating myostatin expression. Bioactivity of these 
PMOs was compared to MSTN-30D, the PMO inducing exon skipping which targets the 
MSTN exon 2  (Kang et al., 2011b).  
In order to design optimal PMO chemistries, bioinformatic tools can be used to predict 
the ability and specificity of a short DNA sequence binding to its target (Popplewell et 
al., 2009; Golshirazi et al., 2018). Extensive research has been carried out to assess how 
to design successful antisense oligonucleotides which induce exon exclusion (Mann et 
al., 2002) to either disrupt or restore reading frames (Malerba et al., 2012). Importantly, 
since they involve nucleotide sequences, the findings of these studies can be applied to 
the design of AON targeting other regulatory elements present within transcript 
sequences.  
Polyadenylation of the 3’ end of pre-mRNAs is essential for maturation of the message 
and its export from the nucleus (Chapter 1). The most important element determining 
the cleavage site is the polyA signal which consists of a six-nucleotide motif (Tian et al., 
2005b). In mammals, the consensus sequence AAUAAA or AUUAAA is recognised by 
cleavage and polyadenylation factors which demark a cleavage site 10-30 nt 
downstream of the polyA signal (Proudfoot, Furger and Dye, 2002b; Wada et al., 2012). 
Previous studies have successfully targeted the polyA signal using PMO chemistry for 
antisense oligonucleotides, to downregulate gene expression (Marsollier et al., 2016). 
In Marsollier's study, targeting of the polyA signal was more effective than targeting 
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other 3’UTR elements such as the DSE site where the pre-mRNA is cleaved. This is why 
targeting the polyA signal was used to downregulate myostatin in this study.  
Many studies have been carried out to assess the ‘hit rate’ of AON oligonucleotides: 
thermodynamic stability, secondary structure of target mRNA, length of the AON and 
proximity of its hybridisation to a functional gene motif have all been found to affect the 
binding and effectiveness of synthetic 'drug' AONs (Chan, Lim and Wong, 2006; Aartsma-
Rus, et al., 2009; Popplewell et al., 2009). It is widely accepted that the following four 
considerations are effective for increasing bioactivity of designed AONs: i) prediction of 
RNA secondary structure; ii) GC content; iii) Tm of AON (a prediction of how tightly it 
binds its target) and iv) total-free binding energy of AON to the target sequence. 
Bioinformatics tools are provided gratis to perform each of these calculations (Section 
3.1). In this study, all the above factors were considered, and PMOs were designed as 
carefully as possible using bioinformatics alone, and the constraints of the target. The 
target itself was selected bioinformatically, based on homology between mouse and 
human sequences; homology indicates conservation of function. Given the very specific 
target sequence, it was necessary to work with PMOs where the percentage GC was 
below the ideal of 55%, suggested by Ho et al. (1996) as the minimum GC content for 
very stable AON binding. For this reason, the length of the newly designed PMOs was 
increased to 30 nucleotides, to increase the percentage GC as far as possible and 
increase the Tm of the PMO. An increase in length was found by Popplewell et al. (2009) 
to increase PMO bioactivity. The Tm of the designed PMOs were between 45-50°C which 
was shown to be optimal by Aartsma Rus et al. (2009) .  
126 
 
The role of secondary pre-mRNA structure in the efficacy of AONs has been studied, and 
there has been a general consensus that less local structure predicted at the target 
sequence, the more successful the AON (Bowen, Jenkins and Fraser, 2013). In the 
Popplewell study (Popplewell et al., 2009), it was shown that when testing PMOs, the 
secondary structure of the target sequence does not significantly correlate with the 
success of the PMO, but when looking at successful PMOs, the ones that target 
sequences with less local structure are definitely more effective. PMOs in this study 
were therefore designed so that they bound different parts of the target, with respect 
to predicted secondary structures (Figure 3.4). The weakest PMO, HpA1, was predicted 
to bind the target sequence with both ends of the PMO in loops, one end being the open 
polyA signal sequence, but the other in the loop of a stem-loop structure. HpA2 was 
predicted to bind with both ends targeting stems or double helix, closed RNA 
conformation. However, it has better thermodynamic properties, with a higher GC 
content and higher overall binding energy. The best of the three PMOs, HMpA, had 
lower binding energy and GC content but targeted the polyA sequence with one end, 
where RNA is in the open conformation, and the other end of the PMO wraps around a 
stem-loop (like HpA1 but with the other end around the loop). These three combinations 
allowed some comparison of the putative effects of different factors; for a rigorous 
assessment of RNA secondary structure, every PMO would have had the same GC 
content and Tm/free binding energy.  
Having designed three PMOs targeting the polyA signal they were tested in RD cells 
along with the MSTN exon 2 targeting PMO, MSTN-D30, which is also a 30-mer. Semi-
quantitative analysis by RT-PCR showed that although all four PMOs caused a decrease 
in MSTN expression, the HpA2, HMpA and MSTN-D30 PMOs showed significant 
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downregulation; in our hands, MSTN-D30 PMO resulted in nearly no MSTN expression, 
while HMpA resulted in significant downregulation.  
When semi-quantitative analysis was previously used to quantify the effect of exon 
skipping (Kinali et al., 2009b; Popplewell et al., 2009; Kang et al., 2011b), both the 
skipped product and full-length product were amplified in the PCR reaction, products 
run on an agarose gel and the ratio of the full-length band and skipped band quantified. 
In our case, we only amplified the full-length Mstn. It is possible that more out-of-frame 
(exon-skipped) Mstn was produced using MSTN-D30, but as this was not quantified it 
was not possible to say whether the new polyA-targeted PMOs were more effective. In 
other words, MSTN-D30 may have resulted in aberrant Mstn production which was not 
measured. In the case of targeting the polyA signal, there was no secondary product 
expected, as messages lacking the polyA tail are not even transported out of the nucleus 
(section 1.10).  
Although the multiplex PCR, optimised and used for this study, showed a clear 
downregulation of Mstn mRNA expression, the PCR amplification of MSTN mRNA was 
only semiquantitative, so not the most sensitive assay for our purposes. Due to this 
limitation, RT-qPCR was performed to more accurately quantitate MSTN mRNA. 
Predesigned primers were used to assess total RNA levels using, GAPDH, a housekeeping 
gene, for normalisation. It has previously been shown that RT-qPCR of total RNA is 
sensitive to mRNA loss by nonsense-mediated decay (NMD) (Pereverzev et al., 2015): in 
the case of degradative exon skipping, the truncated mRNA missing an exon no longer 
has a reading frame, so the transcript is subject to NMD (Ward et al., 2014). Using RT-
qPCR is therefore ideal for quantifying gene expression with both polyA targeting PMOs 
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and the exon skipping PMO. This also suggests that semi-quantitative analysis may not 
be representative of the extent of knockdown by PMOs designed for degradative exon 
skipping.  
RT-qPCR results showed a similar pattern to the semi-quantitative analysis. Knockdown 
by each PMO was significant, with MSTN-D30 PMO showing the greatest 
downregulation, followed by HMpA. This confirmed that exon skipping using the MSTN-
D30 PMO is more effective for myostatin knockdown than polyA targeted PMOs.  
HMpA was predicted to be least likely to bind its target as predicted by thermodynamic 
properties but proved to be the most effective in vitro assays. This could be due to the 
fact that HMpA completely targeted the putative 22-nucleotide sequence motif 
(presumably a control sequence) that are conserved between mouse and human. This 
result highlights the significance of this region in gene expression and the use of 
interspecies homologous motifs. Another factor contributing to the effectiveness of 
HMpA could be the fact that it binds to the predicted secondary structure at an open 
configuration at the 5’ end (in the polyA signal motif). This, combined with it targeting a 
significant orthologous conserved region may compensate for the less optimal 
thermodynamic properties. 
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4. Design of antisense oligonucleotides to target out-of-frame 
exons and downregulate Periostin in human and mouse   
4.1 Introduction  
4.1.1 Objectives  
PMOs have been made to target and downregulate Mstn (Chapter 3). This Chapter is 
concerned with designing PMO AONs targeting exons whose skipping will induce a 
reading frame shift in the human and mouse POSTN1 gene mRNA. This involved 
identifying candidate exons in the POSTN gene, of both human and mouse, using 
different bioinformatic tools to design PMOs, targeting ESE sites within conserved 
regions between mouse and human, with the most ideal thermodynamic properties, 
then testing the PMOs in transfected cells for downregulation of POSTN1 message.   
4.1.2 Modification of pre-mRNA splicing antisense oligonucleotides   
AONs have been extensively used in a variety of fields to target sequences around the 
splice sites where they interfere with the splicing machinery, and so disrupt the splicing 
process. Depending on the sequence targeted this can lead to exon inclusion or exon 
exclusion. In the latter case this can lead to restoration of the open reading frame in a 
mutated gene or disruption of the natural open reading frame. 
For DMD, a lot of effort has gone into designing AONs targeted to various exons of the 
DMD mRNA to restore the dystrophin reading frame, for several idiopathic mutations. 
The mRNA product is shorter because of skipping of the targeted exon, but in the 
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selected cases the ORF of flanking exons is in-phase and so the transcript is in-frame. In 
this way the final translation product is a shortened but functional dystrophin protein 
akin to those found in much milder BMD  (Sherratt et al., 1993; Aartsma-Rus et al., 2002; 
Dickson, Hill and Graham, 2002). However, antisense mediated skipping of exons that 
are flanked by out-of phase exons will lead to a transcript where there is a frame shift 
downstream of the skip. In this situation the reading frame will not be open, and a 
nonsense codon will rapidly be encountered. Such “destructive” exon skipping will lead 
to translation termination and a truncated protein product which is most likely inactive 
or dysfunctional, and/or rapidly degraded. AON reagents of this nature thus carry 
potential to downregulate the functional activity of the target gene and its product. 
(Ralston and Shaw, 2008). Operationally, the triplet nature of codons mandates that 
only exons whose nucleotide length is divisible by 3 will have the in-phase flanking exons 
that are required for an in-frame skipped transcript (Popplewell et al., 2009) and 
conversely, skipping of exons of a size non-divisible by 3 will yield a reading frame shift 
and a loss of function.  Exon of this nature can thus be easily identified. 
Although it has previously been shown that AON targeting of exon donor and acceptor 
splice site and branch point sequences successfully leads to exon exclusion (Mann et 
al., 2002; Graham et al., 2004; Wilton and Fletcher, 2005), there is no strong consensus 
(A Aartsma-Rus et al., 2009) and there is also evidence that targeting acceptor/donor 
splice sites does not always lead to skipping (Wilton at al 2006). In contrast targeting 
ESE elements which function to facilitate recognition of exonic sequences and the 
recruitment of the spliceosome machinery to the pre-mRNA has been shown to yield 
more consistent successful activity in terms of antisense-mediated exon exclusion 
(Stojdl and Bell, 1999). 
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In previous studies on the DMD and MSTN genes, AONs have been used to target 
specific exons, and in both cases this reduces exon inclusion. In the case of DMD, 
where the mutated dystrophin mRNA often produces a frame-shift, targeting exons 
flanking mutation sites may lead to the restoration of the ORF and appearance of a 
semi-functional BMD-like dystrophin protein. In the case of myostatin the aim was to 
disrupt gene expression and so AON-mediated exon skipping was designed to induce 
frame-shifting, creating out-of-frame transcripts with premature termination codons 
and a reduction in the level and function of myostatin protein (Kang et al., 2011a; 
Malerba et al., 2012). 
4.1.3 Predicting potential target ESE sites and designing PMOs 
Popplewell et al. (2009) and Aartsma-Rus et al. (2009) both evaluated a range of 
parameters in the design and application of AONs for DMD exon skipping. Their studies 
showed that targeting exonic sequences gave more functional antisense effects than 
targeting intronic sequences. This could be due simply to the higher GC content of exons 
which allowed the design of AONs against GC-rich sequences, leading to stronger AON 
hybridising. These and other studies also showed that AON hybridising to and presumed 
to be blocking ESEs also led consistently to AONs with strong exon skipping 
activity(Caputi, Kendzior and Beemon, 2002; Cartegni and Krainer, 2002; Smith et al., 
2002). T 
he number of ESE sites within the target sequence of AONs also showed a strong 
correlation with AON efficacy  (Annemieke et al., 2009):  ESE sites in these studies were 
predicted and identified using algorithms linked to either the RESCUE-ESE database  
(Fairbrother et al., 2002) or the Human Splicing Finder database (Desmet et al., 2009). 
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Human Splicing Finder (HSF) uses other databases such as ESE-Finder (Cartegni et al., 
2003) and RESCUE-ESE (Fairbrother et al., 2002) but as the title suggests is specific for 
human sequences. Targeting internal ESE sites by these means will imply operationally 
that exon-intron boundaries would not be precisely identified, as ESEs would not be 
recruited (Fairbrother et al., 2002). This, in turn, leads to the exon being excluded from 
the transcript. As discussed previously in chapter 3, other factors such as the GC content, 
Tm, position of binding on the target RNA secondary structure and the overall binding 
energy should also be considered when designing AONs (Popplewell et al., 2009).  
ESE-Finder has an input of a specific nucleotide sequence and outputs 6-8 nucleotide 
predicted ESE binding sites for SR proteins. ESE-Finder does this by using different 
matrices relative to different SR protein motifs to search for possible ESE binding sites 
(Liu, Zhang and Krainer, 1998; Liu et al., 2000). The sequence being examined at is pasted 
into the query interface or uploaded in FASTA format. A graphics output displays the 
exon sequence. Colour-coded bars on the graph represent the scores of different motifs 
above selected thresholds. The position of the bars on the X-axis (the breadth of the bar) 
shows the position and length of the motif on the exon sequence, whereas the height 
of the bar represents the motif score (Cartegni et al., 2003).  
RESCUE-ESE (http://genes.mit.edu/burgelab/rescue-ese/) is another bioinformatics tool 
used to predict ESE sites which uses a different method to find ESEs. In this case, ESE 
motifs are predicted by looking at the frequency of hexamers bound by weak or strong 
splice sites (Fairbrother et al., 2002). ESEs are known to be used by weak splice sites, 
and so hexamers with weaker splice sites are more likely to be dependent on ESEs 
(Fairbrother et al., 2002). 
133 
 
Human Splicing Finder (http://www.umd.be/HSF3/) and ESEfinder 
(http://krainer01.cshl.edu/cgi-bin/tools/ESE3/esefinder.cgi?process=home) were used 
in this Chapter to look at human and mouse ESE sites in Periostin (POSTN).  
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4.2 Results  
4.2.1 Comparison of homology between exons whose skipping will cause a shift in 
the human and mouse POSTN transcript ORF 
Results from Myostatin suggest that it would be ideal for identifying conserved 
sequences between the human and the mouse. Exons 3, 4, 7 and 16 were identified to 
be out-of-frame in the human and mouse POSTN transcript (below). In order to find 
conserved stretches within each exon sequence, pairwise alignment was used between 
the mouse and human sequences, using EMBOSS Matcher to calculate the percentage 
similarity for each exon (Figure 4.1). Exon 3 and 16 had the highest percentage similarity 
of 92.2% and 95.7% respectively. Exon 7 had a similarity of 91.5% while exon 4 and exon 
10 similarity scores were 82.6% and 85.8% respectively. Finding homology between 
these orthologues not only increases chances of targeting significant sequences (see 
Chapter 3) but also allowed the design of PMO sequences to target mouse and human 
POSTN at identical sequences, making the clinical application of the AON likely to be 
more reliable as the sequence being tested in the mouse would be the exact same 
sequence as that being used against the human genome in patients. 
 The sequences for each exon were accessed on the NCBI nucleotide database and 
clearly show (for Exons 3 and 16 only) the ends of each exon amino acid codon, 
demonstrating that the exon does not begin or end with a complete triplet encoding an 
amino acid (Figures 4.2A1, 4.3A1, 4.4A1, 4.5A1, 4.6A1).  
SnapGene software was then used to align the mouse and human exon sequences 
(Figures 4.2A2, 4.3A2, 4.4A2, 4.5A2, 4.6A2) and confirm the homologies found above 
(Figure 4.1). 
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Figure 4.1 Alignments of mouse and human POSTN exons 3,4,7,10 and 16 
Alignment was carried out using EMBOSS Matcher and sequences were obtained from Ensembl. Each exon is highly conserved with the highest 
percentage similarity being 95.7% in exon 16 and the lowest being 82.6% in exon 4 (see text). Dots represent mismatched nucleotides, bars homology. 
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4.2.2 Prediction of exon splicing enhancers (ESEs) and suppressors (ESSs) in exons 
3, 4, 7, 10 and 16 of human and mouse POSTN genes  
POSTN transcript ID ENSMUST00000107985.9 from Ensembl 
https://www.ensembl.org/index.html was used in the Human Splicing Finder 
programme (http://www.umd.be/HSF3/). Exons 3, 4 ,7, 10 and 16 were analysed 
individually. The outputs, shown in Figures 4.2B, 4.3B, 4.4B, 4.5B, 4.6B respectively, 
were a graph with the X-axis representing the sequence and scores for motifs on the Y-
axis and. Putative splicing enhancer motifs ESE (hot colours) and splicer silencer (ESS) 
motifs (cold colours) were identified. Wherever a peak along the exon indicated a higher 
score on the Enhancer side of the Y-axis, an ESE site was predicted.  
ESEs were predicted at the following positions (Figures 4.2B, 4.3B, 4.4B, 4.5B, 4.6B): on 
exon 3, two peaks were shown at nucleotide positions 4-11 and 53-65 of the exon 
sequence, with a score of ~10; exon 4 had two peaks at nucleotide positions 75-105 and 
46-66 with scores of ~12 and 28, respectively;  exon 7 had two peaks on the exon in 
positions 32-50 and 79-101, both with a score of ~10; exon 10 showed two peaks, one 
at 40-52 with a score of 20 and a smaller peak at 116-124 with a score of ~8. Exon 16 
being merely 46bp in length showed only a very weak peak with a score of ~5 at position 
1-31.  
Human Splicing Finder predicted ESE sites in the human genome only. In order to 
confirm the findings and also compare ESE sites between the human and mouse to 
identify conserved ESE motifs, ESEfinder was used. The human and mouse exon 
sequences were inserted into the ESEfinder software query box individually, and output 
generated (Figures 4.7, 4.8, 4.9, 4.10, 4.11). Putative human and mouse ESE sites were 
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compared, to look for conservation between the two species. Quite similar patterns in 
positions of some of the SR motifs suggested that ESE sites could be found in the same 
location in both the human and mouse POSTN exons. This allowed the design of PMOs 
to the same sequence on both human and mouse 
An Mfold prediction of the secondary structures is also shown for each, isolated exon 
sequence (Figures 4.2C, 4.3C, 4.4C, 4.5C, 4.6C). In each case, the exon exhibits a 
structure which could be folded so that the exon is 'pinched out' of the pre-mRNA during 
splicing, with the 3' and 5' ends located naturally adjacent to one another. 
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Figure 4.2 Analysis of human POSTN exon 3 for homology, ESE sites and secondary 
structure.  
(A1) Output from NCBI nucleotide database showing human POSTN exon 3 (lower black 
line, with nucleotide sequence top).  
(A2) Output from SnapGene aligning exon 3 of human (upper) and mouse (highlighted 
in grey). Mismatches are highlighted with red boxes.  
(B) Human Splicing Finder output for exon 3 (highlighted in grey). Different red and pink 
coloured bars show different Splicing Enhancer Matrices and green and blue bars show 
different Splicing Silencer Matrices as labelled (below). The Y axis displays the score for 
presence of the particular motif above a set threshold, with stronger motifs represented 
by higher scores. In this case exon 3 is predicted to have two ESE sites at the beginning 
and end of the exon.  
(C) Secondary structure of human POSTN exon 3 in isolation, as predicted by Mfold. 
140 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
141 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 Analysis of human POSTN exon 4 for homology, ESE sites and secondary 
structure. 
(A1) Output from NCBI nucleotide database showing human POSTN exon 4 (lower black 
line, with nucleotide sequence top).  
(A2) Output from SnapGene aligning exon 4 of human (upper) and mouse (highlighted in 
grey). Mismatches are highlighted with red boxes.  
 (B) Human Splicing Finder output for exon 4 (highlighted in grey). Different red and pink 
coloured bars show different Splicing Enhancer Matrices and green and blue bars show 
different Splicing Silencer Matrices as labelled (below). The Y axis displays the score for 
presence of the particular motif above a set threshold, with stronger motifs represented by 
higher scores.  
(C) Secondary structure of the human POSTN exon 4 predicted by Mfold. 
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Figure 4.4 Analysis of human POSTN exon 7 for homology, ESE sites and secondary 
structure. 
(A1) Output from NCBI nucleotide database showing human POSTN exon 7 (lower black 
line, with nucleotide sequence top).  
(A2) Output from SnapGene aligning exon 7 of human (upper) and mouse (highlighted in 
grey). Mismatches are highlighted with red boxes.  
 (B)  Human Splicing Finder output for exon 7 (highlighted in grey). Different red and pink 
coloured bars show different Splicing Enhancer Matrices and green and blue bars show 
different Splicing Silencer Matrices as labelled (below). The Y axis displays the score for 
presence of the particular motif above a set threshold, with stronger motifs represented 
by higher scores. In this case exon 7 is predicted to have two ESE sites at the beginning 
and end of the exon.  
(C) Secondary structure of the human POSTN exon 7 as predicted by Mfold. 
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Figure 4.5 Analysis of human POSTN exon 10 for homology, ESE sites and secondary structure. 
(A1) Output from NCBI nucleotide database showing human POSTN exon 10 (lower black line, with nucleotide sequence top).  
(A2) Output from SnapGene aligning exon 10 of human (upper) and mouse (highlighted in grey). Mismatches are highlighted with red 
boxes.  
 (B)  Human Splicing Finder output for exon 10 (highlighted in grey). Different red and pink coloured bars show different Splicing Enhancer 
Matrices and green and blue bars show different Splicing Silencer Matrices as labelled (below). The Y axis displays the score for presence 
of the particular motif above a set threshold, with stronger motifs represented by higher scores. In This case exon 10 is predicted to have 
two ESE sites at the beginning and end of the exon.  
(C) Secondary structure of human POSTN exon 10 as predicted by Mfold. 
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Figure 4.6  Analysis of human POSTN exon 16 for homology, ESE sites and secondary structure. 
(A1) Output from NCBI nucleotide database showing human POSTN exon 16 (lower black line, with nucleotide sequence top).  
(A2) Output from SnapGene aligning exon 16 of human (upper) and mouse (highlighted in grey). Mismatches are highlighted with red boxes.  
 (B)  Human Splicing Finder output for exon 16 (highlighted in grey). Different red and pink coloured bars show different Splicing Enhancer Matrices 
and green and blue bars show different Splicing Silencer Matrices as labelled (below). The Y axis displays the score for presence of the particular 
motif above a set threshold, with stronger motifs represented by higher scores. In this case exon 16 is predicted to have two ESE sites at the 
beginning and end of the exon. 
(C) Secondary structure of the human POSTN exon 16 as predicted by Mfold. 
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Figure 4.7 Comparison of  ESE sites predicted in exon 3 of human and mouse POSTN. 
ESEfinder output for mouse and human POSTN exon 3. The width of each column displays the location where the motif may be present. The 
X axis shows the sequence of the exon. The height of each bar depicts the score of the predicted motif above a set threshold. The higher the 
score the more likely the motif is present in that particular position on the X axis. 
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Figure 4.8 Comparison of  ESE sites predicted in exon 4 of human and mouse POSTN. 
ESEfinder output for mouse and human POSTN Exon 4. The width of each column displays the location where the motif may be present. The X axis 
shows the sequence of the exon. The height of each bar depicts the score of the predicted motif above a set threshold. The higher the score the 
more likely the motif is present in that particular position on the X axis 
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Figure 4.9 Comparison of  ESE sites predicted in exon 7 of human and mouse POSTN. 
ESEfinder output for mouse and human POSTN Exon 7. The width of each column displays the location where the motif may be present. The X 
axis shows the sequence of the exon. The height of each bar depicts the score of the predicted motif above a set threshold. The higher the score 
the more likely the motif is present in that particular position on the X axis. 
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Figure 4.10 Comparison of  ESE sites predicted in exon 10 of human and mouse POSTN. 
ESEfinder output for mouse and human POSTN Exon 10. The width of each column displays the location where the motif may be present. 
The X axis shows the sequence of the exon. The height of each bar depicts the score of the predicted motif above a set threshold. The higher 
the score the more likely the motif is present in that particular position on the X axis.  
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Figure 4.11 Comparison of  ESE sites predicted in exon 16 of human and mouse POSTN. 
ESEFinder output for mouse and human POSTN Exon 16. The width of each column displays the location where the motif may be present. The 
X axis shows the sequence of the exon. The height of each bar depicts the score of the predicted motif above a set threshold. The higher the 
score the more likely the motif is present in that particular position on the X axis 
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4.2.3 Relationship of selected ESEs and designed AON PMOs to the predicted RNA 
secondary structure of targeted POSTN exons  
PMOs were designed to target conserved regions of exon 3, 7, 10 and 16 at regions 
containing ESE sites and avoiding ESS sites. They were designed considering overall 
binding energy and GC content of the PMO. For exon 3, one 25mer PMO sequence was 
designed to target the predicted ESE shared between the mouse and human in the 
conserved region of the exon (Figure 4.12). Exon 7 contained longer stretches of the 
sequence where there was only one mismatch between the mouse and human, which 
also contained ESE motifs. In order to cover these regions of interest, two 30mer PMOs 
were designed as well as one 25mer PMO (Figure 4.13). In the same way, three 
overlapping 30mer PMOs were designed for exon 10 (Figure 4.14) and two overlapping 
25mer PMOs for exon 16 (Figure 4.15). 
Mfold was used to predict the secondary structure of each exon within the pre-mRNA 
for human and mouse genes. This allowed investigation of conservation between the 
human and mouse on the level of secondary structure. Each exon sequence along with 
100nt of intron on either side was pasted, in FASTA format, as input into the Mfold 
software. Secondary structures showed identical secondary structures for exon 3 from 
human and mouse. Very similar structures were predicted for exons 7, 10 and 16, but a 
very different structure for mouse versus human exon 4 (Figures 4.16, 4.17, 4.18, 4.19, 
4.20). The very different secondary structure for exon 4 was probably due to the fact 
that exon 4 had more mismatches in sequence between the human and mouse; 
therefore it was eliminated for PMO design and further investigation as it would have 
been not possible to confidently design a single PMO for both human and mouse.  The 
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position on which the newly designed PMOs (above) bind on the secondary structure of 
both human and mouse are shown (Figures 4.16, 4.17, 4.18, 4.19, 4.20). 
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A) 
B) 
Figure 4.12 Overview of PEX3 AON targeting exon 3 in the human and mouse POSTN gene transcript 
A) Human and mouse POSTN exon 3 alignment generated by SnapGene. Mismatches are highlighted in red. Binding position of Pex 3 PMO is shown 
in blue.  
B) PEX3 PMO sequence and thermodynamic properties outlined in the table. Overall binding energy calculated using RNAup server. Tm and %GC 
were calculated using OligoAnalyzer. 
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A) 
B) 
Figure 4.13 Overview of PEX7.1, 7.2 and 7.3 AON targeting exon 7 in the human and mouse POSTN gene transcript.   
A) Human and mouse POSTN exon 7 alignment generated by SnapGene. Mismatches are highlighted in red. Binding position of Pex 7.1, Pex7.2 
and Pex7.3 PMO are shown in blue, yellow and green respectively. 
 B) Pex7.1, Pex7.2 and Pex7.3 PMO sequences and thermodynamic properties outlined in the table. Overall binding energy calculated using 
RNAup server. Tm and %GC were calculated using OligoAnalyzer  
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A) 
B) 
Figure 4.14 Overview of PEX10.1,10.2 and 10.3 AON targeting exon 10 in the human and mouse POSTN gene transcript. 
A) Human and mouse POSTN exon 10 alignment generated by SnapGene. Mismatches are highlighted in red. Binding position of Pex 10.1, 
Pex10.2 and Pex10.3 PMO are shown in blue, yellow and green respectively. 
 B) Pex10.1, Pex10.2 and Pex10.3 PMO sequences and thermodynamic properties outlined in the table. Overall binding energy calculated using 
RNAup server. Tm and %GC were calculated using OligoAnalyzer. 
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A) 
B) 
Figure 4.15 Overview of PEX16.1 and 16.2 AON targeting exon 16 in the human and mouse POSTN gene transcript. 
A) Human and mouse POSTN exon 16 alignment generated by SnapGene. Mismatches are highlighted in red. Binding positions of Pex 16.1 and 
Pex16.3 PMOs are shown in blue and yellow respectively. 
 B) Pex16.1 and Pex16.2 PMO sequences and thermodynamic properties are listed in the table. Overall binding energy was calculated using 
RNAup server. Tm and %GC were calculated using OligoAnalyzer. 
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Mouse Human 
Figure 4.16 Predicted RNA secondary structure around exon 3 of mouse and human POSTN gene transcript 
Secondary structures were predicted using Mfold Both mouse and human exon 3 are 65 nucleotides long and the numbers indicate the position 
of the specific nucleotide in the exon. Binding position of PEX3 PMO designed to target exon 3 is shown in red. Both ends of the PMO bind the 
secondary structure in open conformation. 
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Human Mouse 
Figure 4.17. Predicted RNA secondary structure around exon 4 of mouse and human POSTN gene transcript 
Secondary structures were predicted using Mfold. Secondary structure of mouse and human POSTN exon 4 as predicted by Mfold. Both mouse 
and human exon 4 are 158 nucleotides long and the numbers indicate the position of the specific nucleotide in the exon. 
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Mouse Human 
Figure 4.18 Predicted RNA secondary structure around exon 7 of mouse and human POSTN gene transcript 
Secondary structures were predicted using Mfold. Both mouse and human exon 7 are 142 nucleotides long and the numbers indicate the 
position of the specific nucleotide in the exon. Binding position of PEX7.1, PEX7.2 and PEX7.3 PMOs designed to target exon 7 are shown in 
blue, red and yellow respectively 
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Figure 4.19 Predicted RNA secondary structure around exon 10 of mouse and human POSTN gene transcript 
Secondary structures were predicted using Mfold. Both mouse and human exon 10 are 149 nucleotides long and the numbers indicate the position of 
the specific nucleotide in the exon. Binding position of PEX10.1, PEX10.2 and PEX10.3 PMOs designed to target exon 10 are shown in red, blue and 
yellow respectively. 
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Human Mouse Human 
Figure 4.20 Predicted RNA secondary structure around exon 16 of mouse and human POSTN gene transcript 
Secondary structures were predicted using mfold. Both mouse and human exon 16 are 46 nucleotides long and the numbers indicate the position 
of the specific nucleotide in the exon. Binding position of PEX16.1 and PEX16.2 designed to target exon 16 are shown in blue and red respectively. 
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4.3 Discussion 
In this Chapter, nine AONs for synthesis by PMO chemistry (Chapter 5) were designed 
to target POSTN and deliver a message with out-of-frame exons; this should result, in 
vivo, in a reduction of POSTN mRNA due to NMD. Targeting ESE motifs has been explored 
extensively and targeting ESE motifs with antisense oligonucleotides and more 
specifically PMO chemistries has been shown to be successful in exon exclusion in DMD 
(Malerba, Kang, McClorey, Saleh, Popplewell, Gait, Matthew Ja Wood, et al., 2012). 
To design the oligonucleotides, bioinformatics tools were used to identify ESE motifs, 
the mouse and human exons were compared to find homology and appropriate 
thermodynamic properties were considered. AONs were mostly designed with 
alternative overlapping binding sites on the RNA secondary structure. Bioinformatics 
software are commonly used in the literature to predict the position of ESE motifs, so 
for this work, recommended software included RESCUE-ESE (Fairbrother et al., 2002, 
2004) and ESEfinder (Cartegni et al., 2003). Human Splicing Finder (HSF) uses both 
RESCUE-ESE and ESEfinder algorithms but only human sequences (Desmet et al., 2009). 
Here, HSF was used to predict ESE motifs in the human POSTN sequences, and ESEfinder 
used to look at both human and mouse sequences. The combined data from HSF and 
ESE finder were used to compare and find overlapping predicted ESE motifs across the 
two species, and AONs were designed targeting selected ESE motifs which are present 
in both the human and mouse. Previously we found that targeting mouse-human 
homologous regions gave better downregulation of target gene (Chapter 3). 
One of the downsides of evaluating AON-mediated exon skipping in mouse and other 
in-vivo animal models is that human-specific AONs generally cannot be  validly tested 
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since sequence homology may be limited. Thus while mouse models for example  allow 
general studies on the proof of concept of therapeutic exon skipping strategies, the 
testing of precise human medicinal product AON going into clinical application or clinical 
trials may not be feasible unless humanised models have been developed(Veltrop et al., 
2018). In order to tackle this problem, this study focused on regions of exons where 
human-mouse homology is high. This has the added advantage of adding evolutionary 
conservation to our knowledge-base for the PMO, and conservation of sequence may 
indicate conservation of function. Nine PMOs were designed to either have no 
mismatches in the human and mouse or have a maximum of one mismatch with the 
mouse. Prior to clinical studies, human-specific AONs have been screened in-silico 
against the human genome for off-target hybrisation sites,  and hits within genes with 
one, two or three mismatches tested for AON-mediated changes in mRNA transcript 
levels  (Kamola et al., 2015; Schoch and Miller, 2017). These studies indicate that the 
presence of 1 or 2 base mismatches do not stop an AON being effective at inducing exon 
skipping or changing mRNA levels. The success in this test, of the PMOs designed in this 
study, when tested in vitro in the mouse C2C12 cell line allowed proof of concept for 
postn exon skipping and allowed moving on towards further testing of these AONs which 
are specific to the human gene.  
As previously discussed (Chapter 3, Discussion), factors affecting bioactivity of AONs 
have been widely researched. Previous studies by Vickers, Wyatt and Freier (2000) argue 
that local secondary structure of the precise region of the mRNA where AONs are 
targeted may be critical for bioactivity of an AON: targeting unstructured sites gives 
better results and increases AON efficacy. On the other hand, a more recent study by 
Popplewell et al. (2009) showed that when it comes to designing PMOs for exon skipping 
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the predicted overall binding energy of PMO to target sequence is the most important 
factor along with PMO length. Long oligonucleotides bind more tightly and specifically 
as their Tm and %GC can be dramatically increased. Popplewell et al. also show that the 
position of PMO binding with respect to RNA secondary structure does not have a 
significant effect on bioactivity unless choosing between successful PMOs, where the 
more bioactive PMOs show binding to targets with an open conformation. In this 
Chapter, PMOs were designed focusing on the overall binding energy of PMO to target 
and increasing the length of the PMO to increase binding energy where necessary. The 
secondary structure of mRNA was also considered and where possible PMOs were 
designed to target open confirmations or sequences where there is less putative local 
structure, but this factor was not seen to be detrimental. Percentage GC of the designed 
PMOs was kept at around 50% as recommended by Ho et al. (1996). However, %GC was 
lower in some PMOs due to the low GC content of the exon sequence. 
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5. In vitro analysis of antisense oligonucleotide targeting human 
and mouse POSTN out-of-frame exons  
5.1 Introduction  
As discussed in Chapter 4, splicing of pre-mRNA results in the production of functional 
mRNA with only protein coding sequences and the consequent production of 
biochemically active protein (Proudfoot, Furger and Dye, 2002b). The use of AONs to 
mask an exon and produce a shorter, out-of-frame transcript, that is consequently 
degraded through NMD, is well established in the literature (Kang et al., 2011a; Lu-
Nguyen et al., 2017; Golshirazi et al., 2018). AONs were designed in the previous chapter 
to target four out-of-frame exons in the mouse and human POSTN1 pre-mRNA. The 
PMOs were designed to bind their target and prevent a specific exon from being 
included in the transcript, making the resulting mRNA shorter and lacking the correct 
reading frame (Aartsma-Rus and van Ommen, 2007). Successful PMOs should, in theory, 
decrease the amount of in-frame transcript produced since AON reagents do not work 
to 100% efficiency and because the half-life of mRNAs ranges from minutes to hours 
(Chen, Ezzedine and Shyu, 2008), but they do effectively reduce the amount of 
functional protein in the cell.  
Following the design of AONs targeting exons 3, 7, 10 and 16 of POSTN1 in both human 
and mouse sequences, they were synthesised with PMO chemistry (Chapters 1, 2). it 
was important to demonstrate the capability of the PMOs in inducing specific exon 
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skipping in both human and mouse cell culture systems. This process is well established 
in the laboratory. 
Prior to transfection, muscle cells and fibroblasts were treated with TGF-b1 to stimulate 
POSTN expression; this mimics the transcriptional and translational process that occurs 
following injury (Chapter 1, March et al., 2018). The effect of TGF-b treatment on POSTN 
and Collagen I expression was assessed prior to transfection with PMO, to determine a 
dose at which the pathways related to damage and fibrosis are activated.  
A suitable TGF-b dose was tested in two cell lines: human muscle cells from DMD 
patients; and mouse C2C12 cells. Then these cell lines were therefore treated with TGF-
b and then transfected with the newly designed PMOs, using Endo-Porter as the 
transfection reagent (Chapter 2). Initially, semi-quantitative analysis of POSTN1 
transcripts was used to compare the efficiency of each PMO in its ability to induce exon 
skipping.  
The most successful PMO, based on full-length transcript reduction (the PCR primers 
bound to the start and end of full-length POSTN1 transcripts), was then chosen to test 
in the mouse fibroblast cell system as these cells are believed to have a major burst in 
POSTN production in the event of fibrosis (Crawford et al., 2015). RT-qPCR and Western 
blots were then used to more accurately investigate the efficiency of the most successful 
PMO in the mouse cell system at mRNA and protein levels, respectively.  
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5.2 Results  
5.2.1 Effect of TGF-β on Periostin and Collagen expression  
An important consideration for the transfection of AONs designed for exon skipping is 
that they need to be transfected at the stage of target gene transcription. TGF-b 
activates POSTN expression as well as other genes involved in regeneration and repair, 
such as collagen-I (March et al., 2018). In order to determine that TGF-b stimulates 
POSTN expression and mimics a fibrotic pathway, C2C12 cells were plated in six-well 
plates, and when confluent, cultures were treated with 2ng or 10ng of TGF-b. 24 hours 
after treatment, RNA was harvested and subjected to RT-qPCR to detect POSTN message 
expression levels (Figure 5.1). To normalise the expression (effectively to get a clear 
percentage reduction per cell) RT-qPCR of GAPDH was used; GAPDH is a constantly 
expressed housekeeping gene. Levels of POSTN message were normalised to the GAPDH 
expression by a division sum. 
The purity of the PCR products (discrimination of the PCR primers) was assessed by a 
melting curve, which showed two distinct peaks, one for the POSTN transcript and the 
other, GAPDH. Two clean peaks indicated no issues with the two sets of primers and no 
contamination in the samples or reagents (Figure 5.1A).  
The normalised qPCRs show an increase in POSTN expression at both 2ng and 10ng 
treatments of TGF-b. At 10ng there is a threefold increase in expression relative to no 
treatment, with a statistical significance (p<0.001) using one-way ANOVA (Figure 5.1B); 
using 2ng gave only a two-fold increase with no statistical significance.  
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RT-qPCR was also used to look at the effect of TGF-b on Collagen I expression. This was 
to confirm the activation of fibrotic pathways, not just POSTN (Figure 5.2). The melting 
curve for these sets of primers revealed two distinct, clean peaks, one for GAPDH and 
one for POSTN, indicating functional primers with no contaminating binding sites (Figure 
5.2A). Despite the low activation of POSTN expression at 2ng of TGF-b, collagen I was 
significantly increased by four-fold at both 2ng and 10ng of TGF-b treatment with a 
significance of p<0.01 (Figure 5.2B).  This result shows that TGF-b treatment activates 
the fibrotic pathways and concomitantly stimulates POSTN transcription. As 10ng shows 
a significant increase in POSTN expression, it was decided to treat cell cultures with 10ng 
of TGF-b for our experiments with AONs. 
To measure the effect of AON on POSTN1 expression induced by TGF-b, it was decided 
to treat cells with TGF-b just 1 hour prior to transfection with AONs. After that, cells 
were left for 24h before harvesting, as above.  
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Figure 5.1 Treatment of C2C12 cells with TGF-β and quantification of POSTN expression 
C2C12 cells were treated with 2ng or 10ng of TGF-β, or no TGF-β as negative control. 24 
hours after treatment RNA was extracted followed by qPCR to quantify POSTN. GAPDH was 
quantified and used as housekeeping gene for normalisation.  
A) Melting curve from the qPCR reaction showing two distinct peaks indicating two specific 
distinct products with no overlap: POSTN (green);  GAPDH (red).  
B) Quantification of POSTN expression normalised to GAPDH expression. Dose dependent 
increase is seen upon TGF-β treatment with statistical significance calculated for 10ng 
treatment using one-way Anova test. (***p<0.001, N=3). 
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Figure 5.2 Treatment of C2C12 cells with TGF-β and quantification of type I Collagen 
expression 
C2C12 cells were treated with 2ng or 10ng TGF-β, or no TGF-β as negative control. 24 hours 
after treatment RNA was extracted followed by qPCR to quantify type I Collagen. GAPDH 
was quantified and used as housekeeping gene for normalisation.  
A) Melting curve from the qPCR reaction showing two distinct peaks indicating specific 
distinct products with no overlap: Collagen (green); GAPDH (red).  
B) Quantification of Collagen expression normalised to GAPDH expression from qPCR. Dose 
dependent increase is seen upon both TGF-β treatments, with statistical significance 
calculated for both 2ng and 10ng treatment using one-way Anova test. (**p<0.01, N=3). 
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5.2.2 PMO induced skipping of POSTN  
5.2.2.1 Determination of optimal conditions for Endo-Porter as transfection reagent  
As previously discussed (Chapter 3), Endo-Porter is a peptide-based reagent that 
mediates endocytosis allowing the uptake of peptides, proteins and neutral PMOs in the 
presence of serum and has been shown to deliver PMOs at various concentrations. 
Recent work in our laboratory has shown that the concentration of Endo-Porter used 
may have significant impact on the effect of AONs designed for exon skipping 
(Popplewell, L. 2009, personal communication, 2019). The length of time for which cells 
are incubated with Endo-Porter has also been shown to be a crucial factor. Both these 
factors were therefore investigated to determine the best concentration at which to use 
Endo-Porter and to verify that cells remain viable after 24 hours of incubation with Endo-
Porter present in the media.  
Initially, C2C12 cells were seeded in 6-well plates and allowed to grow to confluency. 
8µM of Endo-Porter was then added to 3 of the 6 wells along with fresh media. A time 
course of the treated and control cells was made, counting the number of floating cells 
(this cell line normally adheres to the bottom) and live cells (using Trypan blue) by 
microscopic observation, at time intervals of 24h, 48h and 72h and percentage cell death 
was calculated (Figure 5.3A). This shows that Endo-Porter has a toxic effect on the cells 
with approximately 20% +/- 0.3 cell death at 24 hours. This cell death doubles at 48 
hours to 40% +/-0.2. It was therefore decided that the previously practised protocol of 
harvesting RNA 24 hours after transfection with Endo-Porter is best practice: a 24 hour 
period was needed to get a significant upregulation of POSTN message (above).  
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In order to determine the optimal concentration of transfection reagent, C2C12 cells 
were seeded in six-well plates and transfected with a 10µM solution of a PMO that 
targets exon 7 of POSTN1, with 6µM or 8µM Endo-Porter; the Endo-Porter website, 
Genetools, suggests 6µM as the optimum concentration for transfection and 8µM the 
maximum concentration to use. RNA was harvested 24 hours following transfection at 
these two concentrations (Figure 5.3B). The fragment of POSTN amplified in the nested 
RT-PCR is exons 5-8 which is 643bp in length. Exclusion of exon 7 results in an RT-PCR 
product of 402 bp. The results show a visually stronger and more consistent skip band 
when using 8µM of Endo-Porter, indicating a more effective transport of PMO into cells. 
Semi-quantitative densitometric analysis of the gel using Image J (Figure 5.3B) also 
confirmed that stronger skipping seen in samples with 8µM of Endo-Porter. It was 
decided to use 8µM of Endo-Porter for all transfections.  
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Figure 5.3 Evaluation of optimal conditions for Endo-Porter as transfection reagent  
 
A) C2C12 cells were plated and allowed to grow and divide. Media was exchanged for 
fresh media and three of the six wells were treated with 8µM of Endo-Porter and another 
three wells were untreated. Floating/dead cells and live cells were then counted at 24h, 
48h and 72h and percentage cell death calculated: treated cells (green); untreated cells 
(red). N = 3 
B) C2C12 cells were plated and allowed to grow and divide. Cells were then transfected 
with PEX7.1 PMO, for exon 7 exclusion, using 6µM or 8µM of Endo-Porter. RNA was 
harvested 24 hours after transfection and subjected to RT-PCR amplifying the POSTN 
exon 6-8. A 3% agarose gel of the RT-PCR products is shown along with Hyperladder IV 
(H IV). Full length product was present in all lanes including the control lane at 643bp in 
length. The exon skipped band is 402 bp, present in treated lanes and stronger in the 
8µM Endo-Porter treated samples. Semi-quantitative analysis of the gel image, using 
GeneTools, shows nearly twice as much skipping in the 8µM treated samples. This 
analysis was carried out by comparing the intensity of the skipped band to the intensity 
of skipped + full length band. Significance was calculated relative to control samples 
using one way ANOVA. (*p<0.05, **p<0.01, N=3). 
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5.2.2.2 PMO induced exclusion of Periostin exon 3,7,10 and 16 in patient cells  
PEX3, PEX7.1, PEX7.2, PEX7.3, PEX10.1, PEX10.2, PEX10.3, PEX16.1 and PEX16.2 are the 
nine PMOs designed as AONs in Chapter 4 (Figures 4.12-4.20). To see how they perform 
in DMD patient cell lines, cells were pre-treated with TGF-b. Each PMO was transfected 
into these DMD patient cell systems treated with 10ng of TGF-b 1 hour prior to 
transfection, at a concentration of 10µM using 8µM of Endo-Porter transfection reagent 
(above, see Chapter 2 for details of Endo-Porter function). Control AON treated samples 
were included with the Endo-Porter reagent, and a control PMO was supplied from 
GeneTools which has no target and very little biological activity.  
RNA was harvested 24 hours after transfection and subjected to nested RT-PCR to 
amplify specific exons of POSTN, dependant on the PMO used (exons skipped). For RNA 
harvested from PEX3-transfected cells, exon 2-4 was amplified. The longest PCR product 
which contains all exons is expected to be 149bp in length. The exclusion of the 65bp 
exon 3 results in an 84bp product. This is a size difference that is very difficult to resolve 
on a 3% TAE agarose gel and bands were instead resolved on a high-resolution, 10% 
polyacrylamide TBE gel. TBE gels were semi-quantitatively analysed as described. The 
results (Figure 5.4A) show the smaller band lacking exon 3 in the lanes treated with PEX3 
and absent in the control samples. Semi-quantitative analysis of the gel showed 37% +/- 
SD skipping (Figure 5.4B). 
In the case of PEX7.1, PEX7.2 and PEX7.3, exons 5-8 were amplified. The full-length 
product is 544bp in length. The exclusion of the 142bp exon 7 results in a 402bp product. 
This size difference was efficiently resolved on a 2% agarose gel. Results (Figure 5.5A) 
show the smaller band lacking exon 7 to be evident only after transfection with PEX7.1. 
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Both PEX7.2 and PEX7.3 showed the full-length 544bp product but lacked the smaller 
skipped product, as do control samples. Semi-quantitative analysis (Figure 5.5B) showed 
that 18% of POSTN was the skip product using PEX7.1 PMO; there was no skipping 
evident using PEX7.2 and PEX7.3 PMO. 
In the case of PEX10.1-PEX10.3 transfected cells RNA, exons 8-12 were amplified. The 
full-length product is 521bp in length. The exclusion of the 149bp exon 10 resulted in a 
372bp product, a size difference that is resolved on a 2% agarose gel. Results (Figure 5.6) 
showed the presence of the full-length 521bp band in all lanes, but no evidence of the 
shorter 149bp skipped band indicating no successful skipping.  
In the case of PEX16.1- and PEX16.2-transfected cell RNA, exons 14-18 were amplified 
in the first round of the nested RT-PCR and exons 15-17 were amplified in the second 
round of PCR. The full-length product is 168bp in length. The exclusion of the 46bp exon 
16 results in a 122bp product, a size difference that is resolved on a 10% polyacrylamide 
TBE gel. Results (Figure 5.7A) show the smaller 122bp product lacking exon 16 to be 
evident in lanes transfected with both PEX16.1 and PEX16.2. Semi-quantitative analysis 
of the gel shown in Figure 5.7B showed a 41% skip for PEX16.1-transfection and a lower, 
8% skip for PEX16.2 transfection.  
The results show successful skipping of POSTN1 in DMD patient cells when transfected 
with 10µM of four AONs, PEX3, PEX7.1, PEX16.1 and PEX16.2.  PEX7.1 showed the 
poorest skip at below 20% of full-length product. In the case of exon 16 skipping, 
PEX16.1 was more successful. It was therefore decided to take two AONs, PEX3 and 
PEX16.1, both of which showed over 30% skipping, and test them in murine muscle cells 
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since the mouse is the in vivo model used for testing successful PMOs for therapeutic 
use 
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Figure 5.4 Transfection of PEX3 PMO targeting exon 3 in DMD patient muscle cells  
 
DMD patient muscle cells were transfected after reaching confluency, with PEX3 PMO at 10µM using 8µM of Endo-Porter. RNA was extracted 
24 hours after transfection and subjected to RT-PCR amplifying exons 2-4 of POSTN mRNA.  
A) 10% Polyacrylamide TBE gel of the RT-PCR products from amplification of exon 2-4 of POSTN from patient cells transfected with 10µM of 
PEX3. Control sample was transfected with the GeneTools-supplied control PMO at 10µM. Full length exon 2-3-4 product at 149bp, containing 
exon 3, is present in all lanes. The smaller product, without exon 3, at 84bp is present in the three lanes transfected with PEX3 PMO. There is 
also a very short band in all wells. Hyperladder VI (H IV) was used.  
B) Semi-quantitative analysis of the gel using GeneTools software showing 37% skipping of POSTN exon 3 in patient muscle cells. Significance 
was calculated compared to the control sample using a t-test (***p<0.001, N=3). 
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Figure 5.5 Transfection of PEX7.1, PEX7.2, PEX7.3 PMOs targeting exon 7 in DMD patient muscle cells  
 
DMD patient muscle cells were transfected after reaching confluency, with PEX7.1, PEX7.2 and PEX7.3 PMO at 10µM using 8µM of Endo-
Porter transfection reagent. Control samples were transfected with the GeneTools PMO control at 10µM. RNA was extracted 24 hours after 
transfection and subjected to RT-PCR to amplify exons 6-8 of POSTN mRNA.  
A) 2% agarose gel of the RT-PCR products from amplification of exons 6-8 of POSTN from patient cells transfected with 10µM of PEX7.1, 
PEX7.2 and PEX7.3 PMO. Full length product at 544bp containing exon 7 is present in all lanes. The smaller product at 402bp is present in the 
three lanes transfected with PEX7.1 but is not present in other lanes.  Hyperladder IV (HP IV) was used. 
B) Semi-quantitative analysis of the gel using GeneTools showing 18% skipping of POSTN exon 7 in patient cells and no skipping in other 
samples. Significance was calculated with respect to the control sample using one way Anova (****p<0.0001, N=3). 
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Figure 5.6 Transfection of PEX10.1, PEX10.2 and PEX10.3 PMO targeting exon 10 in DMD patient muscle cells. 
 
DMD patient muscle cells were allowed to reach confluency then transfected with PEX10.1, PEX10.2 or PEX10.3 PMO at 10µM using 8µM 
of Endo-Porter. Control samples were transfected with the GeneTools control PMO at 10µM. RNA was extracted 24 hours after transfection 
and subjected to RT-PCR to amplify exons 8-12 of POSTN mRNA.  
A) A 2% agarose gel of the RT-PCR products from amplification of exon 8-12 of POSTN from patient cells transfected with 10µM of PEX10.1, 
PEX10.2 or PEX10.3. Full length product containing exon 10 at 521bp is present in all lanes. The expected smaller product at 372bp is not 
present in any lane (N=3). Hyperladder IV (HP IV) was used. 
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Figure 5.7 Transfection of PEX16.1, PEX16.2 targeting exon 16 in DMD patient muscle cells  
DMD Patient muscle cells were allowed to reach confluency then transfected with PEX16.1 or PEX16.2 PMO at 10µM using 8µM of 
Endo-Porter. Control samples were transfected with the GeneTools PMO control at 10µM. RNA was extracted 24 hours after 
transfection and subjected to RT-PCR to amplify exon 15-17 of POSTN mRNA.  
A) 10% Polyacrylamide TBE gel of the RT-PCR products from amplification of exon 15-17 of POSTN from patient cells transfected with 
10µM of PEX16.1, and PEX16.2 PMO. Full length product at 168bp containing exon 16 was present in all lanes. The smaller product at 
122bp was present in cells transfected with PEX16.1 as well as cells transfected with PEX16.2. Hyperladder IV (HP IV) was used. 
B) Semi-quantitative analysis of the gel using GeneTools software showed 41% skipping of POSTN exon 16 in samples transfected with 
PEX16.1 and 8% skipping in samples transfected with PEX16.2. Significance was calculated using One way Anova with respect to control 
samples with no skipping. (***p<0.001, ****p<0.0001, N=3). 
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5.2.2.3 PMO induced exclusion of Periostin exon 3 and 16 in C2C12 cells  
C2C12 cells are a murine muscle-derived cell line (YAFFE and SAXEL, 1977) that are an 
established myogenic cell line. C2C12 cells have also been extensively used in the laboratory 
to test AON reagents including PMOs (Kang et al., 2011a; Malerba, Kang, McClorey, Saleh, 
Popplewell, Gait, Matthew JA Wood, et al., 2012; Lu-Nguyen et al., 2015; Golshirazi et al., 
2018). The next experiments were designed to investigate the bioactivity of the successful 
PMOs in this mouse in-vitro model, i.e. PMOs were transfected into C2C12 cells. Dose-
response analysis was used to identify the minimal effective transfection concentration of the 
PMOs shown to be effective in previous experiments (above).  
C2C12 cells were seeded in six-well plates and treated with TGF-β for an hour prior to being 
transfected with different PMOs. Initially, cells were transfected with PMOs at concentrations 
of 10µM, 5µM and 2µM (Figure 5.8 and Figure 5.10) with 8µM of Endo-Porter for maximum 
efficacy of transfection (above). As shown in Figure 5.4, RNA was harvested 24 hours after 
transfection and subjected to nested RT-PCR.  The most successful PMO was then transfected 
into C2C12 cells, as before, but at a wider range of concentrations: 10µM, 5µM. 2µM, 0.5 µM 
and 0.2 µM (Figure 5.12).  
The harvested RNA from all transfections was also subjected to RT-qPCR to give a more 
accurate quantitative result of skipping (Figures 5.9, 5.11 and 5.13) using the predesigned 
primers outlined in section 2.4.3.2. GAPDH was used as the housekeeping gene, and all results 
were normalised to GAPDH. Primers for GAPDH were also predesigned as outlined in section 
2.4.3.2.  
In the case of PEX3 transfection, exons 2-4 were amplified. The full-length product was 169bp 
in length. The exclusion of the 65bp exon 3 results in a 104bp product, a size difference that 
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was resolved on a 3% (w/v) agarose gel (Figure 5.8A). Semi-quantitative analysis of the gel 
image showed skipping at 56% +/- 0.2 at 10µM, 40% skipping at 5µM and 25% at 2µM (Figure 
5.8B). RT-qPCR analysis of mRNA from the PEX3-transfected cells (Figure 5.9) confirmed the 
trend seen on the agarose gel but showed a much more significant effect of the PMO, with 
statistically significant downregulation of POSTN at all concentrations of PEX3 transfection; 
p<0.05 at 2µM and p<0.01 at 10µM and 5µM; (calculated by one-way ANOVA).  
In the case of PEX16.1, exons 15-17 were amplified. The full-length product was 131bp in 
length and exclusion of the 46bp exon 16 results in an 85bp product, a size difference that 
was resolved on a 10% TBE polyacrylamide gel (Figure 5.10A). Semi-quantitative analysis of 
the gel using GeneTools software (Chapter 2) revealed 28% at 2µM, 40% skipping at 5µM and 
35% skipping at 10µM (Figure 5.10B). The qPCR analysis of the PEX16.1 transfection RNA 
shown in Figure 5.11 showed a relatively similar downregulation of POSTN at all transfection 
concentrations all of which showed statistical significance using a one-way ANOVA analysis 
p<0.01.  
PEX 3 was the more successful PMO and so used for the dose-response analysis, transfected 
at concentrations of 0.2, 0.5, 2, 5 and 10µM. As before, exons 2-4 +/- exon 3 were amplified 
by RT-PCR and the products resolved on a 3% agarose gel resolving the full length, 169bp, and 
the skipped, 104bp, products (Figure 5.12A). Semi-quantitative analysis of the gel image using 
GeneTools showed a dose-dependent response to PEX3 with skipping of 9.2% at 0.2µM and 
53% at 10µM. qPCR analysis of the RNA showed a statistically significant downregulation of 
POSTN (p<0.005) at all concentrations, with a dose-dependent pattern confirming the trend 
observed on the gel. Transfection at 0.2µM PMO was the anomaly, showing a greater 
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decrease in POSTN expression than that seen at 0.5, 1 and 2µM although this difference was 
not found to be statistically significant (Figure 5.13). 
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Figure 5.8 Transfection of PEX3 PMO targeting exon 3 in C2C12 cells 
C2C12 cells, after reaching confluency, were transfected with PEX3 at 2, 5 and 10µM using 
8µM of Endo-Porter. Control samples were transfected with the GeneTools control PMO at 
10µM. RNA was extracted 24 hours after transfection and RT-PCR used to amplify exons 2-
4 of POSTN mRNA.  
A) 3% agarose gel of the RT-PCR products from amplification of exon 2-4 of POSTN from 
C2C12 transfected with 10, 5 and 2µM of PEX3..Full length product at 149bp containing 
exon 3 is present in all lanes. The smaller product at 84bp is present in all three 
concentrations of the transfection.  Hyperladder IV (H IV) was used.  
B) Semi-quantitative analysis of the gel in section A using GeneTools showing 25% skipping 
at 2µM, 40% at 5µM and 56% skipping at 10µM. (****p<0.0001, N=3). 
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Figure 5.9 Quantification of POSTN expression in PEX3 transfected C2C12 cells 
C2C12 cells after reaching confluency were transfected with PEX3 at 2, 5 and 10µM using 
8µM of Endo-Porter. RNA was extracted 24 hours after transfection and qPCR used to 
amplify POSTN mRNA. GAPDH was co-amplified and used as a housekeeping gene to 
normalise quantified POSTN expression levels. Statistical significance was calculated 
using a one-way ANOVA test. (*p<0.05, **p<0.01, N=3). 
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Figure 5.10 Transfection of PEX16.1 PMO targeting exon 16 in C2C12 cells 
C2C12 cells after reaching confluency were transfected with PEX16.1 at 2, 5 and 10µM using 
8µM of Endo-Porter. Control samples were transfected with the GeneTools PMO control at 
10µM. RNA was extracted 24 hours after transfection and RT-PCR used to amplify exons 2-4 of 
POSTN mRNA.  
A) 10% polyacrylamide TBE gel of the RT-PCR products from amplification of exon 15-17 of 
POSTN from C2C12 transfected with 2, 5 and 10µM of PEX16.1. Full length product at 168bp 
containing exon 16 is present in all lanes. The smaller product at 122bp is present in all three 
concentrations of the transfection. Due to the sensitivity of the gel various small unspecific 
bands were also visualised. Hyperladder IV (H IV) was used 
B) Semi-quantitative analysis of the gel in section A using GeneTools software showing 28% 
skipping at 2µM, 40% at 5µM and 35% skipping at 10µM. Statistical analysis was carried out 
using one way ANOVA with respect to control samples with no skipping (*p<0.05, N=3). 
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Figure 5.11 Quantification of POSTN expression in PEX16.1 transfected C2C12 cells 
C2C12 cells after reaching confluency were transfected with PEX16.1 PMO at 10µM, 5 µM 
and 2 µM using 8µM of Endo-Porter. RNA was extracted 24 hours after transfection and 
subjected to RT-qPCR to amplify POSTN mRNA. GAPDH was co-amplified and used as a 
housekeeping gene to normalise quantified POSTN expression levels. Statistical significance 
of normalised POSTN transcript levels were calculated using a one-way ANOVA test. 
(**p<0.01, N=3).  
 
 
196 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A) 
B) 
Figure 5.12 Dose response analysis of PEX3 PMO targeting exon 3 in C2C12 cells. 
C2C12 cells after reaching confluency were transfected with PEX3 PMO at 10µM, 5 µM, 2, 0.5 and 0.2 
µM using 8µM of Endo-Porter. Control samples were transfected with the GeneTools PMO control at 
10µM. RNA was extracted 24 hours after transfection and subjected to RT-PCR to amplify exons 2-4 of 
POSTN mRNA.  
A) A 3% agarose gel of the RT-PCR products from amplification of exon 2-4 of POSTN from C2C12 
transfected with 0.2, 0.5, 2, 5 and 10µM of PEX3. Full length product containing exon 3 at 149bp is 
present in all lanes. The smaller product at 84bp is present in all six concentrations of the transfection. 
B) Semiquantitative analysis of the gel in section A using GeneTools showing 9% skipping at 0.2µM, 
42% at 0.5µM, 38% at 2µM, 49% at 5µM and 53% skipping at 10µM (****p<0.0001, N=3). Hyperladder 
IV (H IV) was used 
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Figure 5.13 Quantification of POSTN expression in dose analysis of PEX3 transfected 
C2C12 cells 
C2C12 cells after reaching confluency were transfected with PEX3 PMO at 0.2, 0.5, 2, 5 
and 10µM using 8µM of Endo-Porter. RNA was extracted 24 hours after transfection and 
subjected to qPCR to amplify POSTN mRNA. GAPDH was co-amplified and used as a 
housekeeping gene to normalise POSTN expression levels. Statistical significance was 
calculated using a one-way ANOVA test. (****p<0.0001, N=3).  
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5.2.2.4 PMO induced exclusion of POSTN exon 3 using 28mer PMOs 
The 25mer PEX3 showed promising skipping in the C2C12 cell system with a (non-
significant) 9% skip at 0.2µM and as much as 53% at 10µM (p<0.0001). As previously 
mentioned, it has been shown in the literature that the longer the PMO, the more 
successful at it is at skipping (Popplewell et al., 2009). The longest PMO that can be 
synthesised for in vivo purposes is 28 nucleotides. It was therefore decided to extend 
the PEX3 PMO by three bases and design some 28mer PMOs. Two PMOs were designed, 
PEX3.28.1 and PEX3.28.2. both targeting the secondary structure of exon 3 with the 3’ 
end of the PMO binding an open loop (Figure 5.14). Pex3.28.1 and Pex3.28.2 were 
predicted to have overall binding energy of -48.31 and -50.81 respectively (Figure 5.15) 
As before, C2C12 cells were seeded in six-well plates and treated with TGF-β an hour 
prior to being transfected with one of the two PMOs. The cells were transfected at 
concentrations of 0.2, 0.5, 2, 5 and 10µM (Figures 5.16, 5.18) to allow a dose-response 
analysis as carried out for PEX3 above. RNA was harvested 24 hours after transfection 
and subjected to nested RT-PCR amplifying exons 2-4 as before, giving a full-length 
product of 169bp and a skipped product of 104bp; PCR products were resolved on a 3% 
agarose gel.  
The harvested RNA was subjected to RT-qPCR using the same primers as before for PEX3 
analysis. outlined in section 2.4.3.2. POSTN message expression was quantified using RT-
qPCR (Figures 5.17 and 5.19) and all expression normalised to GAPDH expression.  
The result for PEX3.28.1 (Figure 5.14) shows a clear dose-dependent decrease with 4% 
skipping at 0.2µM and 80% skip at 10µM, the best seen so far. RT-qPCR analysis of the 
199 
 
RNA also showed a clear dose response to the PMO with significant downregulation 
shown at 1, 2, 5 and 10µM but not 0.2 and 0.5µM (Figure 5.17). 
The results for PEX3.28.2 (Figure 5.18A) also showed a clear dose-response very similar 
to that of PEX3.28.1. Semi-quantitative analysis showed very similar results to PEX3.28.1 
with 6% exon skipping at 0.2 µM going up to an 80% skip at 10 µM (Figure 5.18B). qPCR 
analysis of the RNA showed a much more significant effect of the PEX3.28.2 PMO. Even 
concentrations as low as 0.2µM showed highly significant downregulation of POSTN 
with p<0.00001 (Figure 5.19).  
To determine if the treatment of C2C12 cells with PEX3.28.2 had an effect on POSTN 
protein expression in-vitro, protein was extracted from cells transfected with 0.2, 5 and 
10µM PMO 48 hours after transfection. Whole cell extracts were subjected to Western 
blotting to detect Periostin expression with POSTN-specific polyclonal antibody ab1404 
and α-tubulin as a loading control for normalisation of protein expression (Figure 5.20).  
POSTN has previously been shown to be detected using this antibody, running at a 
molecular weight of 90-100kda (Semba et al., 2018a). Low POSTN protein expression 
was found even in control samples which confirms the low expression found in qPCR 
analysis on the RNA level. Quantification of the image showed reduced POSTN 
expression in a dose-dependent manner with PEX3.28.2 transfection. No statistical 
significance was seen. 
Fibronectin protein expression was also assessed as a fibrotic marker and to investigate 
whether POSTN protein downregulation had a downstream effect on fibronectin 
expression. Fibronectin was detected using fibronectin-specific polyclonal antibody 
ab2413. Vinculin was used as its loading control, to normalise expression (Figure 5.21) 
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The fibronectin Western blot (Figure 5.21) showed high fibronectin expression in the 
control samples in comparison to POSTN expression. The results, with the expected 
band at 280kDa, shows a dose-dependent decrease in fibronectin expression upon 
PEX3.28.2 transfection. This is a similar pattern to that of POSTN protein expression 
described above. Statistical significance was barely noted at 10µM when analysed using 
a one-way ANOVA test (*p<0.05, N=3). 
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Figure 5.14 Secondary structure of mouse and human POSTN exon 3 and binding position of Pex3.28.1 and Pex3.28.2  
Secondary structures were predicted using Mfold. Both mouse and human exon 3 are 65 nucleotides long; numbers indicate the position of the 
nucleotide in the exon. Binding position of PEX3.28.1 (red) and Pex3.28.2 (blue) were designed to target exon 3. The 3’ end of each PMO binds the 
secondary structure in open conformation. 
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Figure 5.15 Exon 3 targeting 28mer PMOs  
A) Human and mouse Postn exon 3 alignment generated by SnapGene. Mismatches are highlighted in red. Binding position of Pex 3.28.1 and 
Pex3.28.2 are shown in blue and yellow respectively. B) Pex 3.28.1 and Pex3.28.2 PMO sequences and thermodynamic properties outlined in 
the table. Overall binding energies were calculated using the RNAup server. Tm and %GC were calculated using IDT OligoAnalyser. 
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Figure 5.16 Dose response analysis of PEX3.28.1 PMO targeting exon 3 in C2C12 cells. 
C2C12 cells after reaching confluency were transfected with PEX3.28.1 PMO at 0.2, 0.5, 
2, 5, and 10µM using 8µM of Endo-Porter. Control samples were transfected with the 
GeneTools PMO control at 10µM. RNA was extracted 24 hours after transfection and 
subjected to RT-PCR to amplify exons 2-4 of POSTN mRNA.  
A) 3% agarose gel of the RT-PCR products from amplification of exons 2-4 of POSTN from 
C2C12 transfected with PEX3.28.1..Full length product at 149bp containing exon 3 is 
present in all lanes. The smaller product at 84bp is present at all six concentrations of 
PMO transfection. Hyperladder IV (H IV) was used. 
B) Semi-quantitative analysis of the gel in section A using GeneTools software measures 
4% skipping at 0.2µM, 32% at 0.5µM, 37% at 1µM, 60% at 2 and 5µM and 80% skipping 
at 10µM. Statistical significance was calculated using one way ANOVA with respect to 
control samples (****p<0.0001,***p<0.001, N=3). 
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Figure 5.17 Quantification of POSTN expression in dose analysis of PEX3.28.1  
transfected C2C12 cells 
C2C12 cells after reaching confluency were transfected with PEX3.28.1 at  0.2, 0.5, 2, 5 
and 10µM using 8µM of Endo-Porter. RNA was extracted 24 hours after transfection and 
subjected to qPCR to amplify POSTN mRNA. GAPDH was co-amplified and used as a 
housekeeping gene to normalise quantified POSTN expression levels. Statistical 
significance was calculated using a one-way ANOVA test. (**p<0.01, *p<0.05, N=3). 
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Figure 5.18 Dose response analysis of PEX3.28.2 PMO targeting exon 3 in C2C12 cells. 
C2C12 cells after reaching confluency were transfected with PEX3.28.2 PMO at 0.2, 0.5, 1, 
2, 5 and 10µM using 8µM of Endo-Porter. Control samples were transfected with the 
GeneTools PMO control at 10µM. RNA was extracted 24 hours after transfection and 
subjected to RT-PCR to amplify exons 2-4 of POSTN mRNA.  
A) A 3% agarose gel of the RT-PCR products from amplification of exons 2-4 of POSTN from 
C2C12 transfected with PEX3.28.2. Full length product at 149bp containing exon 3 is 
present in all lanes. The smaller product at 84bp is present in all six concentrations of the 
transfection although very faint in the 0.2µM PMO transfected cells. Hyperladder IV (H IV) 
was used. 
B) Semi-quantitaitve analysis of the gel in section A using GeneTools software showing  
skipping at 6% at 0.2µM, 31% at 0.5µM, 33% at 1µM, 59% at 2µM, 57% at 5µM and 80% 
skipping at 10µM. Statistical significance was calculated using one way ANOVA with respect 
to control samples with no skipping (****p<0.0001, N=3). 
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Figure 5.19 Quantification of POSTN expression in dose analysis of PEX3.28.3 
transfected C2C12 cells 
C2C12 cells after reaching confluency were transfected with PEX3.28.2 PMO at 0.2, 
0.5, 1, 2, 5 and 10µM using 8µM of Endo-Porter. RNA was extracted 24 hours after 
transfection and subjected to qPCR to amplify POSTN mRNA. GAPDH was co- 
amplified and used as a housekeeping gene to normalise quantified POSTN 
expression levels. Statistical significance was calculated using a one-way ANOVA 
test. (***p<0.001, ****p<0.00001, N=3). 
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Figure 5.20 Western Blot analysis to detect POSTN protein expression from PEX2.28.2 
PMO transfected C2C12 cells. 
C2C12 cells were plated in 6 well multiplates and allowed to grow to confluency before 
being transfected with 0.2, 5 and 10µM of PEX3.28.2 PMO using 8µM Endo-Porter. 
Control samples were treated with gene tools PMO at 10µM. Protein was extracted 48 
hours after transfection and POSTN expression analysed with Western blotting using 
fluorescently tagged secondary antibodies and imaged using NIR fluorescence imaging 
Odyssey as described in Methods and Materials.  
A) Western blot of protein extracted from PEX3.28.2 transfected C2C12 cells. POSTN 
expression was probed with POSTN specific polyclonal antibody ab1404. Secondary 
antibodies with green fluorescence was used to show POSTN expression. α-tubulin was 
used as loading control, to normalise POSTN expression. Red fluorescently-tagged 
secondary antibody was used to probe tubulin. Bands corresponding to POSTN (100kDa) 
and tubulin (50kDa) are labelled (predicted molecular weights).  
B) Semi-quantitative analysis of the Odyssey image shown in A using Image Studio 
showed a dose dependent decrease in POSTN expression. No statistical significance was 
seen when analysed using a one-way ANOVA test (N=3).  
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Figure 5.21 Western Blot analysis to detect Fibronectin protein expression from 
PEX2.28.2 PMO transfected C2C12 cells. 
C2C12 cells were plated in 6-well plates and allowed to grow to confluency before 
being transfected with 0.2, 5 or 10µM of PEX3.28.2 PMO using 8µM Endo-Porter. 
Control samples were transfected with the GeneTools control PMO at 10µM. 
Protein was extracted 48 hours after transfection. Fibronectin expression was 
analysed by Western blotting using fluorescently tagged secondary antibodies and 
imaged using Odyssey Image Studio.  
A) Western blot of proteins extracted from PEX3.28.2 (transfected as described 
above). Fibronectin expression was probed with fibronectin-specific polyclonal 
antibody ab2413. Secondary antibody with green fluorescence was used to visualise 
fibronectin. Vinculin was used as a loading control and to normalise fibronectin 
expression. Red fluorescently-tagged secondary antibody was used to visualise 
vinculin. Fibronectin (280kDa) and vinculin  (124kDa) are labelled (predicted 
molecular weights).  
B) Semiquantitative analysis of the Odyssey image shown in A. Dose dependent 
decreases in fibronectin expression are visible but there is arguable statistical 
significance at 10µM when analysed using a one-way ANOVA test (*p<0.05, N=3). 
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5.2.2.5 PEX3.28.2 Transfection in cultured murine fibroblast cells  
To investigate the bioactivity of PEX3.28.2 in mouse fibroblasts, cells were treated 
with PEX3.28.2 in order to abrogate POSTN expression which is a big contributor 
to fibrosis (Katsuragi et al., 2004). Fibroblasts were seeded in 6-well plates, treated 
with TGF-β as before and an hour afterwards transfected with 0.5, 1, 5 or 10µM 
of PEX3.28.2 using 8 µM of Endo-Porter. Control samples were transfected with 
10 µM of the GeneTools control PMO and mock samples were not treated with 
either TGF-β, PMO or Endo-Porter. RNA harvesting and nested RT-PCR as well as 
RT-qPCR for exon 3 was carried out as for C2C12 cells (above).  
Initially, the effect of TGF-β on POSTN protein expression in fibroblasts was 
assessed, as before, by Western blotting; as expected, TGF- β treatment caused a 
significant increase in POSTN protein expression (Figure 5.22). 
Nested RT-PCR (Figure 5.23) showed production of both the full-length 169bp 
product and the smaller, skipped 104bp product. There was a clear dose response 
to PEX3.28.2. Semi-quantitative analysis of the agarose gel using GeneTools 
software (Figure 5.23B) verified this: no skipping was measurable at 0.2µM, while 
17% was observed at 1µM, 33% at 5µM and 10µM transfection show 38% 
skipping. RT-qPCR analysis (Figure 5.24) confirmed those semi-quantitative results 
in terms of trend, but showed a much more significant effect of the PMO, with 
close to no periostin expression at 10 µM and statistically significant 
downregulation at 1, 5 and 10 µM.  
To determine whether the PEX3.28.2 treatment of the fibroblast cells has an effect 
on periostin (POSTN) and fibronectin protein expression, Western blotting was 
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carried out (Figure 5.25). Fibroblast cells were treated in the same way, 
transfected with 0.2, 1, 5 or 10µM PEX3.28.2 or controls. Protein was harvested, 
and Western blotting carried out for POSTN as above.  Similarly, for fibronectin 1, 
5 or 10 µM and control transfections were carried out and whole cell protein 
samples used on the Western blot (these concentrations were chosen based on 
the results from the POSTN Western). Figure 5.25 shows a dose-dependent 
downregulation of POSTN at 1, 5 and 10 µM with no downregulation seen at 0.2 
µM, confirming the trend seen at the RNA level. Fibronectin Western blotting is 
shown in Figure 5.26 and shows dose-dependent downregulation of fibronectin 
with statistical significance seen at 5 and 10 µM transfection with p<0.05 (N=3). 
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Figure 5.22 Western Blot analysis to detect POSTN protein expression from TGF-β treated 
fibroblast cells. 
Fibroblast cells were plated in 6 well multi-plates and allowed to grow to confluency before 
being treated with 10ng of TGF-β. Control samples were not treated with TGF-β. Protein 
was extracted 48 hours after transfection and POSTN expression analysed with western 
blotting using fluorescently tagged secondary antibodies and imaged using Odyssey as 
described in Methods and Materials. A) Western blot of protein extracted from TGF-β 
treated fibroblast cells at 10ng. Periostin expression probed with POSTN specific polyclonal 
antibody ab1404. Secondary antibody with green fluorescence was used to show POSTN 
expression. α-tubilin was used as loading control and to normalise POSTN expression. Red 
fluorescently tagged secondary antibody was used to probe tubulin. The bands 
corresponding to POSTN and tubulin are labelled. POSTN has a predicted weight of 100kDa 
and α-tubilin has a predicted weight of 50kDa. B) Image Studio, provided by Odyssey clx, 
was used for semiquantitative analysis of the Odyssey image shown in section  A statistically 
significant increase in POSTN protein levels was calculated using a one-way ANOVA test. 
(*p<0.05, N=3).  
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Figure 5.23 Dose response analysis of PEX3.28.2 PMO targeting exon 3 in murine 
fibroblast cells. 
Fibroblast cells after reaching confluency were transfected with PEX3.28.2 at 0.2, 1, 5 
and 10µM PMO using 8µM of Endo-Porter. Control samples were transfected with the 
GeneTools control PMO at 10µM. RNA was extracted 24 hours after transfection and 
subjected to RT-PCR.  
A) A 3% agarose gel of the RT-PCR products from amplification of exons 2-4 of POSTN. 
Full length product at 149bp containing exon 3 is present in all lanes. The smaller product 
at 84bp is present in lanes transfected with 1, 5 and 10µM. Hyperladder IV (H IV) was 
used. 
B) Semi-quantitative analysis of the gel in A using GeneTools, shows 17% skipped 
product at 1µM,  33% at 5µM and 37% skipping at 10µM with no skipping detectable at 
0.2µM. Statistical significance was calculated using one way ANOVA with respect to 
control samples with no skipping (****p<0.0001,***p<0.001, N=3). 
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Figure 5.24 Quantification of POSTN expression in dose analysis of PEX3.28.2 transfected 
fibroblast cells 
Fibroblast cells after reaching confluency were transfected with PEX3.28.2 PMO at 1, 5 and 
10µM using 8µM of Endo-Porter. RNA was extracted 24 hours after transfection and 
subjected to qPCR to amplify POSTN mRNA. GAPDH was also amplified and used as a 
housekeeping gene to normalise quantified POSTN expression levels. Statistical significance 
was calculated using a one-way ANOVA test (****p<0.00001, N=3).  
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Figure 5.25 Western Blot analysis to detect POSTN protein expression from PEX2.28.2 PMO 
transfected fibroblast cells. 
Fibroblast cells were plated in 6-well plates and allowed to grow to confluency before being 
transfected with 0.2, 1, 5 or 10µM of PEX3.28.2 PMO using 8µM Endo-Porter. Control samples 
were treated with the GeneTools negative control PMO at 10µM. Mock samples were 
untreated cells with no TGF-β treatment. Protein was extracted 48 hours after transfection 
and POSTN expression analysed by Western blotting using fluorescence-tagged secondary 
antibodies and imaged using Odyssey.  
A) Western blot of proteins from PEX3.28.2 transfected fibroblast cells probed for POSTN 
expression with POSTN-specific polyclonal antibody. Secondary antibodies with green 
fluorescence show POSTN expression. α-tubulin was used as loading control and to normalise 
POSTN expression. Tubulin was probed with anti-tubulin and picked out with red 
fluorescence-tagged secondary antibodies. Bands corresponding to POSTN (100kDa) and 
tubulin (50kDa, predicted molecular weights) are labelled.  
B) Semiquantitative analysis of the digital image in A was with Image Studio. Dose dependent 
decreases in POSTN expression is visible but no statistical significance was found upon 
analysis using a one-way ANOVA test (N=3).  
 
222 
 
 
 
 
 
 
 
 
 
 
 
223 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.26 Western Blot analysis to detect Fibronectin protein expression from 
PEX2.28.2 PMO transfected fibroblast cells. 
Fibroblast cells were plated in 6 well plates and allowed to grow to confluency before 
being transfected with 1, 5 and 10µM of PEX3.28.2 PMO using 8µM Endo-Porter. 
Control samples were treated with the GeneTools negative control PMO at 10µM. 
Protein was extracted 48 hours after transfection and fibronectin expression analysed 
by Western blotting, visualising using fluorescence-tagged secondary antibodies, 
imaged using Odyssey.  
A) Western blot of protein extracted from PEX3.28.2 transfected fibroblast cells.  
Fibronectin-specific polyclonal antibody ab2413 and secondary antibody with green 
fluorescence was used to probe fibronectin expression. Vinculin, a loading control and 
to normalise fibronectin expression was probed with anti-vinculin and visualised with  
red fluorescence-tagged secondary antibody. Bands corresponding to fibronectin 
(280kDa) and vinculin (124kDa predicted molecular weights) are labelled.  
B) Semi-quantitative analysis of the Odyssey image in A was with Image Studio. Dose 
dependent decreases in fibronectin expression are visible. Statistical significance was 
calculated at 5 and 10µM PMO transfection using a one-way ANOVA test (*p<0.05 
N=3). 
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5.3 Discussion  
As discussed in Chapter 1 section 1, fibroblasts have been shown to be a major source 
of POSTN expression and a big contributor to fibrosis (Katsuragi et al., 2004). To prevent 
fibrosis we wished to find a way to abrogate the upregulation of the mechanisms that 
give rise to this debilitating infilling of muscle tissue with non-muscle components. 
Therefore in this study, AONs aimed at interacting with the pre-mRNA to promote the 
production of out-of-frame, exon-skipped nonsense mRNAs which are likely 
downregulated by NMD, were designed, synthesised and tested in various cell systems 
for their effect on mRNA and protein downregulation. Mouse and human candidate 
sequences were compared so that AONs could be tested in the mouse and then 
potentially used on human patients without alteration; conserved regions are also more 
likely regulatory. 
5.3.1 Effect of TGF-β on POSTN expression in muscle cells  
The fibrotic pathway is stimulated through the TGF-β signalling pathway (March et al., 
2018). TGF-β has been shown to be directly responsible for upregulating POSTN in 
various tissues as well as cell lines (Bowen, Jenkins and Fraser, 2013; Özdemir et al., 
2014; March et al., 2018). 
In this Chapter, we initially looked at the effect of TGF-β treatment on murine muscle 
cells, C2C12, as well as myofibroblasts. Our findings showed that POSTN is expressed at 
relatively low amounts in vitro (Figure 5.1) and increased significantly upon TGF-β 
treatment, as previously shown in other cell lines (Litvin, Selim and Montgomery, 2004; 
Li et al., 2006). Protein readout in fibroblasts also confirmed close to no POSTN protein 
225 
 
expression in cells not treated with TGF-β and a significant increase upon treatment 
(Figure 5.20). This finding confirmed the need to stimulate POSTN expression in cells, 
prior to transfection with antisense oligonucleotides, to activate transcription of POSTN, 
allowing the PMO to bind the newly abundantly produced pre-mRNA, interacting with 
it to promote successful exon skipping.  
5.3.2 PMO induced skipping of Periostin  
AONs have been used to successfully target and downregulate POSTN expression in a 
variety of targets such as the lung, kidney and tumours, in order to diminish fibrosis 
(Tomaru et al., 2017; Semba et al., 2018a). Targeting out-of-frame exons, to remove 
them from transcripts producing an out-of-frame read, leads to exon exclusion, out-of-
frame regions of the transcript and downregulation of the targeted gene at the RNA 
level by NMD leading to subsequent downregulation at the protein level (Kang et al., 
2011a). 
PMOs designed to the out-of-frame exons 3, 7, 10 and 16 were initially tested in a human 
DMD muscle cell line in order to confirm skipping before being tested in murine muscle 
cells. The PMOs being tested in cell lines from different species are nonetheless 
targeting the same sequences, and it was important for skipping to be confirmed in both. 
PMOs targeting exon 10 showed no skipping in the human cell line and were therefore 
eliminated from the further investigation. The most successful PMOs were tested in a 
C2C12 murine muscle cell line and a dose-response analysis performed, with POSTN 
expression assessed both semi-quantitatively and quantitatively. PEX3 showed 
significant exon skipping and POSTN downregulation at 0.5-10µM concentrations.  
Interestingly PEX3 proved to be more successful in the C2C12 cell line, where there is 
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actually a mismatch between the target sequence and the PMO, than in human patient 
cells where the PMO is designed with no mismatches. This could be due to toxicity 
effects of the transfection on the cell line as C2C12 are much easier to grow and 
transfect and are not as sensitive.  
It has previously been shown in our laboratory that longer PMOs are more effective at 
inducing exon skipping (Popplewell et al., 2009) so the maximum length (for human 
therapy) of 28mer PMOs targeting exon 3 were designed and tested: they were found 
indeed to be more effective, with PMO PEX3.28.2 showing significant downregulation 
of POSTN at concentrations as low as 0.2 µM. Protein readout from C2C12 cells 
transfected with PEX3.28.2 also confirmed downregulation of POSTN protein in a dose-
dependent manner although statistical significance was not achieved. The less 
significant downregulation on the protein level compared to RNA level could be due to 
that fact that protein was harvested 48 hours following transfection: this was shown to 
be cytotoxic, resulting in the death of about 20% of cells per 24 hours (above), thus 
reducing protein levels! In addition, this may be too short a time for protein turnover so 
that protein already made is being seen, although we had demonstrated a good increase 
in POSTN production following 24h of TGF- β exposure. Another reason could be the 
high variability between samples and the relatively low expression of Periostin in these 
cells, so more replicates could be run or a more sensitive assay developed.  
Interestingly, fibronectin protein expression was also found to be downregulated in a 
dose-dependent manner in response to POSTN downregulation, with statistical 
significance seen at 10µM. This is in agreement with the literature where it has been 
reported that POSTN is involved in fibronectin secretion (Kii, Nishiyama and Kudo, 2016). 
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Secreted fibronectin is therefore a good marker of POSTN downregulation under these 
conditions, since it is much more abundant and easily analysed by Western blot, 
whereas antibodies to POSTN are less sensitive compared to the normalisation proteins 
and the immunosensitivity remains to be improved: in our hands the Western blotting 
for POSTN was not as straight forward.  
PEX3.28.2 also showed successful skipping in the robust murine fibroblast cells, with 
detectable skipping at concentrations as low as 1µM and significant downregulation at 
the RNA level when assessed by qPCR. Protein readout also confirmed the results of the 
RNA analysis, showing a dose-dependent downregulation of POSTN; however, the 
results were not significant. Despite this, a significant downregulation of secreted 
fibronectin was observed at 5 and 10µM indicating acceptable downregulation of 
POSTN. Fibronectin is downstream of POSTN in the fibrotic pathway.  
The results, therefore, suggest that PMO PEX3.28.2, which removes exon 3 from the 
POSTN pre-mRNA producing a significant quantity of exon skipped message compared 
to full length, could be a successful candidate to take on to in vivo investigations in mice.  
5.3.3 Comparison between the bioinformatic prediction of PMO bioactivity with in-
vitro results of the PMO bioactivity 
Using bioinformatics is essential for the intelligent design of AONs and the uses of 
various parameters to predict bioactivity has been widely studied (Sun, Peng and He, 
2008; Popplewell et al., 2009; Schoch and Miller, 2017) as discussed in Chapters 3 and 
4. Popplewell et al. reported that the most significant thermodynamic property in PMO 
bioactivity is the energy of binding, while, although the binding site did not determine 
PMO bioactivity, amongst successful PMOs those that targeted open structures were 
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more successful . The binding energy is critically affected by another PMO parameter 
cited to be of high significance, i.e. oligonucleotide length with 30mer PMOs more 
successful than their 25mer counterparts. This study confirms the findings above. PMOs 
that lead to successful exon skipping had a minimum overall binding energy of -40 
kcal/mol, with the exception of PEX7.3 PMO which had binding energy of -48.83 
kcal/mol yet was still not successful at promoting exon skipping. This could be due to 
the nature of the target sequence of PEX7.3 rather than the lack of PMO binding, 
although it is not yet possible to see oligonucleotides bind to pre-mRNA targets in cells: 
an in vitro experiment with a synthetic RNA target may show whether PEX7.3 actually 
binds its putative target. From the exon 3 and exon 16 PMOs, PEX3 and PEX16.1, 
PEX16.2, which initially all showed good POSTN mRNA exon skipping, it was PEX3 that 
showed significantly better bioactivity. This correlated with the better energy of binding 
of PEX3 at -44.15  kcal/mol as well as its predicted binding to open loops at both ends of 
the PMO, confirming that increased binding energy and targeting sequences with less 
secondary structure can enhance PMO bioactivity. Increasing the length of Pex3 from a 
25mer to 28mers, in this study, also confirmed that PMO length is a parameter of high 
significance. By an increase in the length of just 3 bases, the bioactivity of the PMO 
increased from 33% skipping to 80% skipping.  
It is worth mentioning that the GC content of all the designed PMOs with the exception 
of Pex10.1 was below 55% as suggested to be ideal by Ho et al. (Ho et al., 1996).  
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6. Antisense modulation of Periostin pre-mRNA splicing in the 
C57 mouse model 
6.1 Introduction  
Investigations in control mouse myoblasts (C2C12 cell line), murine skeletal muscle 
fibroblasts (MH cell line) and immortalised DMD patient myoblasts were used to assess 
the bioactivity of the PMOs designed to affect exon skipping, specifically of exon 3. They 
demonstrated that PMO PEX3.28.2 was the most effective at promoting exon skipping, 
inducing exclusion of exon 3.  
To move to an in vivo system, previous work in the laboratory was considered. 
Intramuscular injection of 25µg of 2OMe-P-AON induced de novo expression of 
dystrophin in the mdx mouse model (Graham et al., 2004). Also, 20µg intramuscular 
injection of AON with "vivo-PMO" chemistry induces expression of dystrophin in the 
mdx mouse model (Akpulat et al., 2018)  
POSTN isoforms have been shown to be involved in the regeneration and healing of 
muscle (Morita and Komuro, 2016), as well as fibrosis. There is concern that reducing 
POSTN expression may interfere with the regeneration and healing process. In skin 
healing studies, Nishiyama et al. (2011) demonstrated defects in re-epithelialisation in 
Postn-/- mice (Nishiyama et al., 2011). In cardiac muscle research, Postn-/- mice were 
found to have significantly decreased survival rates after induction of myocardial 
infarction (Shimazaki et al., 2008). This was attributed to impaired ECM deposition in 
the healing cardiac muscle (Periostin is in the ECM). Studies like this highlight the 
importance of POSTN upregulation following acute injury to quickly restore ECM and 
tissue homeostasis. In skeletal muscle, POSTN is expressed at extremely low levels under 
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normal circumstance but is upregulated upon mechanical stress or damage when it is 
expressed by infiltrating cells such as macrophages and fibroblasts as well as 
regenerating myofibres (Özdemir et al., 2014). It has been shown that in the case of 
sgcd-/- postn-/- double knockouts, the pathology of the dystrophic mouse was a lot less 
severe due to a decrease in fibrosis (Lorts et al., 2012). It is important to achieve POSTN 
downregulation such that fibrotic tissue is reduced but regeneration and healing can still 
take place.  
Therefore, work in this Chapter is concerned with assessing the bioactivity of the 
PEX3.28.2 PMO in vivo and the effect of POSTN downregulation by PEX3.28.2 on skeletal 
muscle regeneration in damaged C57 mice, after having the TA muscle injected with 
BaCl2.  
6.2 Results  
6.2.1 BaCl2 induced muscle damage in 24month old C57 mice 
The first experiment was to assess damage and fibrosis in the TA of mice that had been 
subjected to the intramuscular injection of BaCl2 (Hardy et al., 2016). The left TA of 4 
female. 24-month-old C57/B10 mice were injected with 50µl of 1.2% (w/v) BaCl2. The 
right TA was used as a non-injected control. Animals were sacrificed at 1, 3, 7 and 14 
days after injection and tissue collected as described in section 2.9.  
6.2.1.1 Sirius red staining  
Sections from TA muscle injected with BaCl2 and controlled TA were stained with Sirius 
red as described in Materials and Methods and the results are shown in Figure 6.1. Sirius 
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red staining is one of the most widely used techniques for looking at collagen 
histochemistry (Puchtler, Waldrop and Valentine, 1973; Junqueira, Bignolas and 
Brentani, 1979). Picro-Sirius red dyes have specific reactivity to collagen I and III are 
therefore used for quantitative estimation of tissue fibrosis (Sweat, Puchtler and 
Rosenthal, 1964). Collagen is stained red, and muscle fibres and cytoplasm are stained 
yellow (Figure 6.1A). The staining revealed a peak in collagen I and III 3 days after BaCl2 
treatment, where a 30% increase in red stain, measured using ImageJ, relative to control 
TA, was quantified. This was reduced to a 10% increase at 14 days after injection when 
normal muscle morphology is restored, as indicated by the presence of healthy muscle 
architecture (Figure 6.1B). 
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Figure 6.1 Sirius red staining of C57 TA 
24 month old C57 mice were treated in one thigh with a damage reagent and the other untreated, as control (see text). 
A) Microscope images of sections from treated and untreated TAs harvested 1, 3, 7 or 14 days after Ba2Cl injection into the test TA, stained with 
Sirius red. Visually, there is a clear increase in collagen (red) staining from 1 day after injection to 3 days after injection. After this the muscle 
morphology begins to be restored and collagen expression (red) becomes limited to the ECM of the regenerated fibres. Magnification X20 
B) Collagen (red stain) in three random fields of each section was quantified using ImageJ to calculate the percentage increase in red stain in 
Ba2Cl injected samples compared to the control. A steep increase in collagen expression is seen between 1 day and 3 day after Ba2Cl injection 
after which a more gradual decrease in collagen levels is measured. N=1,  
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6.2.1.2 Immunohistochemistry for Periostin, Fibronectin, Collagen VI, and α-SMA 
Sections from TA muscle injected with BaCl2 and control TA were stained for POSTN, 
fibronectin, collagen VI or α-SMA, as described in Materials and Methods (Chapter 2). 
Results are shown in Figures 6.2, 6.3, 6.4 and 6.5 respectively. Fibronectin, collagen VI 
and α-SMA are commonly used to look at tissue fibrosis (Specks et al., 1995; Veerasamy 
et al., 2009; To and Midwood, 2011). All slides were co-stained with laminin to outline 
skeletal muscle fibres and Dapi to visualise the nuclei. The staining reveals necrosis 
induced by BaCl2 followed by regeneration of the muscle fibres (Caldwell, Mattey and 
Weller, 1990). As observed by the laminin and Dapi stains, in the first 7 days after the 
injection there is an abundance of mononuclear cells, mostly leukocytes and 
macrophages as well as activated satellite cells (Casar, 2004) in the enlarged intercellular 
space between the necrotic fibres. At day 7, regenerated fibres can be seen with nuclei 
in a central position but with heterogenous diameters. Fibres continue to regenerate, 
and by 14 days after injection, the tissue has recovered to normal morphology but still 
showed central nuclei and increased interstitial spaces. 
POSTN has been shown to be expressed in low amounts in healthy skeletal muscle, 
upregulated upon damage within regenerating fibres and finally restricted to the ECM 
following restoration of skeletal muscle morphology (Özdemir et al., 2014). As discussed 
in Chapter 1, POSTN is important in regeneration and repair of damaged muscle. In 
accordance with previous data, Figure 6.2 shows upregulation of POSTN protein 3 days 
after injection with POSTN clearly observed inside the newly forming fibres.  At 7 days, 
when fibres were clearly regenerating, POSTN protein levels were at their peak; 
interestingly the fibres were devoid of POSTN, which was heavily localised to the 
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endomysial space. At 14 days after injection where regenerating fibres had mostly 
recovered their normal morphology, POSTN protein expression was reduced, though 
still high relative to control TA, being limited mainly to the interstitial space deposited 
in the ECM lining the rim of fibres.  
Collagen VI is heavily involved in maintaining skeletal muscle integrity and function (Chu 
et al., 1988; Knupp and Squire, 2001). Collagen I, II, III as well as Collagen V and VI are 
extracellular proteins and localised in the endomysium and perimysium; they are 
upregulated upon damage (Specks et al., 1995; Ricard-Blum and Ruggiero, 2005). Figure 
6.3 shows collagen VI was indeed restricted to the perimysium and endomysium in 
healthy TA. In the injected TA, collagen was upregulated and present in the necrotic 
tissue. Seven days after BaCl2 injection when the fibres were regenerating, collagen was 
highly expressed in the intercellular space. Fourteen days after injection, muscle 
morphology was restored and collagen expression reduced (in comparison to 7 days), 
and its distribution was that of healthy muscle cells, visible in the endomysium and 
perimysium though the perimysium is enlarged. 
Fibronectin protein is expressed at extremely low levels in the ECM of healthy skeletal 
muscle and is upregulated upon tissue damage aiding in ECM remodelling and fibrosis 
(Kharraz et al., 2014; Kii, Nishiyama and Kudo, 2016). Figure 6.4 shows that fibronectin 
expression was relatively low in control TA but upregulated upon damage with BaCl2 
injection. Fibronectin protein was upregulated and expressed in the necrotic tissue, 
being restricted to the intercellular space in regenerating fibres 7 days after injection 
and to the interstitial space 14 days after injection where normal morphology was seen.  
Fibronectin and collagen showed the same patterns of expression in the necrotic and 
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regenerating fibres (Figures 6.3 and 6.4). Figure 6.5 shows upregulation of α-SMA in the 
necrotic tissue 3 days after BaCl2 injection. Expression was at its peak in the regenerating 
fibres 7 days after injection. At 14 days post-injection, α-SMA was downregulated with 
minimum expression in the centrally nucleated fibres. 
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Figure 6.2 Analysis of POSTN expression in TA Muscles treated withBaCl2 
C57 mice were injected with BaCl2 in one TA and the other was left undamaged as control. Both TA of each mouse was recovered 
1,3,7 and 14 days after injection. Cryosections (10µm) of TA muscle were prepared and stained for POSTN, DAPI and laminin as 
described (see text). Primary polyclonal antibody ab1404.was used for POSTN. Magnification X20. 
Fluorescently tagged secondary antibody was used showing POSTN (green), laminin (red) and DAPI (blue). Combined images 
with all three stains overlaid are shown (bottom row).  
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Figure 6.3 Analysis of Collagen VI expression in TA muscle treated with BaCl2 
C57 mice were injected with BaCl2 in one TA and the other was left undamaged as control. Both TA of each mouse wer recovered 1, 3, 7 
and 14 days after injection (see text).  Cryosections (10µm thick) of TA muscle were prepared and stained for Collagen VI, DAPI and laminin 
as described. Magnification is x20. Fluorescently tagged secondary antibody was used showing collagen VI (green), laminin (red) and DAPI 
(blue). Combined images with all three stains overlaid is also shown (bottom row).  
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Figure 6.4 Analysis of Fibronectin expression in TA muscle treated with BaCl2 
C57 mice were injected with BaCl2 in one TA and the other was left undamaged as control. Both TA of each mouse was recovered 1, 3, 7 and 14 
days after injection. Cryosections (10µm) of TA muscle were prepared and stained for Collagen VI, DAPI and laminin as described in Materials 
and Methods. Fluorescently tagged secondary antibody was used showing collagen VI (green), laminin (red) and DAPI (blue). Combined images 
with all three stains overlaid is also shown (bottom row). Magnification x20.  
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Figure 6.5 Analysis of α-SMA expression in TA muscles treated withBaCl2 
C57 mice were injected with BaCl2 in one TA and the other was left undamaged as control. Both TA of each mouse was recovered 1,3,7 and 14 
days after injection. Cryosections (10µm) of TA muscle were prepared and stained for α-SMA, DAPI and laminin as described in Materials and 
Methods. Fluorescently tagged secondary antibody was used showing α-SMA (green), laminin  (red) and DAPI (blue). Combined images with all 
three stains overlaid is also shown (last row). Magnification x20.  
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6.2.1.3 RT-PCR of Periostin in BaCl2 injected TA of C57 mice 
Total RNA was extracted from TA sections as described in Materials and Methods. RNA 
extracts were subjected to a multiplex RT-PCR to amplify POSTN exon 2-4 and 18S 
(Figure 6.6A). The POSTN mRNA expression was semi-quantitatively analysed as 
described in Materials and Methods and normalised to 18S expression. The POSTN 
mRNA expression of the damage TA was then calculated relative to the healthy TA 
(Figure 6.6b).  
POSTN mRNA expression peaked 14 days after BaCl2 injection. In order to reveal when 
POSTN expression began decreasing, mice injected with BaCl2 and harvested 28 days and 
6 weeks after injection was investigated. RNA was extracted, and RT-PCR was performed 
for all samples 1, 3, 7, 14, 28 and 42 days post-injection. Products were separated on a 
3% agarose gel (Figure 6.6A). It can be seen that at 28 days the POSTN RNA levels began 
to decrease. At 6 weeks POSTN expression is only 20% above that of the healthy TA 
(Figure 6.6B).  
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Figure 6.6 RT-PCR of C57 TA RNA 
24 month old C57 mice were used. One TA was injected with Ba2Cl and the opposite TA was not injected as a matched control. Tissue was harvested 
1, 3, 7, 14, 28 and 42 days after injection and sectioned. RNA was harvested and subjected to multiplex RT-PCR amplifying exons 2-4 of POSTN 
mRNA and PCR of 18S mRNA. was included as a normalisation product. N=1  
A) A 3% agarose gel of the RT-PCR products from the amplification of POSTN exons 2-4 and 18S RNA from samples injected with BaCl2 next to 
matched control samples with no injection. In controls there was a clear increase in POSTN message during tissue damage; however there was a 
decrease in POSTN expression relative to control TA 1 day after injection. The levels significantly increase between 1 day and 14 days after injection 
in the control TAs, after which they decrease to normal levels (relative to control samples) at 42 days after injection.  
B) Intensity of the products on the 3% agarose gel was quantified using GeneTools software. Periostin expression in BaCl2 injected TA samples 
were normalised to 18S expression. The semi-quantitative analysis showed an increase in POSTN expression peaking at 14 days after injection 
after which POSTN levels decrease.  
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6.2.2 Effect of Pex3.28.2 induced Periostin skipping in BaCl2 injected TA of C57 mice 
Assessing the traumatising effect of BaCl2 in the TA of 24-month-old C57 mice (section 
6.2.1) confirmed that intramuscular injection of 50µl of 1.2% BaCl2 caused significant 
damage in the TA leading to an upregulation of POSTN expression. Upregulation of 
POSTN was particularly pronounced in regenerating fibres, 7 days after injection, 
confirming the role and importance of POSTN in the regeneration of muscle fibres and 
healing of damage (March et al., 2018).  
In order to test the bioactivity of PEX3.28.2 PMO in vivo, and assess the consequent 
effect of PMO induced POSTN downregulation in regenerating fibres, 1-month-old mice 
were injected with 50 µl of 1.2% BaCl2 in both TA. 4 days after BaCl2 injection, when 
fibres were shown to be regenerating and POSTN expression upregulated (section 
6.2.1), the left TA was injected with 20µg in 50 µl of PEX2.28.2 and the right TA with 50µl 
of saline. Tissue was then harvested at 7, 14, 28 days and 6 weeks after PMO injection, 
to investigate levels of message and protein by RT-qPCR and Western.  
6.2.2.1 q-PCR of Periostin and fibronectin in BaCl2 /PMO and in BaCl2/saline 
injected TA of C57 mice  
As found in Chapter 5, RT-qPCR analysis of harvested RNA was able to efficiently detect 
downregulation of POSTN in PMO treated samples. Total RNA was therefore extracted 
from TA sections as described in Materials and Methods. RNA extracts were subjected 
to RT-qPCR to amplify POSTN and fibronectin message (Figures 6.7, 6.8, 6,9, 6.10). 
Predesigned primers (described in Chapter 2) were used for amplification. GAPDH was 
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used as a housekeeping gene for normalisation. The primers for GAPDH were also 
predesigned and outlined in section 2. 
There was an overall decrease in POSTN RNA expression as assessed by RT-qPCR, in TA 
muscle following PMO or saline injection, showing successful exon exclusion although 
this was not statistically significant (Figure 6.7A). Fibronectin was also tested by RT-PCR 
(Figure 6.7B). There was very little decrease of fibronectin in the PMO injected samples 
with no statistical significance.  
After 14 days the same RT-qPCR tests were performed. Figure 6.8A shows that POSTN 
RNA expression showed an obvious decrease in POSTN expression. Figure 6.8B revealed 
that at 14 days after injection there was still no change in fibronectin RNA levels after 
PMO treatment. 
At 21 days, POSTN RNA levels were still lower in the PMO injected samples than the 
saline-injected TA (Figure 6.9A). This time, a statistically significant decrease (p=0.02) in 
fibronectin RNA levels was detected in the PMO injected samples in comparison to the 
saline-injected samples (Figure 6.9B).  
At 6 weeks after PMO and saline injection, the POSTN levels were too low to 
quantitatively measured, as expected from their diminishing role by that time. 
Fibronectin levels still showed no change (Figure 6.10), and no statistical difference in 
expression levels between the PMO injected, and saline-injected samples.  
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Figure 6.7 Quantification of POSTN and Fibronectin mRNA expression in PEX3.28.2 
injected C57Bl10 mice 7 days after BaCl2 injection 
1 month old C57 mice were injected with 50µl of 1.2% BaCl2 in both TA. Three days 
after BaCl2 injection the left TA was injected with 20µg of PEX3.28.2 PMO and the right 
TA with saline as control. TA of mice was harvested 7 days after PMO injection. RNA 
was harvested from sectioned samples and subject to qPCR amplifying POSTN and 
fibronectin along with GAPDH a house keeping gene. A) Periostin expression was 
quantified and normalised to GAPDH expression. A decrease in POSTN RNA levels is 
observed in the PMO injected samples .N=3  
B) Fibronectin expression was quantified and normalised to GAPDH. No change in 
fibronectin RNA level was seen upon PMO injection. N=3 
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Figure 6.8 Quantification of POSTN and Fibronectin mRNA expression in PEX3.28.2 
injected C57Bl10 mice 14 days after Ba2Cl injection 
1 month old C57 mice were injected with 50µl of 1.2% BaCl2 in both TA. Three days after 
BaCl2 injection the left TA was injected with 20µg of PEX3.28.2 PMO and the right TA with 
saline as control. Both TA of each of the mice was harvested 14 days after PMO injection. 
RNA was harvested from sectioned samples and subject to qPCR amplifying POSTN and 
fibronectin along with GAPDH.  
A) Periostin expression was quantified and normalised to GAPDH expression. A decrease 
in Postn RNA levels is observed in the PMO injected samples (N=3)  
B) Fibronectin expression was quantified and normalised to GAPDH. No change in 
fibronectin RNA level was seen upon PMO injection (N=3). 
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Figure 6.9 Quantification of POSTN and fibronectin mRNA expression in PEX3.28.2 
injected C57Bl10 mice 28 days after BaCl2 injection 
1 month old C57 mice were injected with 50µl of 1.2% BaCl2 in both TA. Three days 
after BaCl2 injection the left TA was injected with 20µg of PEX3.28.2 PMO and the 
right TA with saline as a matched control. TA were harvested 14 days after PMO 
injection. RNA harvested from sectioned samples was subject to RT-qPCR amplifying 
POSTN and fibronectin message along with GAPDH.  
A) Periostin message expression was quantified and normalised to GAPDH 
expression. A maintained decrease in POSTN RNA levels is observed in the PMO 
injected samples at this time point (N=3).  
B) Fibronectin expression was quantified and normalised to GAPDH. PMO-injected 
samples showed a marginally significant decrease in fibronectin RNA levels in 
comparison to the saline treated samples ( *p<0.05, N=3). 
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Figure 6.10 Quantification of POSTN and Fibronectin mRNA expression in PEX3.28.2 
injected C57BI10 mice 6 weeks after BaCl2 injection 
1 month old C57 mice were injected with 50µl of 1.2% BaCl2 in both TA. Three days 
after BaCl2 injection the left TA was injected with 20µg of PEX3.28.2 PMO and the right 
TA with saline as a control. TA of mice were harvested 14 days after PMO injection. 
RNA was harvested from sectioned samples and subject to qPCR amplifying POSTN and 
fibronectin along with GAPDH. POSTN expression could not be quantified presumably 
because RNA levels were too low which is the situation in normal muscle. Fibronectin 
expression was quantified and normalised to GAPDH. PMO injected samples and saline 
injected samples showed no significant difference in fibronectin RNA levels both 
samples showing very low levels of expression. 
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6.2.2.2 Western blotting of periostin and fibronectin in BaCl2 /PMO and in 
BaCl2/saline injected TA of C57 mice 
To determine whether PEX3.28.2 PMO affects protein expression in damaged muscle in 
vivo, Western blotting was carried out. Protein was extracted from sections of TA, as 
described in Methods and Materials (Chapter 2), from PMO injected and saline-injected 
samples at 7, 14, 28 days and 6 weeks after injection. Protein samples were then 
Western blotted to detect POSTN protein, and α-tubulin was used as a loading control 
and to normalise expression. Fibronectin protein was also visualised and vinculin used 
as the loading control. NIR fluorescence imaging or Odyssey was used to visualise the 
blot and the Odyssey software, Image Studio, was used to quantify the image. 
Figures 6.11A, 6.12B, 6.13A and 6.14a show that there was reduced Periostin protein 
expression in PMO injected samples compared to the saline-injected samples, indicating 
that PEX3.28.2 PMO induced exon exclusion successfully, leading in turn to a decrease 
in POSTN protein levels that is visible even at 6 weeks after injection (unlike the RNA 
message which has become undetectable by 6 weeks). The largest difference between 
PMO injected, and saline-injected samples were seen 14 days after injection (Figure 
6.12A), and the lowest difference between PMO injected, and saline-injected samples 
at 7 days after injection (Figure 6.11A) when Postn message is at its height (above). 
Although differences in protein expression were observed between control and PMO 
treated mice, these were not found to be statistically significant.  
Fibronectin protein levels were also reduced by PMO injection (Figures 6.11B, 6.12B, 
6.13B, 6.14B) at 7, 14 and 28 days but there was no statistical significance due to the 
large error bars as also seen in both Periostin Western blots and POSTN q-PCR. As for 
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Periostin, the largest difference in fibronectin levels, between PMO and saline-injected 
samples, was 7 days after injection (Figure 6.11B). At 6 weeks (Figure 6.14B), fibronectin 
protein levels in the PMO injected samples were no longer lower than the saline-injected 
samples. 
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Figure 6.11 Analysis of POSTN and fibronectin protein in PEX3.28.2 injected C57 mice 1 weeks after PMO injection 
C57 mice were injected with Ba2Cl in both TA, and later with PMO in the left TA and saline right. TA of mice were taken and tissue harvested for 
Western blotting as described in Methods and Materials (Chapter 2). POSTN was detected with rabbit polyclonal antibody ab1404, and 
fibronectin with rabbit polyclonal ab2413. α-tubulin and vinculin were used as loading controls and for semi-quantitative analysis. Fluorescently 
tagged secondary antibodies allowed blots to be imaged using Odyssey and analysed in Image Studio.  
A) Western Blot of protein extracts from TA muscle developed with antibodies for POSTN and α-tubulin. Each pair of lanes (3 pairs) represent 
biological repeats: each pair consists of PMO injected and saline injected TA. Periostin (green), and tubulin (red). Periostin had a predicted weight 
of 100kDa and has been reported to appear between 90-100kDa from in vivo samples. Tubulin has a predicted weight of 50kDa.  
B) Semiquantitative analysis of the Odyssey image in A . A decrease in total POSTN protein levels is seen in PMO injected samples, without 
statistical significance due to large error bars, because one of three replicates showed no change in POSTN levels (N=3). 
C) Western Blot of protein extracts from TA muscle developed with antibodies against fibronectin and vinculin. Each pair of lanes (3 pairs) 
represent biological repeats: each pair consists of PMO injected and saline injected TA. Fibronectin (green) and vinculin (red). Fibronectin has a 
predicted weight of 100kDa but has been reported to run at 280kDa from in vivo samples. Vinculin has a predicted weight of 124kDa.  
D) Semiquantitative analysis of image in C. Fibronectin protein levels decreased in PMO injected samples  (N=3). 
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Figure 6.12 Analysis of POSTN and Fibronectin protein in PEX3.28.2 injected C57 mice 2 weeks after PMO injection 
C57 mice were injected with Ba2Cl in both TA then with PEX3.28.2 PMO in the left and saline, right, as control. After two weeks, TA of mice were 
recovered and tissue harvested from sectioned samples for Western Blotting. POSTN was detected with rabbit polyclonal antibody ab1404, and 
fibronectin with rabbit polyclonal ab2413. α-tubulin and vinculin were used as loading controls. Fluorescently tagged secondary antibodies were 
used and blots imaged using Odyssey and analysed with Image Studio as described in Methods and Materials (Chapter 2). 
A) Western Blot of protein extracts from TA muscle developed with antibodies against  POSTN and α-tubulin. Each pair of lanes (3 pairs) represent 
biological repeats: each pair consists of PMO injected and saline injected TA. POSTN (green), tubulin (red). Periostin had a predicted weight of 
100kDa and has been reported to appear between 90-100kDa from in vivo samples. Tubulin has a predicted weight of 50kDa.  
B) Semiquantitative analysis of the image in A . Decreased POSTN protein levels were seen in PMO injected samples, but there was no statistical 
significance (N=3).C) Western Blot of protein extracts from TA muscle developed with antibodies against fibronectin and vinculin. Each pair of 
lanes (3 pairs) represent biological repeats: each pair consists of PMO injected and saline injected TA. Fibronectin (green), vinculin (red). 
Fibronectin (100kDa) and has been reported to run at 280kDa from in vivo samples. Vinculin has a predicted weight of 124kDa.  
D) Semiquantitative analysis of the image in C. A decrease in total fibronectin protein levels is seen in PMO injected samples, without statistical 
significance (N=3). 
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Figure 6.13 Analysis of POSTN and Fibronectin protein in PEX3.28.2 injected C57 mice 4 weeks after PMO injection 
C57 mice were injected with Ba2Cl in both TA then with PEX3.28.2 PMO in the left and saline, right, as control. After two weeks, TA of mice 
were recovered and tissue harvested from sectioned samples for Western Blotting. POSTN was detected with rabbit polyclonal antibody 
ab1404, and fibronectin with rabbit polyclonal ab2413. α-tubulin and vinculin were used as loading controls. Fluorescently tagged secondary 
antibodies were used and blots imaged using Odyssey and analysed with Image Studio as described in Methods and Materials (Chapter 2). 
A) Western Blot of protein extracts from TA muscle developed with antibodies against  POSTN and α-tubulin. Each pair of lanes (3 pairs) 
represent biological repeats: each pair consists of PMO injected and saline injected TA. POSTN (green), tubulin (red). Periostin had a predicted 
weight of 100kDa and has been reported to appear between 90-100kDa from in vivo samples. Tubulin has a predicted weight of 50kDa.  
B) Semiquantitative analysis of the image in A . Decreased POSTN protein levels were seen in PMO injected samples, but there was no statistical 
significance (N=3). 
C)  Western Blot of protein extracts from TA muscle developed with antibodies against fibronectin and vinculin. Each pair of lanes (3 pairs) 
represent biological repeats: each pair consists of PMO injected and saline injected TA. Fibronectin (green), vinculin (red). Fibronectin (100kDa) 
and has been reported to run at 280kDa from in vivo samples. Vinculin has a predicted weight of 124kDa.  
D) Semiquantitative analysis of the image in C. A decrease in total fibronectin protein levels is seen in PMO injected samples, without statistical 
significance (N=3). 
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Figure 6.14 Analysis of POSTN and fibronectin protein in PEX3.28.2 injected C57 mice 6 weeks after PMO injection 
C57 mice were injected with Ba2Cl in both TA then with PEX3.28.2 PMO in the left and saline, right, as control. After two weeks, TA of mice 
were recovered and tissue harvested from sectioned samples for Western Blotting. POSTN was detected with rabbit polyclonal antibody 
ab1404, and fibronectin with rabbit polyclonal ab2413. α-tubulin and vinculin were used as loading controls. Fluorescently tagged secondary 
antibodies were used and blots imaged using Odyssey and analysed with Image Studio as described in Methods and Materials (Chapter 2). 
A) Western Blot of protein extracts from TA muscle developed with antibodies against  POSTN and α-tubulin. Each pair of lanes (3 pairs) 
represent biological repeats: each pair consists of PMO injected and saline injected TA. POSTN (green), tubulin (red). Periostin had a predicted 
weight of 100kDa and has been reported to appear between 90-100kDa from in vivo samples. Tubulin has a predicted weight of 50kDa.  
B) Semiquantitative analysis of the image in A . Decreased POSTN protein levels were seen in PMO injected samples, but there was no statistical 
significance (N=3). 
C)  Western Blot of protein extracts from TA muscle developed with antibodies against fibronectin and vinculin. Each pair of lanes (3 pairs) 
represent biological repeats: each pair consists of PMO injected and saline injected TA. Fibronectin (green), vinculin (red). Fibronectin (100kDa) 
and has been reported to run at 280kDa from in vivo samples. Vinculin has a predicted weight of 124kDa.  
D) Semiquantitative analysis of the image in C. No significant difference in fibronectin protein levels is seen in PMO injected samples (N=3). 
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6.2.2.3 Sirius red staining  
The effect of PMO injection on collagen distribution during muscle injury was examined 
by Picro-Sirius red staining of tissue sections. Sections were taken from TA muscle 
injected with BaCl2/PEX3.28.2 PMO or BaCl2/saline, stained as described in Materials 
and Methods (Chapter 2) and the results showed (Figure 6.15). Picro-Sirius red dyes have 
specific reactivity to collagen I and III are therefore used for quantitative estimation of 
tissue fibrosis (section 6.2.1). Collagen is stained red, and muscle fibres and cytoplasm 
are stained in yellow. At 1 and 2 weeks after PMO/saline injection the saline-injected TA 
showed significantly higher expression of collagen I/III in comparison to PMO injected 
TA (p<0.01). The lowered expression levels in PMO injected sections was still seen at 4 
weeks after PMO injection, but at 6 weeks this difference was no longer observable.  
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Figure 6.15 Analysis of Collagen I/III expression in TA muscles treated withBaCl2 and PEX3.28.2 PMO 
C57 mice were injected with BaCl2 in both TA. 3 days after Ba2Cl injection the left TA was injected with PEX3.28.2 PMO and the right TA with 
saline as a matched control. TA of mice were recovered 1, 2, 4 and 6 weeks after PMO injection. Cryosections (10µm) of TA muscle were 
prepared and stained for Collagen I and III using Sirius red staining. 
A) Representative image of each time point in both control and PMO injected TA samples. Collagen I/III e shown in red (Magnification x10)  
B) Red staining on sections was measured using image J and shown using arbitrary units. Statistical Significance was calculated using a T test 
(*p<0.05,**p<0.01,  N=3).  
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6.2.2.4 Immunohistochemistry for Periostin, Fibronectin, Collagen VI and α-SMA 
Tissue fibrosis was investigated in PMO treated mouse muscle, an in vivo  model. 
Sections from TA muscle injected with BaCl2 / Pex3.28.2 PMO and BaCl2 /saline were 
stained for POSTN, fibronectin, collagen VI, and α-SMA as described in materials and 
methods and results are shown in Figures 6.16, 6.17, 6.18 and 6.19 respectively. 
Fibronectin, collagen VI and α-SMA are commonly used to look at tissue fibrosis (Specks 
et al., 1995; Shi-Wen et al., 2009; To and Midwood, 2011). All slides were co-stained 
with laminin to outline skeletal muscle fibres and Dapi to visualise nuclei. The staining 
revealed that there was no longer any necrosis at one week after PMO/saline injection, 
(3 days after BaCl2 injection), but instead, the presence of regenerating fibres with 
centrally nucleated fibres was seen. These fibres appear narrow with heterogenous 
diameters. The fibres continued to regenerate up to six weeks after PMO/saline 
injection when the tissue had recovered mostly to normal morphology but showing 
central nuclei and varying fibre diameters.  
As shown in section 6.2.1, POSTN is expressed in low amounts in healthy skeletal muscle 
and upregulated upon damage within regenerating fibres. It is restricted to the ECM 
upon recovery of muscle tissue to normal morphology (Özdemir et al., 2014). 7 days 
after PMO injection (3 days after BaCl2 injection) so 10 days after injury, POSTN was seen 
to be upregulated and mainly localised to the endomysial space (Figure 6.16), though 
this appeared to be more significant in control TA without PMO. POSTN levels gradually 
decreased in both control and PMO injected samples up until 6 weeks, showing visibly 
lower POSTN in PMO injected tissue at each time point; there were extremely low levels 
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in both control and PMO injected samples at 6 weeks, where muscle morphology was 
restored, as expected for healthy muscle.   
Fibronectin protein is also expressed at extremely low levels in healthy muscle (section 
6.2.1). Figure 6.17 shows fibronectin levels were upregulated and restricted to 
intracellular space in regenerating tissue at 1 week after PMO injection. At 14 days after 
injection fibronectin was limited to the interstitial space lining the regenerating fibres. 
Between 1 and 6 weeks after injection, fibronectin levels were seen to gradually reduce 
in both control and PMO injected sections but appear to be at a lower level in the PMO 
injected tissue. This mirrors the expression pattern seen in the POSTN stained sections.  
Collagen VI (Figure 6.18) was upregulated and restricted to the enlarged interstitial 
space in the regenerating fibres. At 4 weeks and 6 weeks after PMO injection collagen 
VI staining intensity was visibly lower in the PMO treated samples in comparison to 
controls. At 6 weeks after injection both control and PMO injected samples showed 
close to normal morphology with healthy expression patterns of Collagen VI.  
Figure 6.19 shows upregulation of α-SMA inside the regenerating fibres with visually 
higher levels seen in control sections compared to the PMO injected sections. This 
expression in both control and PMO injected samples is absent from 2 weeks after 
injection onwards with α-SMA only seen lining vessels. This suggests that tissue repair 
may be occurring in controls but is repressed by the PMO. 
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Figure 6.16 Analysis of POSTN expression in TA Muscles treated withBaCl2 and PEX3.28.2 PMO 
C57 mice were injected with BaCl2 in both TA. 3 days after Ba2Cl injection the left TA was injected with PEX3.28.2 PMO and the right TA with 
saline as a control. TA of mice were recovered 1, 2, 4 and 6 weeks after PMO injection. Cryosections (10µm) of TA muscle were prepared and 
stained for POSTN, DAPI and laminin as described in Materials and Methods. Primary polyclonal antibody ab1404.was used for POSTN. 
Fluorescence-tagged secondary antibodies was used showing POSTN (green), laminin (red); DAPI (blue). Combined images with all three stains 
overlaid is shown (last row). (Magnification x20)  
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Figure 6.17 Analysis of Fibronectin expression in TA Muscles treated withBaCl2 and PEX3.28.2 PMO 
C57 mice were injected with BaCl2 in both TA. 3 days after BaCl2 injection the left TA was injected with PEX3.28.2 PMO and the right TA with saline 
as control. TA of mice were recovered 1, 2, 4 and 6 weeks after PMO injection. Cryosections (10µm) of TA muscle were prepared and stained for 
fibronectin, DAPI and laminin as described in Materials and Methods. Primary polyclonal antibody ab2413was used for fibronectin. Fluorescence 
tagged secondary antibodies was used to anti-fibronectin (green), laminin (red); DAPI (blue). Combined images with all three stains overlaid is also 
shown (last row). (Magnification x20)  
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Figure 6.18 Analysis of Collagen VI expression in TA Muscles treated withBaCl2 and PEX3.28.2 PMO 
C57 mice were injected with BaCl2 in both TA. 3 days after BaCl2 injection the left TA was injected with PEX3.28.2 PMO and the right TA with saline 
as a control. TA of mice were recovered 1, 2, 4 and 6 weeks after PMO injection. Cryosections (10µm) of TA muscle were prepared and stained 
for collagenVI, DAPI and laminin as described in Materials and Methods. Fluorescence-tagged secondary antibody was used showing Collagen 
(green), laminin (red); DAPI (blue). Combined images with all three stains overlaid is also shown (last row). (Magnification x20)  
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Figure 6.19 Analysis of α-SMA expression in TA muscles treated withBaCl2 and PEX3.28.2 PMO 
C57 mice were injected with BaCl2 in both TA. 3 days after BaCl2 injection the left TA was injected with PEX3.28.2 PMO and the right TA with 
saline as a control. TA of mice were recovered 1, 2, 4 and 6 weeks after PMO injection. Cryosections (10µm) of TA muscle were prepared 
and stained for α-SMA, DAPI and laminin as described in Materials and Methods. Primary polyclonal antibody ab5694 was used for α-SMA. 
Fluorescence-tagged secondary antibodies were used showing α-SMA (green), laminin (red); DAPI (blue). Combined images with all three 
stains overlaid is also shown (last row). (Magnification x20)  
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6.3 Discussion  
6.3.1 Effect of BaCl2 on TA of 24month old C57 mice  
BaCl2 intramuscular injection leads to necrosis of skeletal muscle tissue followed by 
regeneration and restoration of muscle morphology (Caldwell, Mattey and Weller, 1990; 
Hardy et al., 2016). In this Chapter, we initially looked at the effect of intramuscular 
injection of BaCl2 in TA of 24-month-old C57 mice which are more likely to exhibit a 
fibrotic phenotype. Our findings confirmed that BaCl2 induces necrotic damage in the 
injected tissue, which then regenerates, after which normal morphology is restored with 
no scar tissue left behind. Interestingly, contrary to findings by Özdemir et al. (2014) 
where POSTN RNA levels were shown to be at their highest 7 days after BaCl2 injection 
in rats, we show that in mice, POSTN RNA levels are at their peak 14 days after BaCl2 
injection. This may be a difference in the animal models and the age of the animals: the 
mice used in our study were 24 months old whereas the Sprague Dawley rats used by 
Özdemir were young, at 3 months old.  
Immunohistochemistry studies of samples were also in agreement with protein 
expression results from the study on rats by Özdemir et al.; we demonstrated that 
POSTN protein expression in C57 mice was reduced, in comparison to control samples 
with healthy TA, one day after BaCl2 injection when tissue is necrotic. At 3 days after 
injection, POSTN protein levels were increased in comparison to control samples and 
continued increasing to a peak at 7 days after injection. Contrary to the Özdemir studies 
in rats, where POSTN protein levels were restored to normal at day 10, in our hands, the 
24-month-old mice showed elevated POSTN protein levels at day 14. This might be due 
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to the old age of the mice leading to slower regeneration and healing (di Schiaffino, 
Gorza and Parry, 1993; Joanisse et al., 2016).  
Collagen and fibronectin staining also confirmed that the effects of BaCl2 injection were 
necrosis, regeneration then restoration of normal muscle morphology. Since POSTN has 
a role in the localisation of fibronectin and collagen to the ECM, the correlation between 
POSTN expression pattern and fibronectin and collagen expression patterns is as 
expected (Takayama, Arima and Kanaji, 2006; Butcher et al., 2007; Kii et al., 2010). 
α SMA staining was successfully used to identify regenerating muscle as it is reported to 
be upregulated in activated myofibroblasts and repairing fibres and it is indeed seen to 
be expressed within regenerating fibres 7 days after injection (March et al., 2018). It is 
worth mentioning that the limitation to this study was the limited sample size of 1.  
The findings from this study show firstly, that POSTN is temporally expressed in 
regenerating and differentiating C57 TA muscle when damaged using intramuscular 
injection of BaCl2. This made damage by BaCl2 a suitable model upon which to induce 
POSTN expression and test exon skipping, using the PEX3.28.2 PMO designed and tested 
in previous chapters.  
6.3.2 PEX3.28.2 induced Periostin exon 3 exclusion in BaCl2 injected C57 mice  
Having confirmed the effects of BaCl2 intramuscular injection in C57 TA muscle and 
looked at changes in POSTN expression in response to BaCl2 injected tissue, we looked 
at the effect of PEX3.28.2 PMO in damaged, BaCl2 injected TA. PMO was injected into 
the damaged TA muscle 3 days after BaCl2 injection when the fibres were regenerating 
and POSTN expression upregulated (section 6.3.1).  We confirmed that PEX3.38.2 lead 
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to a successful reduction of POSTN expression at the RNA and protein levels. RNA levels 
quantified by RT-qPCR showed reduced POSTN levels in PMO injected samples 
compared to saline-injected samples, with reduced RNA levels in PMO injected samples 
maintained for up to 21 days after injection. 6 weeks after injection, POSTN levels could 
no longer be quantified, this could be due to very low levels of POSTN expression in the 
recovered muscle tissue, as expected. Protein expression patterns were examined by 
Western blots, which on the other hand show consistently reduced POSTN levels in the 
PMO injected samples; this effect remains even 6 weeks after injection.  
Fibronectin RNA expression was not affected by PMO injection, but there was a 
reduction in protein level by Western blot. This work confirms literature showing that 
POSTN is involved in the transport of fibronectin protein to the ECM (Kudo, 2011) but 
suggests POSTN downregulation has no effect on fibronectin transcription in vivo, but 
at the protein level, translation of fibronectin is reduced (by the lower levels of Postn); 
Chapter 5 also suggests that reducing POSTN levels in vitro had a transcriptional effect 
on fibronectin transcription reducing fibronectin RNA levels. The work in vivo (this 
Chapter) indicates that the reduction in POSTN levels, achieved by PEX3.28.2 PMO, had 
no detrimental effect on muscle regeneration and repair as muscle morphology was 
restored in PMO injected samples no later, if not sooner, than control saline injected 
samples.  
Fibronectin, Collagen I/III and Collagen VI levels were all reduced towards normal levels 
earlier in the PMO injected samples than the saline-injected samples in correlation with 
the appearance of normal muscle morphology indicating improved muscle recovery. 
This finding is in agreement with work by Lorts et al. (2012a) where sgcd -/-,postn-/- 
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mice showed enhanced regeneration. Hara et al. (2018) also showed improved muscle 
recovery after partial laceration injuries in samples treated with Postn-monoclonal 
antibody and suggested this was due to reduced fibroblast migration to the site of injury. 
Statistical significance was not seen in vivo in response to PMO injection; however only 
3 sets of control/experimental samples were generated and often one out of three 
showed a different result. This is to be expected in vivo as different mice will have 
different physiological responses to insult or the application of PMO may have been 
different in our hands. This could be due to loss of PMO in the regenerating fibres (Aoki 
et al., 2013). The effect of PMO is likely transient due to protein turnover, and a weekly 
injection of PMO could be necessary in order to see a significant downregulation of 
POSTN. 
It can, therefore, be concluded, secondly, that PEX3.28.2 was successful at decreasing 
POSTN expression both at RNA and protein levels in vivo after injection into TA muscle 
in old mice. Also, thirdly, that PMO application had no negative impact on tissue 
regeneration and repair. It also indicated that the reduction in POSTN levels using the 
PEX3.28.2 PMO lead to reduced localisation of fibrotic proteins such as Collagen and 
Fibronectin to the ECM, confirming that the downstream processing by POSTN was 
compromised by the PMO.  
Though this in vivo model allows examination of the bioactivity of PEX3.28.2 and its 
safety, it is limited in that it is based on acute injury rather than chronic and so does not 
result in permanent fibrotic replacement of muscle tissue. The effect of POSTN 
downregulation on fibrosis and the fibrotic pathway is therefore yet to be assessed. In 
addition to this, though POSTN targeted PMOs shows an effect it may not be strong 
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enough to affect the regeneration/fibrosis pathways significantly and so it would be 
beneficial to test more potent knock down such as use of AAV-shRNAs for POSTN.  
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7. General discussion and conclusion  
7.1 Summary of findings 
7.1.1 Targeting PolyA signal to downregulate MSTN mRNA expression 
In this thesis PMO AONs were designed to target the polyA signal in the Myostatin 
(MSTN) 3’UTR. The PMOs were tested in the RD cell system to see that they decreased 
MSTN mRNA expression; the bioactivity of the designed PMOs were compared to that 
of a published PMO targeting exon 3 of MSTN. The results from this experiment 
demonstrated that targeting the PolyA signal lead to successful downregulation of 
MSTN; however, targeting exon 3 to create an out-of-frame transcript of MSTN led to a 
more significant downregulation of total MSTN mRNA expression.  
The experiments in Chapter 3 indicate that targeting gene expression through disruption 
of transcript reading frame is a more efficient method than targeting polyadenylation 
through binding to the polyA signal. Use of PMOs to target polyA signals was 
investigated in the FSHD disease model where DUX4 expression was altered through 
targeting of the polyadenylation process (Marsollier et al., 2016). The potential 
disadvantage of targeting the polyA signal for expression knockdown is the ability of 
many human genes to use more than one polyA / cleavage site (Vickers et al., 2001; Raz 
et al., 2014); blocking one polyA signal could lead the cell to use an alternative. Another 
concern with targeting 3’UTR elements is the specificity of the designed PMOs as these 
elements are highly conserved between genes and also species (Verrotti et al., 1996). It 
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is therefore likely that inducing an exon skip to disrupt the transcript reading frame using 
an AON is a more specific and efficient way to knockdown gene expression.  
7.1.2 Designing PMO AONs to target out of frame exons in POSTN 
In Chapter 4, AONs were created aimed at generating POSTN out-of-frame transcription 
products by exon skipping, in both human and mice. PMOs were designed 
bioinformatically, to exclude one of the out-of-frame exons 3, 7, 10 or 16. Human and 
mouse conserved sequences and position of ESE binding motifs within those conserved 
regions of the transcript were taken into consideration when designing the AON. Human 
Splicing Finder and ESEfinder were both used to identify and compare ESE binding 
motifs. Mfold was used to determine the secondary structure of the target sequence, 
whereas RNAup was utilised to analyse the binding position and the thermodynamic 
properties of the designed PMOs as well as their overall binding energy. As a result, 11 
PMOs were designed.  
7.1.3 PMO mediated exon exclusion of POSTN in-vitro 
In Chapter 5, POSTN expression was stimulated using TGF-β treatment in vitro models: 
DMD human patient muscle cells; the murine C2C12 cell system and murine 
myofibroblast cells. Bioactivity of the designed PMOs was assessed in these cell systems 
and the PMO targeting exon 3 was shown to the most successful in human and mouse 
muscle cells as well as mouse fibroblast cells, showing statistical significance in both 
quantitative and semi-quantitative PCR analysis. The PMO was increased in length to a 
28mer in order to increase binding energy and improve the efficiency of exon skipping. 
qPCR analysis of POSTN total mRNA expression proved to be a better read out of PMO 
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effectiveness in downregulation of POSTN mRNA. This also showed that POSTN 
downregulation in vitro leads to downregulation of fibronectin mRNA.  
TGF-β treatment has been shown to stimulate POSTN expression (March et al., 2018). 
Özdemir et al. (2014) also showed that POSTN expression in C2C12 cells is very low and 
increased significantly 48 hours after differentiation. In order for an AON to be effective, 
transcription of its target gene needs to be active for pre-mRNA to be produced and the 
AON to bind (Popplewell et al., 2009; Mael-ainin et al., 2014). It is therefore of 
importance to stimulate POSTN expression in vitro in order to investigate AON 
bioactivity. This is perhaps a limitation in testing POSTN targeted molecules in vitro. On 
the other hand, POSTN is stimulated in acute injury, making it a method for study in in 
vivo systems. It remains to be seen how closely a stimulated system matched the DMD 
model for POSTN expression.  
Previous studies have shown overall binding energy to target and the length of PMO 
(which affects the former) to be the two most important factors affecting PMO 
bioactivity (Marsollier et al., 2016). We confirmed these findings showing that the local 
position of binding of the PMO to the secondary structure to be less decisive in PMO 
success in exon exclusion, whereas the length of PMO significantly increased the success 
of PMO (Popplewell et al., 2009). 
POSTN is alternatively spliced with 6 protein-coding variants (Viloria and Hill, 2016) with 
additional isoforms expressed during foetal development. The role of these different 
splice variants is yet to be discovered, but it has been shown that the choice of C 
terminal, which is affected by alternative splicing, has functional significance. Highly 
tissue-specific expression patterns of POSTN have been reported (Wahab, Brinkman and 
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Mason, 2001; Morra and Moch, 2011) with isoform 1 expressed in heart tissue (Ensembl, 
accessed March 2016). POSTN expression in vitro and in vivo is therefore likely to be 
regulated in different ways and this should be taken into consideration when 
investigating POSTN downregulation in vitro.  
7.1.4 Antisense modulation of POSTN expression in BaCl2 injected C57 TA. 
Chapter 6 explored the efficacy of the PMO in tissue repair in vivo. Healthy muscle tissue 
expresses low levels of POSTN as the TGF-β induced expression is not active (Özdemir et 
al., 2014). In order to activate POSTN expression, muscle damage in mice was induced 
using BaCl2 intramuscular injection. This study showed POSTN expression decreased one 
day after injection caused necrotic muscle tissue and then rose as myotubes began 
maturing. These findings were also reported by Özdemir et al. (2014) in rats injected 
with BaCl2, so we confirmed that this pattern of expression of POSTN in regenerating 
muscle is conserved between the two species.  
Following confirmation that POSTN expression significantly increases in maturing 
myotubes following BaCl2  damage, data in Chapter 6 showed that injecting the damaged 
TA with the 28mer PMO, 3 days after BaCl22 injection, lead to a decrease in POSTN 
expression. The study also showed that fibronectin protein expression was also reduced 
in response to POSTN downregulation.  
Other studies have previously reported the successful use of AONs to target POSTN 
expression. Tomaru (2017) showed that targeting of POSTN using AONs by direct 
administration into the fibrotic lungs of mice leads to a downregulation of POSTN, 
ameliorating pulmonary fibrosis. The mice were injected with 20µg of AON and 
harvested 22 days after injection. Periostin levels in the lung tissue were shown to 
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decrease significantly compared to mice injected with saline. This reduction of POSTN 
was also linked to a decrease in fibrotic changes in the lung as subpleural fibrosis and 
destruction of lung parenchymal architecture was less prominent. Mael Ainin et al. 
(2014) also reported that targeting POSTN, using a cocktail of two AONs directed to the 
ATG signal, protected the kidney from fibrosis following L-NAME injection. AONS cocktail 
was injected intraperitoneally every 24 hours with a pre-injection 48 hours before 
administration of L-NAME. 
Our study also showed that damaged TA injected with PMO recovered at a faster rate 
than the control TA, with less collagen and fibronectin deposition in the ECM and lower 
intracellular α-SMA expression . Similar reports have been previously described by Lorts 
et al. (2012a) where POSTN was deleted in Sgcs-/- mice it led to enhanced tissue 
regeneration and reduced levels of fibrosis. Having said this, another study by Chen et 
al. (2017) reported that ablation of POSTN inhibited post-infraction myocardial 
regeneration in neonatal mice. This highlights the complexity of POSTN function and 
expression at different time points and in different tissues. More investigation into 
POSTN expression patterns, isoforms and function is required in order to target POSTN 
in a completely specific and safe way.  
Although BaCl2 induces muscle necrosis that is repaired by infiltration of mononuclear 
cells such as neutrophils and macrophages and subsequent regeneration, it does not 
lead to chronic inflammation and fibrosis (Hardy et al., 2016). Therefore, though BaCl2 
injection increases POSTN expression and allows assessing bioactivity of AONs it is not a 
suitable model for investigating the subsequent effect of POSTN down-regulation on 
fibrosis.  
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7.2 Evaluation and future directions 
The role of POSTN in fibrosis is rapidly expanding in various fields especially in lung, 
kidney and heart fibrotic disease. Periostin’s role in skeletal muscle fibrosis in dystrophic 
muscle are virtually unexplored, and this work offers the first study in designing 
antisense oligonucleotides targeting POSTN expression through exon exclusion and 
disruption of the open reading frame. With significant results being achieved in the 
restoration of dystrophin in DMD models (Liang et al., 2004; Lu-Nguyen et al., 2017) the 
fibrosis of muscle tissue is one of the biggest barriers in humans when it comes to 
tackling DMD and restoring dystrophin (More in chapter 1). Multi-combinatorial 
treatment of DMD addressing fibrosis and restoration of dystrophin seems like the only 
logical way forward. Knockdown of POSTN is showing significant results in lowering 
fibrosis levels in models such as the heart, kidney, lung and skeletal muscle (Mael-ainin 
et al., 2014; Zhao et al., 2014; Semba et al., 2018b).  
Having shown the success of the designed Pex3.28.2 PMO in downregulation of POSTN 
in vitro and in vivo, it is important to investigate the effects of PMO induced POSTN 
knockdown in skeletal muscle of dystrophic models such as the mdx mouse, or the more 
fibrotic DMD rat where fibrosis is more similar to that found in human DMD muscle 
(Larcher, Lafoux, Tesson, Remy et al., 2014). Following investigations into the effect of 
Periostin knockdown on muscle fibrosis in such models, it would then be logical to assess 
the effect of a multi-combinatorial treatment in the DMD rat where dystrophin is 
restored while POSTN and  MSTN are downregulated.  
We have shown that exclusion of exon 3 of POSTN, disrupting the open reading frame, 
is an effective way of reducing POSTN expression, but it is also worth noting that 
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targeting exon 3 would be targeting all POSTN isoforms. More investigation is required 
on POSTN expression in muscle tissue and the role of different POSTN isoforms in muscle 
function in order to assure the safety of downregulating all isoforms. Investigating 
muscle repair and regeneration in more detail in the absence or reduction of POSTN 
using AONs may provide valuable insight into POSTN function in muscle and fibrosis. It 
would also be preferable to test more extreme knock down of POSTN. Short hairpin 
RNA(shRNA) has been shown to be successful in efficient and reversible knockdown of 
target genes (Seibler et al., 2007). Using shRNA would allow a more complete study into 
the full extent of POSTN knockdown on dystrophic muscle tissue and the fibrotic 
pathway.  
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